

CLINICAL TRIAL MAGNIFIER WEEKLY

A WEEKLY TRACKING OF ESSENTIAL CHANGES IN THE U.S. TRIAL REGISTRY

Vol. 2, No. 39
Sept. 26, 2013

INSIDE THIS ISSUE

New Sponsors	Page 2
New Studies	Page 3
New Results	Page 7
New Study Status.....	Page 8
Studies Opening a First Site in a New Country ...	Page 15
Studies Opening Additional Sites in a Country ..	Page 24
Study Sites by Country	Page 50
Studies Under Planning.....	Page 51
Studies Ended or Halted.....	Page 63

Highlights of Changes This Week at ClinicalTrials.gov:

New Sponsors: Nine sponsors registered studies at ClinicalTrials.gov for the first time this week. Those sponsors are bioRASI, DiaVacs, inSleep Technologies, MDbackline, Mirabilis Medica, OxOnc Development, Proximagen, Skeletal Dynamics and StratiHealth. For more details, see **New Sponsors on Page 2**.

New Studies: One hundred and six new studies were registered this week, including studies sponsored by AbbVie, Allergan, AstraZeneca, Baxter, Bayer, Boehringer Ingelheim, Celgene, Eli Lilly, GlaxoSmithKline, Hoffmann-La Roche, Janssen, Medtronic, Merck, Novartis, Onyx, Pfizer, Sanofi Pasteur, Takeda and Vertex. For more details, see **New Studies on Page 3**.

New Results: Twenty-eight industry-sponsored studies posted results this week, including studies by Allergan, Amgen, Astellas, AstraZeneca, Eisai, Gilead, GlaxoSmithKline, Merck, Pfizer and Teva. For more details, see **New Results on Page 7**.

New Study Status: One hundred and fifty-four studies are reporting changes in their status as planning, recruiting, ongoing or completed this week. Among the sponsors are AbbVie, Amgen, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Cubist, Eli Lilly, Exelixis, Genentech, Gilead, GlaxoSmithKline, Hoffmann-La Roche, Janssen, MedImmune, Medtronic, Merck, Novartis, Novo

(See **Highlights, Page 2**)

SUMMARY OF LATEST TRIAL UPDATES

Week Ending	Sept. 26	Sept. 19	Sept. 12	Sept. 5	Total
New Sponsors	9	16	12	6	43
New Studies	106	108	101	81	384
New Results	28	24	23	26	102
New Study Status	154	147	171	78	573
Studies Opening a First Site in a New Country	211	237	227	195	899
Studies Opening Additional Sites in a Country	586	325	707	338	2,015
Studies Under Planning	301	284	275	45	906
Studies Ended or Halted	15	18	16	11	72

Highlights, *from Page 1*

Nordisk, Otsuka, Pfizer, Sandoz, Sanofi, Takeda and Vertex. For more details, see **New Study Status on Page 8**.

Studies Opening a First Site in a New Country: Two hundred and eleven new study sites launched this week in countries where the sponsors did not have study sites. For more details, see **Studies Opening a First Site in a New Country on Page 15**.

Studies Opening Additional Sites in a Country: Five hundred and eighty-six new study sites launched this week in countries where the sponsors already had study sites. For more details, see **Studies Opening Additional Sites in a Country on Page 24**.

Study Sites by Country: A handy table that lists all countries with first-time and additional study sites that launched this week can be found at **Study Sites by Country on Page 50**.

Studies Under Planning: About 10% of the studies listed as in the planning stage are replaced each week. This week's 301 listings include planned studies at Abbott, AstraZeneca, Baxter, Bayer, Biogen Idec, Biontronik, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Cytomedix, Daiichi Sankyo, GlaxoSmith-Kline, Hoffmann-La Roche, Janssen, Medtronic, Merck, Novartis, Novo Nordisk, Perle Bioscience, Pfizer, Sanofi, St. Jude, Takeda and Zimmer. For more details, see **Studies Under Planning on Page 51**.

Studies Ended or Halted: Fifteen studies were terminated, suspended or withdrawn this week, including studies sponsored by Amgen, Boehringer Ingelheim, Gilead, Janssen, Merck, Pfizer and St. Jude. For more details, see **Studies Ended or Halted on Page 63**.

NEW SPONSORS

This table lists new sponsors that have never previously registered studies at ClinicalTrials.gov.

IDENTIFIER ¹	SPONSOR	TYPE ²	STATUS	PHASE ³	SIZE (N)	MIN AGE	MAX AGE	CONDITION
NCT01947569	DIAVACS	BIOLOGICAL	1. PLANNING	1	90	12 YEARS	35 YEARS	DIABETES
NCT01945021	OXONC	DRUG	1. PLANNING	2	110	18 YEARS	N/A	CRIZOTINIB
NCT01948024	BIORASI	DRUG	2. RECRUITING	1	66	18 YEARS	80 YEARS	BIPOLAR DISORDER
NCT01945346	PROXIMAGEN	DRUG	2. RECRUITING	2	74	45 YEARS	75 YEARS	OSTEOARTHRITIS, KNEE
NCT01949584	INSLEEP	DEVICE	2. RECRUITING	NA	30	18 YEARS	N/A	HABITUAL, SIMPLE SNORING
NCT01946581	MDBACKLINE	PROCEDURE	2. RECRUITING	NA	200	18 YEARS	90 YEARS	CATARACT
NCT01946178	MIRABILIS	DEVICE	2. RECRUITING	NA	80	18 YEARS	55 YEARS	UTERINE FIBROIDS
NCT01944670	SKELETAL	DEVICE	2. RECRUITING	NA	25	21 YEARS	N/A	ELBOW DISLOCATION
NCT01948544	STRATIHEALTH		2. RECRUITING	NA	30	65 YEARS	85 YEARS	COPD

¹ Identifier: The official study ID given by ClinicalTrials.gov.

² When the type field is empty, it is commonly a noninterventional study.

³ "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

(Return to Page 1)

NEW STUDIES

This table lists every new study registered in the past week.

IDENTIFIER ¹	SPONSOR	TYPE ²	STATUS	PHASE ³	SIZE (N)	MIN AGE	MAX AGE	CONDITION
NCT01949285	NEUROEN-ABLING	DEVICE	1. PLANNING	0	24	21 YEARS	65 YEARS	SPINAL CORD INJURY
NCT01945606	BAYER	DRUG	1. PLANNING	1	10	18 YEARS	75 YEARS	HEART FAILURE
NCT01946789	ALTOR	BIOLOGICAL	1. PLANNING	1	20	18 YEARS	N/A	ADVANCED MELANOMA
NCT01947153	BOEHRINGER INGELHEIM	DRUG	1. PLANNING	1	36	18 YEARS	45 YEARS	HEALTHY
NCT01947569	DIAVACS	BIOLOGICAL	1. PLANNING	1	90	12 YEARS	35 YEARS	DIABETES
NCT01947777	INFINITY	DRUG	1. PLANNING	1	14	18 YEARS	50 YEARS	HEALTHY
NCT01947920	JANSSEN	DRUG	1. PLANNING	1	30	18 YEARS	45 YEARS	HEALTHY
NCT01947933	ELI LILLY	BIOLOGICAL	1. PLANNING	1	40	18 YEARS	N/A	PSORIASIS
NCT01948011	BIOPROJET	DRUG	1. PLANNING	1	52	18 YEARS	45 YEARS	HEALTHY
NCT01948986	MERCK	DRUG	1. PLANNING	1	40	18 YEARS	80 YEARS	DIABETES
NCT01949103	THERAVANCE	DRUG	1. PLANNING	1	48	18 YEARS	55 YEARS	BACTERIAL INFECTIONS
NCT01949532	ONYX	DRUG	1. PLANNING	1	32	18 YEARS	N/A	END-STAGE RENAL DISEASE
NCT01949545	ONYX	DRUG	1. PLANNING	1	40	18 YEARS	N/A	HEPATIC IMPAIRMENT
NCT01945021	OXONC	DRUG	1. PLANNING	2	110	18 YEARS	N/A	CRIZOTINIB
NCT01945086	JANSSEN	DRUG	1. PLANNING	2	72	20 YEARS	65 YEARS	DERMATITIS, ATOPIC
NCT01945281	MERCK	DRUG	1. PLANNING	2	90	N/A	3 MONTHS	CANDIDIASIS, INVASIVE
NCT01946477	CELGENE	DRUG	1. PLANNING	2	85	18 YEARS	N/A	MULTIPLE MYELOMA
NCT01946945	REPROGENET-ICS	GENETIC	1. PLANNING	2	240	22 YEARS	42 YEARS	PREGNANCY LOSS
NCT01947478	MEDTRONIC	DEVICE	1. PLANNING	2	100	20 YEARS	85 YEARS	POPLITEAL ARTERY OCCLUSION
NCT01948180	CELL MEDICA	BIOLOGICAL	1. PLANNING	2	30	18 YEARS	N/A	EBV
NCT01948219	PROTIP	DEVICE	1. PLANNING	2	15	18 YEARS	N/A	LARYNGECTOMY
NCT01948817	NOVARTIS	DRUG	1. PLANNING	2	45	2 YEARS	N/A	TRANSFUSION DEPENDENT

¹ Identifier: The official study ID given by ClinicalTrials.gov.

² When the type field is empty, it is commonly a noninterventional study.

³ "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

New Studies, from Page 3

IDENTIFIER ¹	SPONSOR	TYPE ²	STATUS	PHASE ³	SIZE (N)	MIN AGE	MAX AGE	CONDITION
NCT01949051	GSK	DRUG	1. PLANNING	2	78	18 YEARS	65 YEARS	RHINITIS
NCT01949090	GSK	BIOLOGICAL	1. PLANNING	2	360	65 YEARS	N/A	INFLUENZA
NCT01949324	NEUROTECH	BIOLOGICAL	1. PLANNING	2	68	21 YEARS	80 YEARS	MACULAR TELANGIECTASIA
NCT01949441	CIRCASSIA	BIOLOGICAL	1. PLANNING	2	40	18 YEARS	65 YEARS	RHINOCONJUNCTIVITIS
NCT01944969	H LUNDBECK	DRUG	1. PLANNING	3	1,184	18 YEARS	N/A	DEPRESSIVE DISORDER
NCT01945034	PFIZER	DRUG	1. PLANNING	3	340	12 YEARS	N/A	SPRAINS AND STRAINS
NCT01945294	MERCK	DRUG	1. PLANNING	3	410	18 YEARS	N/A	HEPATITIS C, CHRONIC
NCT01945593	BAXTER	BIOLOGICAL	1. PLANNING	3	250	N/A	75 YEARS	HEMOPHILIA A
NCT01946204	ARAGON	DRUG	1. PLANNING	3	1,200	18 YEARS	N/A	PROSTATIC NEOPLASMS
NCT01946412	VERTEX	DRUG	1. PLANNING	3	MISSING	2 YEARS	N/A	CYSTIC FIBROSIS
NCT01946620	MUNDIPHARMA	DRUG	1. PLANNING	3	1,530	40 YEARS	N/A	COPD
NCT01946711	PARI PHARMA	DRUG	1. PLANNING	3	20	18 YEARS	N/A	CHRONIC POLYPOSIS
NCT01947491	PROMIUS	DRUG	1. PLANNING	3	396	18 YEARS	N/A	PSORIASIS
NCT01947855	BOEHRINGER INGELHEIM	DRUG	1. PLANNING	3	60	20 YEARS	74 YEARS	DIABETES
NCT01947946	ASTRAZENECA	BIOLOGICAL	1. PLANNING	3	846	18 YEARS	75 YEARS	ASTHMA
NCT01948193	SANOFI	BIOLOGICAL	1. PLANNING	3	177	6 WEEKS	8 WEEKS	INVASIVE HIB INFECTIONS
NCT01948830	NOVARTIS	DRUG	1. PLANNING	3	644	50 YEARS	N/A	MACULAR DEGENERATION
NCT01948856	PIERRE FABRE	DRUG	1. PLANNING	3	1,000	3 YEARS	4 YEARS	URTI
NCT01949142	OTONOMY	DRUG	1. PLANNING	3	264	6 MONTHS	12 YEARS	TYMPANOSTOMY TUBE PLACEMENT
NCT01949155	OTONOMY	DRUG	1. PLANNING	3	264	6 MONTHS	12 YEARS	TYMPANOSTOMY TUBE PLACEMENT
NCT01949311	REGENERON	DRUG	1. PLANNING	3	800	18 YEARS	N/A	ATOPIC DERMATITIS
NCT01945489	ALLERGAN	BIOLOGICAL	1. PLANNING	4	258	18 YEARS	N/A	OVERACTIVE BLADDER
NCT01947803	XIAN-JANSSEN	DRUG	1. PLANNING	4	353	18 YEARS	65 YEARS	SCHIZOPHRENIA
NCT01947868	ASTRAZENECA		1. PLANNING	4	356	20 YEARS	N/A	LUNG CANCER

1 Identifier: The official study ID given by ClinicalTrials.gov.

2 When the type field is empty, it is commonly a noninterventonal study.

3 "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventonal study, but it can also represent an interventonal device trial.

(Return to Page 1)

(See New Studies, Page 5)

New Studies, from Page 4

IDENTIFIER ¹	SPONSOR	TYPE ²	STATUS	PHASE ³	SIZE (N)	MIN AGE	MAX AGE	CONDITION
NCT01948791	NOVARTIS	DRUG	1. PLANNING	4	186	50 YEARS	85 YEARS	ALZHEIMER'S DISEASE
NCT01949675	SANOFI	BIOLOGICAL	1. PLANNING	4	336	1 YEAR	N/A	CHOLERA
NCT01945580	BOSTON SCIENTIFIC	PROCEDURE	1. PLANNING	NA	454	18 YEARS	N/A	PELVIC ORGAN PROLAPSE
NCT01945762	ASTRAZENECA	DRUG	1. PLANNING	NA	80	18 YEARS	N/A	THYROID CANCER
NCT01945970	UNILEVER	OTHER	1. PLANNING	NA	30	40 YEARS	65 YEARS	VASCULAR FUNCTION
NCT01946126	ALLERGAN		1. PLANNING	NA	200	18 YEARS	65 YEARS	HEADACHE
NCT01947309	CELGENE	DRUG	1. PLANNING	NA	600	18 YEARS	N/A	MULTIPLE MYELOMA
NCT01947829	B.BRAUN AVITUM		1. PLANNING	NA	120	18 YEARS	N/A	KIDNEY DISEASE
NCT01947894	PFIZER	OTHER	1. PLANNING	NA	900	18 YEARS	N/A	GROWTH HORMONE DEFICIENCY
NCT01948869	BAYER	DEVICE	1. PLANNING	NA	55	18 YEARS	60 YEARS	DERMATITIS, ATOPIC
NCT01948882	BAYER	DEVICE	1. PLANNING	NA	590	21 YEARS	44 YEARS	CONTRACEPTION
NCT01949220	FRANCAIS		1. PLANNING	NA	80	N/A	N/A	VON WILLEBRAND DISEASE
NCT01949415	CIRCASSIA		1. PLANNING	NA	105	16 YEARS	65 YEARS	RHINOCONJUNCTIVITIS
NCT01949428	CIRCASSIA		1. PLANNING	NA	100	18 YEARS	65 YEARS	RHINOCONJUNCTIVITIS
NCT01944683	ACORDA	OTHER	2. RECRUITING	1	28	18 YEARS	75 YEARS	HEART FAILURE
NCT01944735	CELTAXSYS	DRUG	2. RECRUITING	1	36	18 YEARS	55 YEARS	CYSTIC FIBROSIS
NCT01945710	EISAI	DRUG	2. RECRUITING	1	96	18 YEARS	N/A	SOLID TUMORS
NCT01946074	ABBVIE	DRUG	2. RECRUITING	1	75	18 YEARS	N/A	ADVANCED SOLID TUMORS
NCT01946386	LEO	DRUG	2. RECRUITING	1	35	18 YEARS	50 YEARS	PSORIASIS VULGARIS
NCT01946568	DURATA	DRUG	2. RECRUITING	1	36	3 MONTHS	11 YEARS	BACTERIAL INFECTIONS
NCT01946867	NANOBIOTIX	DEVICE	2. RECRUITING	1	48	65 YEARS	N/A	HEAD AND NECK CANCER
NCT01948024	BIORASI	DRUG	2. RECRUITING	1	66	18 YEARS	80 YEARS	BIPOLAR DISORDER
NCT01944774	TAIGEN	DRUG	2. RECRUITING	2	210	18 YEARS	75 YEARS	PNEUMONIA
NCT01945346	PROXIMAGEN	DRUG	2. RECRUITING	2	74	45 YEARS	75 YEARS	OSTEOARTHRITIS, KNEE

¹ Identifier: The official study ID given by ClinicalTrials.gov.

² When the type field is empty, it is commonly a noninterventional study.

³ "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

(Return to Page 1)

(See New Studies, Page 6)

New Studies, from Page 5

IDENTIFIER ¹	SPONSOR	TYPE ²	STATUS	PHASE ³	SIZE (N)	MIN AGE	MAX AGE	CONDITION
NCT01946841	LACTALIS	DIETARY SUP.	2. RECRUITING	2	20	18 YEARS	N/A	NUTRITIONAL DISORDERS
NCT01947907	ASCENDIS	DRUG	2. RECRUITING	2	52	3 YEARS	12 YEARS	GROWTH HORMONE DEFICIENCY
NCT01948401	HOFFMANN-LA ROCHE	DRUG	2. RECRUITING	2	97	12 YEARS	75 YEARS	ASTHMA
NCT01944839	OPHTHOTECH	DRUG	2. RECRUITING	3	622	50 YEARS	N/A	MACULAR DEGENERATION
NCT01945684	DAEWOONG	DRUG	2. RECRUITING	3	MISS-ING	18 YEARS	N/A	UPPER LIMB SPASTICITY
NCT01945775	BIOMARIN	DRUG	2. RECRUITING	3	429	18 YEARS	N/A	BRCA 2 GENE MUTATION
NCT01945788	BIO SIDUS	DRUG	2. RECRUITING	4	110	50 YEARS	81 YEARS	OSTEOPOROSIS
NCT01946243	AVID	DRUG	2. RECRUITING	4	96	N/A	N/A	ALZHEIMERS DISEASE
NCT01946425	SANOFI	BIOLOGICAL	2. RECRUITING	4	60	6 MONTHS	8 YEARS	INFLUENZA
NCT01946438	SANOFI	BIOLOGICAL	2. RECRUITING	4	208	18 YEARS	N/A	INFLUENZA
NCT01944670	SKELETAL	DEVICE	2. RECRUITING	NA	25	21 YEARS	N/A	CHRONIC ELBOW DISLOCATION
NCT01944748	RAND	BEHAVIORAL	2. RECRUITING	NA	200	12 YEARS	19 YEARS	FAMILY FUNCTIONING
NCT01944917	AEROTEL		2. RECRUITING	NA	40	35 YEARS	75 YEARS	MUSCULO-SKELETAL PAIN
NCT01945216	TAKEDA	DRUG	2. RECRUITING	NA	3,000	N/A	N/A	DIABETES
NCT01945424	SANOFI	BIOLOGICAL	2. RECRUITING	NA	500	18 YEARS	N/A	INFLUENZA
NCT01946178	MIRABILIS	DEVICE	2. RECRUITING	NA	80	18 YEARS	55 YEARS	UTERINE FIBROIDS
NCT01946581	MDBACKLINE	PROCEDURE	2. RECRUITING	NA	200	18 YEARS	90 YEARS	CATARACT
NCT01947816	ABBVIE		2. RECRUITING	NA	1,500	N/A	N/A	ULCERATIVE COLITIS
NCT01947959	BAYER	DRUG	2. RECRUITING	NA	20,000	2 YEARS	89 YEARS	PULMONARY EMBOLISM
NCT01947985	BAYER	DRUG	2. RECRUITING	NA	20,000	2 YEARS	89 YEARS	PULMONARY EMBOLISM
NCT01947998	BAYER	DRUG	2. RECRUITING	NA	20,000	2 YEARS	89 YEARS	PULMONARY EMBOLISM
NCT01948427	HYPERION		2. RECRUITING	NA	500	N/A	N/A	UREA CYCLE DISORDER
NCT01948544	STRATIHEALTH		2. RECRUITING	NA	30	65 YEARS	85 YEARS	COPD
NCT01949584	INSLEEP	DEVICE	2. RECRUITING	NA	30	18 YEARS	N/A	HABITUAL, SIMPLE SNORING

1 Identifier: The official study ID given by ClinicalTrials.gov.

2 When the type field is empty, it is commonly a noninterventional study.

3 "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

(Return to Page 1)

(See New Studies, Page 7)

New Studies, from Page 6

IDENTIFIER ¹	SPONSOR	TYPE ²	STATUS	PHASE ³	SIZE (N)	MIN AGE	MAX AGE	CONDITION
NCT01948297	DEBIOPHARM	DRUG	3. ONGOING	1	106	18 YEARS	N/A	SOLID TUMOURS
NCT01945242	TAKEDA	DRUG	3. ONGOING	NA	1,000	N/A	N/A	DIABETES
NCT01945827	CODMAN & SHURTLEFF	DEVICE	3. ONGOING	NA	150	18 YEARS	80 YEARS	INTRACRANIAL ANEURYSMS
NCT01947387	INTEGRA		3. ONGOING	NA	400	18 YEARS	N/A	LOWER EXTREMITY WOUNDS
NCT01948258	SPD		3. ONGOING	NA	395	18 YEARS	45 YEARS	PREGNANCY
NCT01947738	VIROBAY	DRUG	4. COMPLETED	1	89	18 YEARS	60 YEARS	HEALTHY
NCT01949610	JOHNSON & JOHNSON	DRUG	4. COMPLETED	1	10	18 YEARS	55 YEARS	HEALTHY
NCT01948440	INFLEXXION	BEHAVIORAL	4. COMPLETED	2	39	N/A	N/A	SUBSTANCE ABUSE
NCT01948531	DERMING	DRUG	4. COMPLETED	4	33	35 YEARS	65 YEARS	WRINKLES
NCT01948583	DERMING	DRUG	4. COMPLETED	4	28	N/A	N/A	MENOPAUSE
NCT01948570	DERMING		4. COMPLETED	NA	40	16 YEARS	N/A	ACNE
NCT01947608	NOVARTIS	DRUG	7. OTHER	NA	MISSING	18 YEARS	N/A	LUNG CANCER

NEW RESULTS

This table lists all industry-sponsored studies with results posted during the past week.

IDENTIFIER ¹	SPONSOR	TYPE ²	STATUS	PHASE ³	SIZE (N)	MIN AGE	MAX AGE	CONDITION
NCT01000376	EISAI	DRUG	4. COMPLETED	1	12	18 YEARS	N/A	CANCER
NCT01660815	AVID	DRUG	4. COMPLETED	1	7	45 YEARS	N/A	ALZHEIMER'S DISEASE
NCT00507689	GILEAD	DRUG	4. COMPLETED	2	40	18 YEARS	75 YEARS	CHRONIC HEPATITIS B
NCT00619099	EISAI	DRUG	4. COMPLETED	2	67	18 YEARS	N/A	MYELODYSPLASTIC SYNDROME
NCT01145560	ASTRAZENECA	DRUG	4. COMPLETED	2	300	N/A	N/A	SEPTIC SHOCK
NCT01163721	GILEAD	DRUG	4. COMPLETED	2	80	18 YEARS	75 YEARS	DIABETES
NCT01334918	ASTELLAS	DRUG	4. COMPLETED	2	124	45 YEARS	N/A	CORONARY ARTERY DISEASE
NCT01662882	AVID	DRUG	4. COMPLETED	2	48	50 YEARS	N/A	COGNITIVE IMPAIRMENT
NCT00799825	GSK	BIOLOGICAL	4. COMPLETED	3	346	18 YEARS	N/A	HUMAN PAPILLOMAVIRUS
NCT00838201	AMGEN	DRUG	4. COMPLETED	3	384	18 YEARS	N/A	TUMORS

¹ Identifier: The official study ID given by ClinicalTrials.gov.

² When the type field is empty, it is commonly a noninterventional study.

³ "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

New Results, from Page 7

IDENTIFIER ¹	SPONSOR	TYPE ²	STATUS	PHASE ³	SIZE (N)	MIN AGE	MAX AGE	CONDITION
NCT00856635	TEVA	DRUG	4. COMPLETED	3	44	18 YEARS	45 YEARS	OPTIC NEURITIS
NCT01210716	FENWAL	DEVICE	4. COMPLETED	3	37	18 YEARS	N/A	ONCOLOGIC DISORDERS
NCT01216943	ALLERGAN	DRUG	4. COMPLETED	3	126	18 YEARS	N/A	OCULAR HYPERTENSION
NCT01646398	PFIZER	BIOLOGICAL	4. COMPLETED	3	764	65 YEARS	N/A	PNEUMOCOCCAL VACCINE
NCT00535145	ORTHO-MCNEIL	DRUG	4. COMPLETED	4	121	18 YEARS	N/A	PSYCHOTIC DISORDERS
NCT01556451	MERCK	BIOLOGICAL	4. COMPLETED	4	180	50 YEARS	N/A	SHINGLES
NCT00739102	CORDIS	DEVICE	4. COMPLETED	NA	250	30 YEARS	N/A	FEMORAL ARTERY
NCT01142661	EISAI	DRUG	4. COMPLETED	NA	9	18 YEARS	N/A	BREAST CANCER
NCT01181778	MERCK		4. COMPLETED	NA	1,919	18 YEARS	40 YEARS	CONTRACEPTION
NCT01225926	ALCON	DEVICE	4. COMPLETED	NA	24	21 YEARS	N/A	CATARACT
NCT01540370	ALLERGAN	OTHER	4. COMPLETED	NA	102	18 YEARS	N/A	OCULAR HYPERTENSION
NCT01568008	ALLERGAN	DRUG	4. COMPLETED	NA	933	18 YEARS	N/A	OCULAR HYPERTENSION
NCT01488877	PFIZER	DRUG	7. TERMINATED	1	9	18 YEARS	65 YEARS	DIABETIC NEPHROPATHY
NCT01627002	PROTAFIN	BIOLOGICAL	7. TERMINATED	1	49	18 YEARS	65 YEARS	HEALTHY VOLUNTEERS
NCT01214174	ICON	DRUG	7. TERMINATED	2	42	40 YEARS	N/A	OCULAR INFLAMMATION
NCT01824602	BIAL PORTELA	DRUG	7. TERMINATED	2	38	18 YEARS	N/A	BIPOLAR I DISORDER
NCT01011283	EISAI	DRUG	7. TERMINATED	4	26	18 YEARS	N/A	MYELODYSPLASTIC SYNDROMES
NCT01302938	PFIZER	DRUG	7. TERMINATED	4	18	21 YEARS	N/A	OVERACTIVE BLADDER

NEW STUDY STATUS

This table lists studies that reported updates in their status in the past week such as recruiting, ongoing or completed.

IDENTIFIER ¹	SPONSOR	TYPE ²	STATUS	PHASE ³	SIZE (N)	MIN AGE	MAX AGE	CONDITION
NCT01143753	HOFFMANN-LA ROCHE	DRUG	2. RECRUITING	1	93	18 YEARS	N/A	MELANOMA, NEOPLASMS
NCT01583777	SPECTRUM	DRUG	2. RECRUITING	1	6	18 YEARS	N/A	CANCER

1 Identifier: The official study ID given by ClinicalTrials.gov.

2 When the type field is empty, it is commonly a noninterventional study.

3 "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

New Study Status, from Page 8

IDENTIFIER ¹	SPONSOR	TYPE ²	STATUS	PHASE ³	SIZE (N)	MIN AGE	MAX AGE	CONDITION
NCT01671904	GENENTECH	DRUG	2. RECRUITING	1	70	18 YEARS	N/A	LYMPHOCYTIC LEUKEMIA, CHRONIC
NCT01680991	HOFFMANN-LA ROCHE	DRUG	2. RECRUITING	1	45	18 YEARS	N/A	LYMPHOMA, LEUKEMIA
NCT01691807	GSK	DRUG	2. RECRUITING	1	70	18 YEARS	N/A	CANCER
NCT01810315	CONRAD	DRUG	2. RECRUITING	1	40	21 YEARS	89 YEARS	HIV
NCT01830010	NOVARTIS	DRUG	2. RECRUITING	1	10	18 YEARS	65 YEARS	HEMATOLOGICAL MALIGNANCIES
NCT01841463	PIRAMAL	DRUG	2. RECRUITING	1	100	18 YEARS	N/A	MELANOMA
NCT01854944	OTSUKA	DRUG	2. RECRUITING	1	12	18 YEARS	45 YEARS	SCHIZOPHRENIA
NCT01857193	NOVARTIS	DRUG	2. RECRUITING	1	185	18 YEARS	N/A	BREAST CANCER
NCT01925638	BAYER	DRUG	2. RECRUITING	1	30	18 YEARS	45 YEARS	DRUG INTERACTIONS
NCT01938846	BOEHRINGER INGELHEIM	DRUG	2. RECRUITING	1	90	18 YEARS	N/A	NEOPLASMS
NCT01943084	NOVO NORDISK	DRUG	2. RECRUITING	1	30	18 YEARS	40 YEARS	HEALTHY
NCT01482390	HOFFMANN-LA ROCHE	DRUG	2. RECRUITING	2	120	18 YEARS	N/A	HEPATITIS C, CHRONIC
NCT01640158	POSIT	BEHAVIORAL	2. RECRUITING	2	132	18 YEARS	40 YEARS	BRAIN INJURY
NCT01717326	MERCK	DRUG	2. RECRUITING	2	450	18 YEARS	N/A	HEPATITIS C
NCT01757691	NOVARTIS	DRUG	2. RECRUITING	2	126	18 YEARS	50 YEARS	OPTIC NEURITIS
NCT01821118	PFIZER	BIOLOGICAL	2. RECRUITING	2	36	55 YEARS	80 YEARS	CEREBRAL ANGIOPATHY
NCT01843062	ASTRAZENECA	DRUG	2. RECRUITING	2	228	18 YEARS	N/A	THYROID CANCER
NCT01844765	NOVARTIS	DRUG	2. RECRUITING	2	70	1 YEAR	18 YEARS	PROTEIN KINASE INHIBITOR
NCT01885195	NOVARTIS	DRUG	2. RECRUITING	2	70	18 YEARS	N/A	MALIGNANCIES
NCT01886378	ULTRAGENYX	DRUG	2. RECRUITING	2	20	6 YEARS	25 YEARS	LCHAD DEFICIENCY
NCT01891305	VIAMET	DRUG	2. RECRUITING	2	48	18 YEARS	65 YEARS	TINEA PEDIS
NCT01903265	TONIX	DRUG	2. RECRUITING	2	120	18 YEARS	65 YEARS	PRIMARY FIBROMYALGIA
NCT01923753	ACTEGY	DEVICE	2. RECRUITING	2	43	16 YEARS	N/A	CYSTIC FIBROSIS
NCT01930461	STALLERGENES	BIOLOGICAL	2. RECRUITING	2	480	18 YEARS	50 YEARS	MITE ALLERGY

1 Identifier: The official study ID given by ClinicalTrials.gov.

2 When the type field is empty, it is commonly a noninterventional study.

3 "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

New Study Status, from Page 9

IDENTIFIER ¹	SPONSOR	TYPE ²	STATUS	PHASE ³	SIZE (N)	MIN AGE	MAX AGE	CONDITION
NCT01941836	ESPERION	DRUG	2. RECRUITING	2	322	18 YEARS	80 YEARS	HYPERCHOLESTEROLEMIA
NCT01560637	UNITED THERAPEUTICS	DRUG	2. RECRUITING	3	858	18 YEARS	75 YEARS	PULMONARY HYPERTENSION
NCT01623310	OPTINOSE	DRUG	2. RECRUITING	3	200	18 YEARS	N/A	CHRONIC SINUSITIS
NCT01623323	OPTINOSE	DRUG	2. RECRUITING	3	700	18 YEARS	N/A	CHRONIC SINUSITIS
NCT01846611	JANSSEN	DRUG	2. RECRUITING	3	670	18 YEARS	N/A	FALLOPIAN TUBE NEOPLASMS
NCT01908426	EXELIXIS	DRUG	2. RECRUITING	3	760	18 YEARS	N/A	HEPATOCELLULAR CARCINOMA
NCT01922102	NOVARTIS	DRUG	2. RECRUITING	3	475	18 YEARS	N/A	VISUAL IMPAIRMENT
NCT01429792	HOFFMANN-LA ROCHE	DRUG	2. RECRUITING	4	200	18 YEARS	N/A	HEPATITIS C, CHRONIC
NCT01862263	NOVARTIS	DRUG	2. RECRUITING	4	238	18 YEARS	80 YEARS	DIABETES
NCT01917110	COOPERVISION	DEVICE	2. RECRUITING	4	78	8 YEARS	12 YEARS	MYOPIA
NCT01065103	INTERVENTIONAL CARDIOLOGY	PROCEDURE	2. RECRUITING	NA	70	19 YEARS	N/A	MYOCARDIAL INFARCTION
NCT01755754	PARTNERSHIP FOR MICROBICIDES	DRUG	2. RECRUITING	NA	160	18 YEARS	45 YEARS	CONDOM FUNCTIONALITY
NCT01869738	INSPIREMD	DEVICE	2. RECRUITING	NA	1,114	18 YEARS	N/A	MYOCARDIAL INFARCTION
NCT01899040	SCION	DEVICE	2. RECRUITING	NA	76	18 YEARS	65 YEARS	MIGRAINE
NCT01901289	COOK	DEVICE	2. RECRUITING	NA	200	18 YEARS	N/A	PERIPHERAL ARTERIAL DISEASE
NCT01902472	GILEAD		2. RECRUITING	NA	150	18 YEARS	N/A	HIV
NCT01906255	GILEAD		2. RECRUITING	NA	7,000	18 YEARS	N/A	HIV
NCT01916278	Q-MED	DEVICE	2. RECRUITING	NA	MISSING	18 YEARS	65 YEARS	LIP FILLER INJECTIONS
NCT01943500	VIATAR		2. RECRUITING	NA	55	18 YEARS	N/A	COLORECTAL CANCER
NCT01094288	MILLENNIUM	DRUG	3. ONGOING	1	40	18 YEARS	N/A	ADENOCARCINOMA PROSTATE
NCT01324830	BOEHRINGER INGELHEIM	DRUG	3. ONGOING	1	140	18 YEARS	N/A	NEOPLASMS
NCT01390337	AMBIT	DRUG	3. ONGOING	1	58	18 YEARS	60 YEARS	LEUKEMIA, MYELOID, ACUTE
NCT01468467	AMBIT	DRUG	3. ONGOING	1	30	18 YEARS	N/A	LEUKEMIA, MYELOID, ACUTE
NCT01530022	UCB	DRUG	3. ONGOING	1	50	18 YEARS	55 YEARS	HEALTHY

1 Identifier: The official study ID given by ClinicalTrials.gov.

2 When the type field is empty, it is commonly a noninterventional study.

3 "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

(Return to Page 1)

(See New Study Status, Page 11)

New Study Status, from Page 10

IDENTIFIER ¹	SPONSOR	TYPE ²	STATUS	PHASE ³	SIZE (N)	MIN AGE	MAX AGE	CONDITION
NCT01560377	NOVADAQ	DEVICE	3. ONGOING	1	150	18 YEARS	N/A	DIVERTICULITIS
NCT01596647	NOVARTIS	DRUG	3. ONGOING	1	38	18 YEARS	N/A	SOLID TUMORS
NCT01673178	PFIZER	OTHER	3. ONGOING	1	100	30 YEARS	70 YEARS	DIABETES
NCT01703286	BOEHRINGER INGELHEIM	DRUG	3. ONGOING	1	42	18 YEARS	65 YEARS	DIABETES
NCT01768663	VERTEX	DRUG	3. ONGOING	1	78	18 YEARS	55 YEARS	CYSTIC FIBROSIS
NCT01769417	MEDIMMUNE	DRUG	3. ONGOING	1	33	18 YEARS	65 YEARS	STAPHYLOCOCCUS AUREUS
NCT01780246	ISIS	DRUG	3. ONGOING	1	28	2 YEARS	15 YEARS	SPINAL MUSCULAR ATROPHY
NCT01815827	HOFFMANN-LA ROCHE	DRUG	3. ONGOING	1	62	18 YEARS	55 YEARS	HEALTHY
NCT01847391	GILEAD	DRUG	3. ONGOING	1	36	18 YEARS	65 YEARS	ISCHEMIC HEART DISEASE
NCT01855945	NOVARTIS	BIOLOGICAL	3. ONGOING	1	600	3 YEARS	65 YEARS	INFLUENZA
NCT00494234	ASTRAZENECA	DRUG	3. ONGOING	2	54	18 YEARS	N/A	BREAST CANCER
NCT00494442	ASTRAZENECA	DRUG	3. ONGOING	2	57	18 YEARS	N/A	OVARIAN NEOPLASM
NCT01069809	ARGOS	BIOLOGICAL	3. ONGOING	2	42	18 YEARS	60 YEARS	HIV
NCT01201265	HOFFMANN-LA ROCHE	DRUG	3. ONGOING	2	41	18 YEARS	N/A	BREAST CANCER
NCT01304524	INOVIO	BIOLOGICAL	3. ONGOING	2	148	18 YEARS	55 YEARS	CERVICAL NEOPLASIA
NCT01496742	GENENTECH	DRUG	3. ONGOING	2	259	18 YEARS	N/A	LUNG CANCER
NCT01602120	GENENTECH	DRUG	3. ONGOING	2	90	60 YEARS	89 YEARS	GEOGRAPHIC ATROPHY
NCT01649297	BOEHRINGER INGELHEIM	DRUG	3. ONGOING	2	983	18 YEARS	N/A	DIABETES
NCT01732198	NURON	BIOLOGICAL	3. ONGOING	2	220	12 MONTHS	15 MONTHS	INFECTIOUS DISEASE
NCT01885104	MERCK	DRUG	3. ONGOING	2	72	18 YEARS	75 YEARS	CONSTIPATION
NCT01934036	CATALYSIS	DIETARY SUP.	3. ONGOING	2	92	35 YEARS	60 YEARS	OVERWEIGHT
NCT00585312	PFIZER	DRUG	3. ONGOING	3	200	10 YEARS	17 YEARS	ADENOMATOUS POLYPOSIS COLI
NCT01072981	NEWLINK GENETICS	BIOLOGICAL	3. ONGOING	3	722	18 YEARS	N/A	PANCREATIC CANCER
NCT01154140	PFIZER	DRUG	3. ONGOING	3	334	18 YEARS	N/A	LUNG CANCER

1 Identifier: The official study ID given by ClinicalTrials.gov.

2 When the type field is empty, it is commonly a noninterventional study.

3 "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

New Study Status, from Page 11

IDENTIFIER ¹	SPONSOR	TYPE ²	STATUS	PHASE ³	SIZE (N)	MIN AGE	MAX AGE	CONDITION
NCT01222884	PHARMACOS-MOS	DRUG	3. ONGOING	3	352	18 YEARS	N/A	CHRONIC KIDNEY DISEASE
NCT01364012	HOFFMANN-LA ROCHE	DRUG	3. ONGOING	3	276	18 YEARS	N/A	LUNG CANCER
NCT01396421	OTSUKA	DRUG	3. ONGOING	3	630	18 YEARS	65 YEARS	SCHIZOPHRENIA
NCT01445678	CUBIST	DRUG	3. ONGOING	3	500	18 YEARS	N/A	INTRA-ABDOMINAL INFECTION
NCT01455194	TAKEDA	DRUG	3. ONGOING	3	450	12 YEARS	70 YEARS	BRONCHIAL ASTHMA
NCT01464905	NURON	BIOLOGICAL	3. ONGOING	3	500	18 YEARS	60 YEARS	MULTIPLE SCLEROSIS
NCT01480245	GSK	DRUG	3. ONGOING	3	220	5 YEARS	N/A	MUSCULAR DYSTROPHIES
NCT01480713	IRSIKAIXA	DRUG	3. ONGOING	3	41	18 YEARS	65 YEARS	HIV
NCT01665430	HOFFMANN-LA ROCHE	DRUG	3. ONGOING	3	38	18 YEARS	N/A	RHEUMATOID ARTHRITIS
NCT01678820	MERCK	DRUG	3. ONGOING	3	750	18 YEARS	79 YEARS	DIABETES
NCT01854528	ABBVIE	DRUG	3. ONGOING	3	150	18 YEARS	65 YEARS	CHRONIC HEPATITIS C
NCT01375465	EUROCOR	DEVICE	3. ONGOING	4	50	18 YEARS	N/A	CORONARY ARTERY
NCT01453374	ALKERMES	DRUG	3. ONGOING	4	30	18 YEARS	N/A	OPIOID DEPENDENCE
NCT00209274	EVALVE	DEVICE	3. ONGOING	NA	1,317	18 YEARS	N/A	MITRAL INSUFFICIENCY
NCT00949676	MEDTRONIC		3. ONGOING	NA	60	18 YEARS	N/A	SYSTOLIC HEART FAILURE
NCT01415154	NEURONETICS	DEVICE	3. ONGOING	NA	50	18 YEARS	70 YEARS	DEPRESSIVE DISORDER
NCT01444456	AMGEN		3. ONGOING	NA	1,264	18 YEARS	N/A	GASTRIC CANCER
NCT01534650	GREAT LAKES		3. ONGOING	NA	100	18 YEARS	N/A	ESSENTIAL TREMOR
NCT01556711	BRAINSCOPE		3. ONGOING	NA	750	18 YEARS	80 YEARS	CRANIOCEREBRAL TRAUMA
NCT01585142	NESTLE	OTHER	3. ONGOING	NA	80	N/A	14 DAYS	DIETARY MODIFICATION
NCT01604122	PFIZER	OTHER	3. ONGOING	NA	500	18 YEARS	85 YEARS	AMYLOIDOSIS
NCT01613287	MILTENYI	DEVICE	3. ONGOING	NA	12	18 YEARS	80 YEARS	PULMONARY HYPERTENSION
NCT01635049	AUXOGYN		3. ONGOING	NA	100	N/A	43 YEARS	INFERTILITY
NCT01690533	BAYER	DRUG	3. ONGOING	NA	497	20 YEARS	N/A	ANTI-INFECTIVE AGENTS

¹ Identifier: The official study ID given by ClinicalTrials.gov.

² When the type field is empty, it is commonly a noninterventional study.

³ "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

New Study Status, from Page 12

IDENTIFIER ¹	SPONSOR	TYPE ²	STATUS	PHASE ³	SIZE (N)	MIN AGE	MAX AGE	CONDITION
NCT01699529	MEDTRONIC	DEVICE	3. ONGOING	NA	50	18 YEARS	80 YEARS	HYPERTENSION
NCT00315731	GSK	BIOLOGICAL	4. COMPLETED	1	15	18 YEARS	N/A	LYMPHOMA, FOLLICULAR
NCT00316940	ONCOTHERAPEUTICS	DRUG	4. COMPLETED	1	36	18 YEARS	N/A	MYELOMA AND PLASMA CELL
NCT00596648	EXELIXIS	DRUG	4. COMPLETED	1	92	18 YEARS	N/A	CARCINOMA, LUNG
NCT00642954	MERCK	DRUG	4. COMPLETED	1	28	18 YEARS	N/A	MYELOMA
NCT00823355	MUNDIPHARMA	DRUG	4. COMPLETED	1	24	20 YEARS	N/A	T/NK-CELL MALIGNANCIES
NCT01100619	EXELIXIS	DRUG	4. COMPLETED	1	40	18 YEARS	N/A	RENAL CELL CARCINOMA
NCT01405963	AMGEN	DRUG	4. COMPLETED	1	31	18 YEARS	60 YEARS	ASTHMA
NCT01763333	BOEHRINGER INGELHEIM	DRUG	4. COMPLETED	1	80	18 YEARS	50 YEARS	HEALTHY
NCT01789788	HOFFMANN-LA ROCHE	DRUG	4. COMPLETED	1	56	18 YEARS	65 YEARS	DIABETES
NCT01803373	JANSSEN	DRUG	4. COMPLETED	1	36	18 YEARS	55 YEARS	BIOLOGICAL AVAILABILITY
NCT01866033	JANSSEN	DRUG	4. COMPLETED	1	8	18 YEARS	55 YEARS	HEALTHY
NCT01873339	GSK	DRUG	4. COMPLETED	1	26	18 YEARS	65 YEARS	ATHEROSCLEROSIS
NCT01887626	ASTRAZENECA	DRUG	4. COMPLETED	1	36	18 YEARS	50 YEARS	HEALTHY
NCT01897493	ELI LILLY	DRUG	4. COMPLETED	1	20	18 YEARS	65 YEARS	HEALTHY
NCT01911637	VIROBAY	DRUG	4. COMPLETED	1	48	18 YEARS	60 YEARS	HEALTHY
NCT01919385	ANIMAS	DEVICE	4. COMPLETED	1	12	21 YEARS	65 YEARS	DIABETES
NCT00269152	ELI LILLY	DRUG	4. COMPLETED	2	122	18 YEARS	N/A	LUNG CANCER
NCT01035502	CLAVIS	DRUG	4. COMPLETED	2	51	18 YEARS	N/A	LEUKEMIA
NCT01038804	ASTELLAS	DRUG	4. COMPLETED	2	101	18 YEARS	N/A	BREAST CANCER
NCT01145560	ASTRAZENECA	DRUG	4. COMPLETED	2	300	N/A	N/A	SEPTIC SHOCK
NCT01435226	GILEAD	DRUG	4. COMPLETED	2	170	18 YEARS	N/A	HEPATITIS C, CHRONIC
NCT01592786	FOREST	DRUG	4. COMPLETED	2	906	6 YEARS	12 YEARS	PERVASIVE DISORDER
NCT01644617	MERCK	DRUG	4. COMPLETED	2	124	18 YEARS	N/A	RHINITIS, ALLERGIC

1 Identifier: The official study ID given by ClinicalTrials.gov.

2 When the type field is empty, it is commonly a noninterventional study.

3 "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

(Return to Page 1)

(See New Study Status, Page 14)

New Study Status, from Page 13

IDENTIFIER ¹	SPONSOR	TYPE ²	STATUS	PHASE ³	SIZE (N)	MIN AGE	MAX AGE	CONDITION
NCT01768975	OLATEC	DRUG	4. COMPLETED	2	79	35 YEARS	80 YEARS	OSTEOARTHRITIS
NCT00104611	NEURONETICS	DEVICE	4. COMPLETED	3	286	18 YEARS	70 YEARS	DEPRESSIVE DISORDER
NCT01120340	SOFAR	DRUG	4. COMPLETED	3	105	18 YEARS	N/A	DIVERTICULAR DISEASE
NCT01147939	CLAVIS	DRUG	4. COMPLETED	3	381	18 YEARS	N/A	LEUKEMIA
NCT01244815	MERCK	DRUG	4. COMPLETED	3	404	10 YEARS	17 YEARS	BIPOLAR DISORDER, PEDIATRIC
NCT01277666	GSK	DRUG	4. COMPLETED	3	608	18 YEARS	N/A	CROHN'S DISEASE
NCT01422876	BOEHRINGER INGELHEIM	DRUG	4. COMPLETED	3	1,406	18 YEARS	N/A	DIABETES
NCT01431274	BOEHRINGER INGELHEIM	DRUG	4. COMPLETED	3	2,624	40 YEARS	N/A	COPD
NCT01445665	CUBIST	DRUG	4. COMPLETED	3	500	18 YEARS	N/A	INTRA-ABDOMINAL INFECTION
NCT01510912	IROKO	DRUG	4. COMPLETED	3	600	40 YEARS	N/A	OSTEOARTHRITIS
NCT01667471	HOFFMANN-LA ROCHE	DRUG	4. COMPLETED	3	6	9 YEARS	18 YEARS	JUVENILE IDIOPATHIC ARTHRITIS
NCT01691846	HOFFMANN-LA ROCHE	DRUG	4. COMPLETED	3	200	18 YEARS	N/A	DIABETES
NCT01718483	SHIRE	DRUG	4. COMPLETED	3	383	18 YEARS	55 YEARS	BINGE EATING DISORDER
NCT01718509	SHIRE	DRUG	4. COMPLETED	3	390	18 YEARS	55 YEARS	BINGE EATING DISORDER
NCT01727700	OTSUKA	DRUG	4. COMPLETED	3	133	7 YEARS	17 YEARS	TIC DISORDER
NCT01735175	SANDOZ	DRUG	4. COMPLETED	3	318	18 YEARS	N/A	BREAST CANCER
NCT01871428	HOFFMANN-LA ROCHE	DRUG	4. COMPLETED	3	13	18 YEARS	N/A	DIABETES
NCT01880697	NOVARTIS	BIOLOGICAL	4. COMPLETED	3	126	18 YEARS	N/A	INFLUENZA
NCT01885117	NOVARTIS	BIOLOGICAL	4. COMPLETED	3	125	18 YEARS	N/A	INFLUENZA
NCT01370356	PFIZER	DRUG	4. COMPLETED	4	1,494	18 YEARS	N/A	SMOKING CESSATION
NCT01586338	SANOFI	DRUG	4. COMPLETED	4	237	30 YEARS	N/A	OSTEOARTHRITIS
NCT01607398	GSK	DRUG	4. COMPLETED	4	56	40 YEARS	N/A	COPD
NCT00739102	CORDIS	DEVICE	4. COMPLETED	NA	250	30 YEARS	N/A	FEMORAL ARTERY DISEASE

¹ Identifier: The official study ID given by ClinicalTrials.gov.

² When the type field is empty, it is commonly a noninterventional study.

³ "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an intervention device trial.

(Return to Page 1)

(See New Study Status, Page 15)

New Study Status, from Page 14

IDENTIFIER ¹	SPONSOR	TYPE ²	STATUS	PHASE ³	SIZE (N)	MIN AGE	MAX AGE	CONDITION
NCT00795873	ELA		4. COMPLETED	NA	2,260	18 YEARS	N/A	HEART FAILURE
NCT01087957	INNOVATIVE NEURO.	DEVICE	4. COMPLETED	NA	496	18 YEARS	N/A	STROKE
NCT01174459	BOEHRINGER INGELHEIM		4. COMPLETED	NA	571	15 YEARS	N/A	RESTLESS LEGS SYNDROME
NCT01577147	SPD	OTHER	4. COMPLETED	NA	600	18 YEARS	45 YEARS	PREGNANCY
NCT01614496	PARC TAULI	OTHER	4. COMPLETED	NA	MISS-ING	18 YEARS	65 YEARS	DIABETES
NCT01697462	HOFFMANN-LA ROCHE		4. COMPLETED	NA	261	18 YEARS	N/A	COLORECTAL CANCER
NCT01779895	NESTLE	DIETARY SUP.	4. COMPLETED	NA	64	20 YEARS	65 YEARS	RHINITIS, ALLERGIC
NCT01790256	CEREVE	DEVICE	4. COMPLETED	NA	144	22 YEARS	N/A	PRIMARY INSOMNIA
NCT01803022	LEO		4. COMPLETED	NA	419	18 YEARS	N/A	VENOUS THROMBOEMBOLISM

STUDIES OPENING A FIRST SITE IN A NEW COUNTRY

This table lists studies that launched a site in a country for the first time in the past week.

IDENTIFIER ¹	COUNTRY	SPONSOR	TYPE ²	STATUS	PHASE ³	SIZE (N)	MIN AGE	MAX AGE	CONDITION
NCT01885208	ARGENTINA	NOVO NORDISK	DRUG	1. PLANNING	3	798	18 YEARS	N/A	DIABETES
NCT01930188	ARGENTINA	NOVO NORDISK	DRUG	1. PLANNING	3	1,200	18 YEARS	N/A	DIABETES
NCT01945788	ARGENTINA	BIO SIDUS	DRUG	2. RECRUITING	4	110	50 YEARS	81 YEARS	OSTEOPOROSIS
NCT01928459	AUSTRALIA	NOVARTIS	DRUG	1. PLANNING	1	55	18 YEARS	N/A	SOLID TUMORS
NCT01949324	AUSTRALIA	NEUROTECH	BIOLOGICAL	1. PLANNING	2	68	21 YEARS	80 YEARS	MACULAR TEL-ANGIECTASIA
NCT01949311	AUSTRALIA	REGENERON	DRUG	1. PLANNING	3	800	18 YEARS	N/A	ATOPIC DERMATITIS
NCT01857193	AUSTRALIA	NOVARTIS	DRUG	2. RECRUITING	1	185	18 YEARS	N/A	BREAST CANCER
NCT01928459	BELGIUM	NOVARTIS	DRUG	1. PLANNING	1	55	18 YEARS	N/A	SOLID TUMORS
NCT01948219	BELGIUM	PROTIP	DEVICE	1. PLANNING	2	15	18 YEARS	N/A	TOTAL LARYNGECTOMY
NCT01945762	BELGIUM	ASTRAZENECA	DRUG	1. PLANNING	NA	80	18 YEARS	N/A	THYROID CANCER
NCT01857193	BELGIUM	NOVARTIS	DRUG	2. RECRUITING	1	185	18 YEARS	N/A	BREAST CANCER
NCT01480479	BELGIUM	CELLEX	DRUG	2. RECRUITING	3	440	18 YEARS	N/A	GLIOMA
NCT01708174	BELGIUM	NOVARTIS	DRUG	2. RECRUITING	3	109	N/A	N/A	MEDULLOBLASTOMA

¹ Identifier: The official study ID given by ClinicalTrials.gov.

² When the type field is empty, it is commonly a noninterventional study.

³ "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

(Return to Page 1)

(See **Studies Opening a First Site in a New Country**, Page 16)

Studies Opening a First Site in a New Country, *from Page 15*

IDENTIFIER ¹	COUNTRY	SPONSOR	TYPE ²	STATUS	PHASE ³	SIZE (N)	MIN AGE	MAX AGE	CONDITION
NCT01839526	BELGIUM	GENZYME	DRUG	2. RECRUITING	NA	100	5 YEARS	25 YEARS	FABRY DISEASE
NCT01869738	BELGIUM	INSPIREMD	DEVICE	2. RECRUITING	NA	1,114	18 YEARS	N/A	MYOCARDIAL INFARCTION
NCT01911897	BELGIUM	VASCULAR DYNAMICS	DEVICE	2. RECRUITING	NA	20	18 YEARS	80 YEARS	HYPERTENSION
NCT01948817	BRAZIL	NOVARTIS	DRUG	1. PLANNING	2	45	2 YEARS	N/A	TRANSFUSION DEPENDENT
NCT01489111	BULGARIA	NOVO NORDISK	DRUG	2. RECRUITING	3	18	12 YEARS	N/A	HAEMOPHILIA A
NCT01928459	CANADA	NOVARTIS	DRUG	1. PLANNING	1	55	18 YEARS	N/A	SOLID TUMORS
NCT01947933	CANADA	ELI LILLY	BIOLOGICAL	1. PLANNING	1	40	18 YEARS	N/A	PSORIASIS
NCT01907100	CANADA	BOEHRINGER INGELHEIM	DRUG	1. PLANNING	2	86	18 YEARS	N/A	MESOTHELIOMA
NCT01949441	CANADA	CIRCASSIA	BIOLOGICAL	1. PLANNING	2	40	18 YEARS	65 YEARS	RHINOCONJUNCTIVITIS
NCT01949311	CANADA	REGENERON	DRUG	1. PLANNING	3	800	18 YEARS	N/A	ATOPIC DERMATITIS
NCT01949415	CANADA	CIRCASSIA		1. PLANNING	NA	105	16 YEARS	65 YEARS	RHINOCONJUNCTIVITIS
NCT01949428	CANADA	CIRCASSIA		1. PLANNING	NA	100	18 YEARS	65 YEARS	RHINOCONJUNCTIVITIS
NCT01831427	CANADA	GILEAD	DRUG	2. RECRUITING	1	74	18 YEARS	65 YEARS	ULCERATIVE COLITIS
NCT01786668	CANADA	PFIZER	DRUG	2. RECRUITING	2	200	18 YEARS	N/A	ANKYLOSING SPONDYLITIS
NCT01843374	CANADA	MEDIMMUNE	DRUG	2. RECRUITING	2	180	18 YEARS	N/A	MESOTHELIOMA
NCT01828112	CANADA	NOVARTIS	DRUG	2. RECRUITING	3	236	18 YEARS	N/A	LUNG CANCER
NCT01841684	CANADA	MERCK	DRUG	2. RECRUITING	3	45	18 YEARS	N/A	HYPERCHOLESTEROLEMIA
NCT01697358	CANADA	MEDTRONIC	DEVICE	2. RECRUITING	4	300	18 YEARS	N/A	PAIN IN LEG, UNSPECIFIED
NCT01897532	CANADA	BOEHRINGER INGELHEIM	DRUG	2. RECRUITING	4	8,300	18 YEARS	N/A	DIABETES
NCT01656395	CHILE	MERCK	DRUG	2. RECRUITING	2	1,475	18 YEARS	65 YEARS	ASTHMA
NCT01945021	CHINA	OXONC	DRUG	1. PLANNING	2	110	18 YEARS	N/A	CRIZOTINIB
NCT01947309	CHINA	CELGENE	DRUG	1. PLANNING	NA	600	18 YEARS	N/A	MULTIPLE MYELOMA
NCT01947829	CHINA	B.BRAUN AVITUM		1. PLANNING	NA	120	18 YEARS	N/A	KIDNEY DISEASE
NCT01944774	CHINA	TAIGEN	DRUG	2. RECRUITING	2	210	18 YEARS	75 YEARS	PNEUMONIA

1 Identifier: The official study ID given by ClinicalTrials.gov.

2 When the type field is empty, it is commonly a noninterventional study.

3 "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

Studies Opening a First Site in a New Country, from Page 16

IDENTIFIER ¹	COUNTRY	SPONSOR	TYPE ²	STATUS	PHASE ³	SIZE (N)	MIN AGE	MAX AGE	CONDITION
NCT01656395	COLOMBIA	MERCK	DRUG	2. RECRUITING	2	1,475	18 YEARS	65 YEARS	ASTHMA
NCT01201356	COSTA RICA	NOVARTIS	DRUG	2. RECRUITING	3	5,000	18 YEARS	N/A	MULTIPLE SCLEROSIS
NCT01949311	CZECH REP	REGENERON	DRUG	1. PLANNING	3	800	18 YEARS	N/A	ATOPIC DERMATITIS
NCT01762852	CZECH REP	GSK	DRUG	2. RECRUITING	2	94	18 YEARS	75 YEARS	GLOMERULO-NEPHRITIS
NCT01767467	CZECH REP	GSK	BIOLOGICAL	2. RECRUITING	3	502	18 YEARS	N/A	HERPES ZOSTER
NCT01574703	DENMARK	PFIZER	DRUG	2. RECRUITING	4	8,000	18 YEARS	75 YEARS	SMOKING CESSATION
NCT01703208	FINLAND	MERCK	DRUG	2. RECRUITING	3	4,000	40 YEARS	N/A	DIABETES
NCT01928459	FRANCE	NOVARTIS	DRUG	1. PLANNING	1	55	18 YEARS	N/A	SOLID TUMORS
NCT01948011	FRANCE	BIOPROJET	DRUG	1. PLANNING	1	52	18 YEARS	45 YEARS	HEALTHY
NCT01949311	FRANCE	REGENERON	DRUG	1. PLANNING	3	800	18 YEARS	N/A	ATOPIC DERMATITIS
NCT01945762	FRANCE	ASTRAZENECA	DRUG	1. PLANNING	NA	80	18 YEARS	N/A	THYROID CANCER
NCT01946386	FRANCE	LEO	DRUG	2. RECRUITING	1	35	18 YEARS	50 YEARS	PSORIASIS VULGARIS
NCT01946867	FRANCE	NANOBIOTIX	DEVICE	2. RECRUITING	1	48	65 YEARS	N/A	HEAD AND NECK CANCER
NCT01717326	FRANCE	MERCK	DRUG	2. RECRUITING	2	450	18 YEARS	N/A	HEPATITIS C
NCT01946841	FRANCE	LACTALIS	DIETARY SUP.	2. RECRUITING	2	20	18 YEARS	N/A	NUTRITIONAL DISORDERS
NCT01479244	FRANCE	GALENA	BIOLOGICAL	2. RECRUITING	3	700	18 YEARS	N/A	BREAST CANCER
NCT01566695	FRANCE	CELGENE	DRUG	2. RECRUITING	3	386	18 YEARS	N/A	LEUKEMIA
NCT01928459	GERMANY	NOVARTIS	DRUG	1. PLANNING	1	55	18 YEARS	N/A	SOLID TUMORS
NCT01840410	GERMANY	NOVARTIS	DRUG	1. PLANNING	3	187	12 YEARS	N/A	MACULAR DEGENERATION
NCT01895777	GERMANY	BOEHRINGER INGELHEIM	DRUG	1. PLANNING	3	270	N/A	17 YEARS	THROMBOEMBOLISM
NCT01946711	GERMANY	PARI PHARMA	DRUG	1. PLANNING	3	20	18 YEARS	N/A	CHRONIC POLYPOSIS
NCT01949311	GERMANY	REGENERON	DRUG	1. PLANNING	3	800	18 YEARS	N/A	ATOPIC DERMATITIS
NCT01945762	GERMANY	ASTRAZENECA	DRUG	1. PLANNING	NA	80	18 YEARS	N/A	THYROID CANCER
NCT01949220	GERMANY	FRANCAIS		1. PLANNING	NA	80	N/A	N/A	VON WILLEBRAND DISEASE

1 Identifier: The official study ID given by ClinicalTrials.gov.

2 When the type field is empty, it is commonly a noninterventional study.

3 "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

(Return to Page 1)

(See **Studies Opening a First Site in a New Country**, Page 18)

Studies Opening a First Site in a New Country, *from Page 17*

IDENTIFIER ¹	COUNTRY	SPONSOR	TYPE ²	STATUS	PHASE ³	SIZE (N)	MIN AGE	MAX AGE	CONDITION
NCT01857193	GERMANY	NOVARTIS	DRUG	2. RECRUITING	1	185	18 YEARS	N/A	BREAST CANCER
NCT01947907	GERMANY	ASCENDIS	DRUG	2. RECRUITING	2	52	3 YEARS	12 YEARS	GROWTH HORMONE DEFICIENCY
NCT01479244	GERMANY	GALENA	BIOLOGICAL	2. RECRUITING	3	700	18 YEARS	N/A	BREAST CANCER
NCT01947959	GERMANY	BAYER	DRUG	2. RECRUITING	NA	20,000	2 YEARS	89 YEARS	PULMONARY EMBOLISM
NCT01840410	GREECE	NOVARTIS	DRUG	1. PLANNING	3	187	12 YEARS	N/A	MACULAR DEGENERATION
NCT01628393	GREECE	RECEPTOS	DRUG	2. RECRUITING	2	210	18 YEARS	55 YEARS	MULTIPLE SCLEROSIS
NCT01930188	HONG KONG	NOVO NORDISK	DRUG	1. PLANNING	3	1,200	18 YEARS	N/A	DIABETES
NCT01857193	HONG KONG	NOVARTIS	DRUG	2. RECRUITING	1	185	18 YEARS	N/A	BREAST CANCER
NCT01949311	HUNGARY	REGENERON	DRUG	1. PLANNING	3	800	18 YEARS	N/A	ATOPIC DERMATITIS
NCT01628393	HUNGARY	RECEPTOS	DRUG	2. RECRUITING	2	210	18 YEARS	55 YEARS	MULTIPLE SCLEROSIS
NCT01947907	HUNGARY	ASCENDIS	DRUG	2. RECRUITING	2	52	3 YEARS	12 YEARS	GROWTH HORMONE DEFICIENCY
NCT01948193	INDIA	SANOFI	BIOLOGICAL	1. PLANNING	3	177	6 WEEKS	8 WEEKS	HIB INFECTIONS
NCT01393626	INDIA	PFIZER	DRUG	2. RECRUITING	2	275	18 YEARS	75 YEARS	CROHN'S DISEASE
NCT01734785	INDIA	BOEHRINGER INGELHEIM	DRUG	2. RECRUITING	3	444	18 YEARS	N/A	DIABETES
NCT01922102	INDIA	NOVARTIS	DRUG	2. RECRUITING	3	475	18 YEARS	N/A	VISUAL IMPAIRMENT
NCT01835431	ISRAEL	NOVO NORDISK	DRUG	1. PLANNING	3	346	1 YEAR	17 YEARS	DIABETES
NCT00625378	ISRAEL	BAYER	DRUG	2. RECRUITING	3	1,000	16 YEARS	N/A	NEOPLASMS
NCT01944917	ISRAEL	AEROTEL		2. RECRUITING	NA	40	35 YEARS	75 YEARS	MUSCULO-SKELETAL PAIN
NCT01928459	ITALY	NOVARTIS	DRUG	1. PLANNING	1	55	18 YEARS	N/A	SOLID TUMORS
NCT01885208	ITALY	NOVO NORDISK	DRUG	1. PLANNING	3	798	18 YEARS	N/A	DIABETES
NCT01948856	ITALY	PIERRE FABRE	DRUG	1. PLANNING	3	1,000	3 YEARS	4 YEARS	URTI
NCT01945762	ITALY	ASTRAZENECA	DRUG	1. PLANNING	NA	80	18 YEARS	N/A	THYROID CANCER
NCT01945970	ITALY	UNILEVER	OTHER	1. PLANNING	NA	30	40 YEARS	65 YEARS	VASCULAR FUNCTION
NCT01949220	ITALY	FRANCAIS		1. PLANNING	NA	80	N/A	N/A	VON WILLEBRAND DISEASE

1 Identifier: The official study ID given by ClinicalTrials.gov.

2 When the type field is empty, it is commonly a noninterventional study.

3 "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

(Return to Page 1)

(See Studies Opening a First Site in a New Country, Page 19)

Studies Opening a First Site in a New Country, from Page 18

IDENTIFIER ¹	COUNTRY	SPONSOR	TYPE ²	STATUS	PHASE ³	SIZE (N)	MIN AGE	MAX AGE	CONDITION
NCT01665391	ITALY	GENZYME	DRUG	2. RECRUITING	2	88	18 YEARS	N/A	GLOMERULO-SCLEROSIS
NCT01671007	ITALY	BOEHRINGER INGELHEIM		2. RECRUITING	NA	18,091	18 YEARS	N/A	ATRIAL FIBRILLATION
NCT01945021	JAPAN	OXONC	DRUG	1. PLANNING	2	110	18 YEARS	N/A	CRIZOTINIB
NCT01945086	JAPAN	JANSSEN	DRUG	1. PLANNING	2	72	20 YEARS	65 YEARS	DERMATITIS, ATOPIC
NCT01947478	JAPAN	MEDTRONIC	DEVICE	1. PLANNING	2	100	20 YEARS	85 YEARS	POPLITEAL ARTERY OCCLUSION
NCT01947855	JAPAN	BOEHRINGER INGELHEIM	DRUG	1. PLANNING	3	60	20 YEARS	74 YEARS	DIABETES
NCT01949311	JAPAN	REGENERON	DRUG	1. PLANNING	3	800	18 YEARS	N/A	ATOPIC DERMATITIS
NCT01945216	JAPAN	TAKEDA	DRUG	2. RECRUITING	NA	3,000	N/A	N/A	DIABETES
NCT01947816	JAPAN	ABBVIE		2. RECRUITING	NA	1,500	N/A	N/A	ULCERATIVE COLITIS
NCT01928459	KOREA, SOUTH	NOVARTIS	DRUG	1. PLANNING	1	55	18 YEARS	N/A	SOLID TUMORS
NCT01945021	KOREA, SOUTH	OXONC	DRUG	1. PLANNING	2	110	18 YEARS	N/A	CRIZOTINIB
NCT01740336	KOREA, SOUTH	GENENTECH	DRUG	2. RECRUITING	2	180	18 YEARS	N/A	BREAST CANCER
NCT01945684	KOREA, SOUTH	DAEWOONG	DRUG	2. RECRUITING	3	MISS-ING	18 YEARS	N/A	LIMB SPASTICITY
NCT01946620	LATVIA	MUNDIPHARMA	DRUG	1. PLANNING	3	1,530	40 YEARS	N/A	COPD
NCT01948817	LEBANON	NOVARTIS	DRUG	1. PLANNING	2	45	2 YEARS	N/A	TRANSFUSION DEPENDENT
NCT01895777	LITHUANIA	BOEHRINGER INGELHEIM	DRUG	1. PLANNING	3	270	N/A	17 YEARS	THROMBOEMBOLISM
NCT01948856	LITHUANIA	PIERRE FABRE	DRUG	1. PLANNING	3	1,000	3 YEARS	4 YEARS	URTI
NCT01560624	MEXICO	UNITED THERAPEUTICS	DRUG	2. RECRUITING	3	858	18 YEARS	75 YEARS	PULMONARY HYPERTENSION
NCT01560637	MEXICO	UNITED THERAPEUTICS	DRUG	2. RECRUITING	3	858	18 YEARS	75 YEARS	PULMONARY HYPERTENSION
NCT01566695	MEXICO	CELGENE	DRUG	2. RECRUITING	3	386	18 YEARS	N/A	LEUKEMIA
NCT01682512	MEXICO	BOEHRINGER INGELHEIM	DRUG	2. RECRUITING	3	306	18 YEARS	80 YEARS	ARTHRITIS, RHEUMATOID
NCT00867815	MEXICO	BAYER	DRUG	2. RECRUITING	4	284	40 YEARS	N/A	OPTIC NEUROPATHY
NCT01574703	MEXICO	PFIZER	DRUG	2. RECRUITING	4	8,000	18 YEARS	75 YEARS	SMOKING CESSATION
NCT01946178	MEXICO	MIRABILIS	DEVICE	2. RECRUITING	NA	80	18 YEARS	55 YEARS	UTERINE FIBROIDS
NCT01945606	NETHERLANDS	BAYER	DRUG	1. PLANNING	1	10	18 YEARS	75 YEARS	HEART FAILURE

1 Identifier: The official study ID given by ClinicalTrials.gov.

2 When the type field is empty, it is commonly a noninterventional study.

3 "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

(Return to Page 1)

(See Studies Opening a First Site in a New Country, Page 20)

Studies Opening a First Site in a New Country, *from Page 19*

IDENTIFIER ¹	COUNTRY	SPONSOR	TYPE ²	STATUS	PHASE ³	SIZE (N)	MIN AGE	MAX AGE	CONDITION
NCT01945762	NETHERLANDS	ASTRAZENECA	DRUG	1. PLANNING	NA	80	18 YEARS	N/A	THYROID CANCER
NCT01905657	NETHERLANDS	MERCK	BIOLOGICAL	2. RECRUITING	2	920	18 YEARS	N/A	LUNG CANCER
NCT01598844	NETHERLANDS	JENAVALVE	DEVICE	2. RECRUITING	NA	180	N/A	N/A	AORTIC STENOSIS
NCT01947985	NETHERLANDS	BAYER	DRUG	2. RECRUITING	NA	20,000	2 YEARS	89 YEARS	PULMONARY EMBOLISM
NCT01949311	NEW ZEALAND	REGENERON	DRUG	1. PLANNING	3	800	18 YEARS	N/A	ATOPIC DERMATITIS
NCT01682512	NORWAY	BOEHRINGER INGELHEIM	DRUG	2. RECRUITING	3	306	18 YEARS	80 YEARS	ARTHRITIS, RHEUMATOID
NCT01839526	NORWAY	GENZYME	DRUG	2. RECRUITING	NA	100	5 YEARS	25 YEARS	FABRY DISEASE
NCT01949675	PHILIPPINES	SANOFI	BIOLOGICAL	1. PLANNING	4	336	1 YEAR	N/A	CHOLERA
NCT01703208	PHILIPPINES	MERCK	DRUG	2. RECRUITING	3	4,000	40 YEARS	N/A	DIABETES
NCT01949311	POLAND	REGENERON	DRUG	1. PLANNING	3	800	18 YEARS	N/A	ATOPIC DERMATITIS
NCT01751776	POLAND	BOEHRINGER INGELHEIM	DRUG	2. RECRUITING	1	121	18 YEARS	70 YEARS	HEALTHY
NCT01566695	POLAND	CELGENE	DRUG	2. RECRUITING	3	386	18 YEARS	N/A	LEUKEMIA
NCT01828099	POLAND	NOVARTIS	DRUG	2. RECRUITING	3	348	18 YEARS	N/A	LUNG CANCER
NCT01511913	POLAND	BMS		2. RECRUITING	NA	1,800	18 YEARS	N/A	MELANOMA
NCT01731600	PORTUGAL	NOVO NORDISK	DRUG	2. RECRUITING	3	60	N/A	11 YEARS	HAEMOPHILIA A
NCT01767090	ROMANIA	ASTELLAS	DRUG	2. RECRUITING	2	600	18 YEARS	45 YEARS	ENDOMETRIOSIS
NCT01682759	ROMANIA	MERCK	DRUG	2. RECRUITING	3	680	18 YEARS	N/A	DIABETES
NCT01947153	RUSSIA	BOEHRINGER INGELHEIM	DRUG	1. PLANNING	1	36	18 YEARS	45 YEARS	HEALTHY
NCT01628393	RUSSIA	RECEPTOS	DRUG	2. RECRUITING	2	210	18 YEARS	55 YEARS	MULTIPLE SCLEROSIS
NCT01947907	RUSSIA	ASCENDIS	DRUG	2. RECRUITING	2	52	3 YEARS	12 YEARS	GROWTH HORMONE DEFICIENCY
NCT01828099	RUSSIA	NOVARTIS	DRUG	2. RECRUITING	3	348	18 YEARS	N/A	LUNG CANCER
NCT01828112	RUSSIA	NOVARTIS	DRUG	2. RECRUITING	3	236	18 YEARS	N/A	LUNG CANCER
NCT01928459	SINGAPORE	NOVARTIS	DRUG	1. PLANNING	1	55	18 YEARS	N/A	SOLID TUMORS
NCT01840410	SINGAPORE	NOVARTIS	DRUG	1. PLANNING	3	187	12 YEARS	N/A	MACULAR DEGENERATION

1 Identifier: The official study ID given by ClinicalTrials.gov.

2 When the type field is empty, it is commonly a noninterventional study.

3 "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

Studies Opening a First Site in a New Country, from Page 20

IDENTIFIER ¹	COUNTRY	SPONSOR	TYPE ²	STATUS	PHASE ³	SIZE (N)	MIN AGE	MAX AGE	CONDITION
NCT01697579	SOUTH AFRICA	MERCK	DRUG	2. RECRUITING	2	256	N/A	17 YEARS	CHEMOTHERAPY NAUSEA/ VOMITING
NCT00625378	SOUTH AFRICA	BAYER	DRUG	2. RECRUITING	3	1,000	16 YEARS	N/A	NEOPLASMS
NCT01814748	SOUTH AFRICA	MERCK	DRUG	2. RECRUITING	3	200	18 YEARS	44 YEARS	DIABETES
NCT01928459	SPAIN	NOVARTIS	DRUG	1. PLANNING	1	55	18 YEARS	N/A	SOLID TUMORS
NCT01948830	SPAIN	NOVARTIS	DRUG	1. PLANNING	3	644	50 YEARS	N/A	MACULAR DEGENERATION
NCT01945762	SPAIN	ASTRAZENECA	DRUG	1. PLANNING	NA	80	18 YEARS	N/A	THYROID CANCER
NCT01295827	SPAIN	MERCK	DRUG	2. RECRUITING	1	1,067	18 YEARS	N/A	CANCER, SOLID TUMOR
NCT01562275	SPAIN	GENENTECH	DRUG	2. RECRUITING	1	108	18 YEARS	N/A	NEOPLASMS
NCT01857193	SPAIN	NOVARTIS	DRUG	2. RECRUITING	1	185	18 YEARS	N/A	BREAST CANCER
NCT01628393	SPAIN	RECEPTOS	DRUG	2. RECRUITING	2	210	18 YEARS	55 YEARS	MULTIPLE SCLEROSIS
NCT01917110	SPAIN	COOPERVISION	DEVICE	2. RECRUITING	4	78	8 YEARS	12 YEARS	MYOPIA
NCT01839526	SPAIN	GENZYME	DRUG	2. RECRUITING	NA	100	5 YEARS	25 YEARS	FABRY DISEASE
NCT01791361	SWEDEN	AMGEN	OTHER	2. RECRUITING	NA	450	18 YEARS	N/A	COLORECTAL CANCER
NCT01916278	SWEDEN	Q-MED	DEVICE	2. RECRUITING	NA	MISS- ING	18 YEARS	65 YEARS	LIP FILLER INJECTIONS
NCT01928459	SWITZERLAND	NOVARTIS	DRUG	1. PLANNING	1	55	18 YEARS	N/A	SOLID TUMORS
NCT01846611	SWITZERLAND	JANSSEN	DRUG	2. RECRUITING	3	670	18 YEARS	N/A	FALLOPIAN TUBE NEOPLASMS
NCT01945021	TAIWAN	OXONC	DRUG	1. PLANNING	2	110	18 YEARS	N/A	CRIZOTINIB
NCT01947868	TAIWAN	ASTRAZENECA		1. PLANNING	4	356	20 YEARS	N/A	LUNG CANCER
NCT01944774	TAIWAN	TAIGEN	DRUG	2. RECRUITING	2	210	18 YEARS	75 YEARS	PNEUMONIA
NCT01098110	TAIWAN	MERCK	DRUG	2. RECRUITING	3	528	20 YEARS	64 YEARS	SCHIZOPHRENIA
NCT01757405	TAIWAN	BAXTER	BIOLOGICAL	2. RECRUITING	3	34	12 YEARS	65 YEARS	HEMOPHILIA B
NCT01948817	THAILAND	NOVARTIS	DRUG	1. PLANNING	2	45	2 YEARS	N/A	TRANSFUSION DEPENDENT
NCT01838044	THAILAND	PFIZER	DRUG	1. PLANNING	4	366	18 YEARS	75 YEARS	BACK PAIN

1 Identifier: The official study ID given by ClinicalTrials.gov.

2 When the type field is empty, it is commonly a noninterventional study.

3 "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

Studies Opening a First Site in a New Country, *from Page 21*

IDENTIFIER ¹	COUNTRY	SPONSOR	TYPE ²	STATUS	PHASE ³	SIZE (N)	MIN AGE	MAX AGE	CONDITION
NCT01641926	THAILAND	MERCK	BIOLOGICAL	2. RECRUITING	3	1,400	18 YEARS	N/A	HEPATITIS B, CHRONIC
NCT01663402	THAILAND	SANOFI	DRUG	2. RECRUITING	3	18,000	40 YEARS	N/A	ACUTE CORONARY SYNDROME
NCT01840410	TURKEY	NOVARTIS	DRUG	1. PLANNING	3	187	12 YEARS	N/A	MACULAR DEGENERATION
NCT01930188	TURKEY	NOVO NORDISK	DRUG	1. PLANNING	3	1,200	18 YEARS	N/A	DIABETES
NCT01928979	UKRAINE	BAYER	OTHER	1. PLANNING	NA	150	18 YEARS	N/A	ATRIAL FIBRILLATION
NCT01393626	UKRAINE	PFIZER	DRUG	2. RECRUITING	2	275	18 YEARS	75 YEARS	CROHN'S DISEASE
NCT01628393	UKRAINE	RECEPTOS	DRUG	2. RECRUITING	2	210	18 YEARS	55 YEARS	MULTIPLE SCLEROSIS
NCT01868061	UKRAINE	HOFFMANN-LA ROCHE	DRUG	2. RECRUITING	3	1,050	18 YEARS	75 YEARS	ASTHMA
NCT01928459	UK	NOVARTIS	DRUG	1. PLANNING	1	55	18 YEARS	N/A	SOLID TUMORS
NCT01853228	UK	JANSSEN	DRUG	1. PLANNING	2	27	1 MONTH	18 YEARS	LEUKEMIA
NCT01945762	UK	ASTRAZENECA	DRUG	1. PLANNING	NA	80	18 YEARS	N/A	THYROID CANCER
NCT01944735	UK	CELTEXSYS	DRUG	2. RECRUITING	1	36	18 YEARS	55 YEARS	CYSTIC FIBROSIS
NCT01945710	UK	EISAI	DRUG	2. RECRUITING	1	96	18 YEARS	N/A	SOLID TUMORS
NCT01945346	UK	PROXIMAGEN	DRUG	2. RECRUITING	2	74	45 YEARS	75 YEARS	OSTEOARTHRITIS, KNEE
NCT01948401	UK	HOFFMANN-LA ROCHE	DRUG	2. RECRUITING	2	97	12 YEARS	75 YEARS	ASTHMA
NCT01752322	UK	GRENENTHAL	DRUG	2. RECRUITING	3	600	18 YEARS	N/A	POSTOPERATIVE PAIN
NCT01868061	UK	HOFFMANN-LA ROCHE	DRUG	2. RECRUITING	3	1,050	18 YEARS	75 YEARS	ASTHMA
NCT01478438	UK	NOVIAN	DEVICE	2. RECRUITING	NA	60	18 YEARS	80 YEARS	MALIGNANT TUMOR
NCT01947998	UK	BAYER	DRUG	2. RECRUITING	NA	20,000	2 YEARS	89 YEARS	PULMONARY EMBOLISM
NCT01946789	USA	ALTOR	BIOLOGICAL	1. PLANNING	1	20	18 YEARS	N/A	MELANOMA
NCT01947569	USA	DIAVACS	BIOLOGICAL	1. PLANNING	1	90	12 YEARS	35 YEARS	DIABETES
NCT01947777	USA	INFINITY	DRUG	1. PLANNING	1	14	18 YEARS	50 YEARS	HEALTHY
NCT01949103	USA	THERAVANCE	DRUG	1. PLANNING	1	48	18 YEARS	55 YEARS	BACTERIAL INFECTIONS
NCT01946945	USA	REPROGENETICS	GENETIC	1. PLANNING	2	240	22 YEARS	42 YEARS	RECURRENT PREGNANCY LOSS

1 Identifier: The official study ID given by ClinicalTrials.gov.

2 When the type field is empty, it is commonly a noninterventional study.

3 "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

(Return to Page 1)

(See Studies Opening a First Site in a New Country, Page 23)

Studies Opening a First Site in a New Country, from Page 22

IDENTIFIER ¹	COUNTRY	SPONSOR	TYPE ²	STATUS	PHASE ³	SIZE (N)	MIN AGE	MAX AGE	CONDITION
NCT01949324	USA	NEUROTECH	BIOLOGICAL	1. PLANNING	2	68	21 YEARS	80 YEARS	MACULAR TEL-ANGIECTASIA
NCT01946412	USA	VERTEX	DRUG	1. PLANNING	3	MISS-ING	2 YEARS	N/A	CYSTIC FIBROSIS
NCT01947491	USA	PROMIUS	DRUG	1. PLANNING	3	396	18 YEARS	N/A	PSORIASIS
NCT01949142	USA	OTONOMY	DRUG	1. PLANNING	3	264	6 MONTHS	12 YEARS	TYMPANOS-TOMY TUBE PLACEMENT
NCT01949155	USA	OTONOMY	DRUG	1. PLANNING	3	264	6 MONTHS	12 YEARS	TYMPANOS-TOMY TUBE PLACEMENT
NCT01945489	USA	ALLERGAN	BIOLOGICAL	1. PLANNING	4	258	18 YEARS	N/A	OVERACTIVE BLADDER
NCT01946126	USA	ALLERGAN		1. PLANNING	NA	200	18 YEARS	65 YEARS	HEADACHE
NCT01691807	USA	GSK	DRUG	2. RECRUITING	1	70	18 YEARS	N/A	CANCER
NCT01944683	USA	ACORDA	OTHER	2. RECRUITING	1	28	18 YEARS	75 YEARS	HEART FAILURE
NCT01946074	USA	ABBVIE	DRUG	2. RECRUITING	1	75	18 YEARS	N/A	SOLID TUMORS
NCT01946568	USA	DURATA	DRUG	2. RECRUITING	1	36	3 MONTHS	11 YEARS	BACTERIAL INFECTIONS
NCT01948024	USA	BIORASI	DRUG	2. RECRUITING	1	66	18 YEARS	80 YEARS	BIPOLAR DISORDER
NCT01885195	USA	NOVARTIS	DRUG	2. RECRUITING	2	70	18 YEARS	N/A	SOLID HEMATOLOGIC MALIGNANCIES
NCT01886378	USA	ULTRAGENYX	DRUG	2. RECRUITING	2	20	6 YEARS	25 YEARS	LCHAD DEFICIENCY
NCT01891305	USA	VIAMET	DRUG	2. RECRUITING	2	48	18 YEARS	65 YEARS	TINEA PEDIS
NCT01941836	USA	ESPERION	DRUG	2. RECRUITING	2	322	18 YEARS	80 YEARS	HYPERCHOLESTEROLEMIA
NCT01623310	USA	OPTINOSE	DRUG	2. RECRUITING	3	200	18 YEARS	N/A	SINUSITIS
NCT01623323	USA	OPTINOSE	DRUG	2. RECRUITING	3	700	18 YEARS	N/A	SINUSITIS
NCT01944839	USA	OPHTHOTECH	DRUG	2. RECRUITING	3	622	50 YEARS	N/A	MACULAR DEGENERATION
NCT01945775	USA	BIOMARIN	DRUG	2. RECRUITING	3	429	18 YEARS	N/A	BRCA 2 GENE MUTATION
NCT01946243	USA	AVID	DRUG	2. RECRUITING	4	96	N/A	N/A	ALZHEIMERS DISEASE
NCT01946425	USA	SANOFI	BIOLOGICAL	2. RECRUITING	4	60	6 MONTHS	8 YEARS	INFLUENZA
NCT01946438	USA	SANOFI	BIOLOGICAL	2. RECRUITING	4	208	18 YEARS	N/A	INFLUENZA

1 Identifier: The official study ID given by ClinicalTrials.gov.

2 When the type field is empty, it is commonly a noninterventional study.

3 "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

(Return to Page 1)

(See **Studies Opening a First Site in a New Country**, Page 24)

Studies Opening a First Site in a New Country, *from Page 23*

IDENTIFIER ¹	COUNTRY	SPONSOR	TYPE ²	STATUS	PHASE ³	SIZE (N)	MIN AGE	MAX AGE	CONDITION
NCT01944670	USA	SKELETAL	DEVICE	2. RECRUITING	NA	25	21 YEARS	N/A	CHRONIC ELBOW DISLOCATION
NCT01944748	USA	RAND	BEHAVIORAL	2. RECRUITING	NA	200	12 YEARS	19 YEARS	FAMILY FUNCTIONING
NCT01945424	USA	SANOFI	BIOLOGICAL	2. RECRUITING	NA	500	18 YEARS	N/A	INFLUENZA
NCT01946581	USA	MDBACKLINE	PROCEDURE	2. RECRUITING	NA	200	18 YEARS	90 YEARS	CATARACT
NCT01948427	USA	HYPERION		2. RECRUITING	NA	500	N/A	N/A	UREA CYCLE DISORDER
NCT01948544	USA	STRATIHEALTH		2. RECRUITING	NA	30	65 YEARS	85 YEARS	COPD
NCT01949584	USA	INSLEEP	DEVICE	2. RECRUITING	NA	30	18 YEARS	N/A	HABITUAL, SIMPLE SNORING

STUDIES OPENING ADDITIONAL SITES IN A COUNTRY

This table lists studies that launched additional sites in a country in the past week.

IDENTIFIER ¹	COUNTRY	SPONSOR	TYPE ²	STATUS	PHASE ³	SIZE (N)	MIN AGE	MAX AGE	CONDITION
NCT01697579	ARGENTINA	MERCK	DRUG	2. RECRUITING	2	256	N/A	17 YEARS	CHEMOTHERAPY NAUSEA/ VOMITING
NCT01201356	ARGENTINA	NOVARTIS	DRUG	2. RECRUITING	3	5,000	18 YEARS	N/A	MULTIPLE SCLEROSIS
NCT01663402	ARGENTINA	SANOFI	DRUG	2. RECRUITING	3	18,000	40 YEARS	N/A	ACUTE CORONARY SYNDROME
NCT01682512	ARGENTINA	BOEHRINGER INGELHEIM	DRUG	2. RECRUITING	3	306	18 YEARS	80 YEARS	ARTHRITIS, RHEUMATOID
NCT01868061	ARGENTINA	HOFFMANN-LA ROCHE	DRUG	2. RECRUITING	3	1,050	18 YEARS	75 YEARS	ASTHMA
NCT01574703	ARGENTINA	PFIZER	DRUG	2. RECRUITING	4	8,000	18 YEARS	75 YEARS	SMOKING CESSATION
NCT01511913	ARGENTINA	BMS		2. RECRUITING	NA	1,800	18 YEARS	N/A	MELANOMA
NCT01907100	AUSTRALIA	BOEHRINGER INGELHEIM	DRUG	1. PLANNING	2	86	18 YEARS	N/A	MESOTHELIOMA
NCT01840410	AUSTRALIA	NOVARTIS	DRUG	1. PLANNING	3	187	12 YEARS	N/A	MACULAR DEGENERATION
NCT01295827	AUSTRALIA	MERCK	DRUG	2. RECRUITING	1	1,067	18 YEARS	N/A	SOLID TUMOR
NCT01393626	AUSTRALIA	PFIZER	DRUG	2. RECRUITING	2	275	18 YEARS	75 YEARS	CROHN'S DISEASE
NCT01740336	AUSTRALIA	GENENTECH	DRUG	2. RECRUITING	2	180	18 YEARS	N/A	BREAST CANCER

¹ Identifier: The official study ID given by ClinicalTrials.gov.

² When the type field is empty, it is commonly a noninterventional study.

³ "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

(Return to Page 1)

(See **Studies Opening Additional Sites in a Country**, Page 25)

Studies Opening Additional Sites in a Country, from Page 24

IDENTIFIER ¹	COUNTRY	SPONSOR	TYPE ²	STATUS	PHASE ³	SIZE (N)	MIN AGE	MAX AGE	CONDITION
NCT01762852	AUSTRALIA	GSK	DRUG	2. RECRUITING	2	94	18 YEARS	75 YEARS	GLOMERULONEPHRITIS
NCT01843374	AUSTRALIA	MEDIMMUNE	DRUG	2. RECRUITING	2	180	18 YEARS	N/A	MESOTHELIOMA
NCT00625378	AUSTRALIA	BAYER	DRUG	2. RECRUITING	3	1,000	16 YEARS	N/A	NEOPLASMS
NCT01201356	AUSTRALIA	NOVARTIS	DRUG	2. RECRUITING	3	5,000	18 YEARS	N/A	MULTIPLE SCLEROSIS
NCT01480479	AUSTRALIA	CELLDEX	DRUG	2. RECRUITING	3	440	18 YEARS	N/A	GLIOBLASTOMA
NCT01489111	AUSTRALIA	NOVO NORDISK	DRUG	2. RECRUITING	3	18	12 YEARS	N/A	HAEMOPHILIA A
NCT01560624	AUSTRALIA	UNITED THERAPEUTICS	DRUG	2. RECRUITING	3	858	18 YEARS	75 YEARS	PULMONARY HYPERTENSION
NCT01560637	AUSTRALIA	UNITED THERAPEUTICS	DRUG	2. RECRUITING	3	858	18 YEARS	75 YEARS	PULMONARY HYPERTENSION
NCT01566695	AUSTRALIA	CELGENE	DRUG	2. RECRUITING	3	386	18 YEARS	N/A	MYELODYSPLASTIC
NCT01641926	AUSTRALIA	MERCK	BIOLOGICAL	2. RECRUITING	3	1,400	18 YEARS	N/A	HEPATITIS B, CHRONIC
NCT01663402	AUSTRALIA	SANOFI	DRUG	2. RECRUITING	3	18,000	40 YEARS	N/A	ACUTE CORONARY SYNDROME
NCT01703208	AUSTRALIA	MERCK	DRUG	2. RECRUITING	3	4,000	40 YEARS	N/A	DIABETES
NCT01708174	AUSTRALIA	NOVARTIS	DRUG	2. RECRUITING	3	109	N/A	N/A	MEDULLOBLASTOMA
NCT01734785	AUSTRALIA	BOEHRINGER INGELHEIM	DRUG	2. RECRUITING	3	444	18 YEARS	N/A	DIABETES
NCT01767467	AUSTRALIA	GSK	BIOLOGICAL	2. RECRUITING	3	502	18 YEARS	N/A	HERPES ZOSTER
NCT01828099	AUSTRALIA	NOVARTIS	DRUG	2. RECRUITING	3	348	18 YEARS	N/A	LUNG CANCER
NCT01846611	AUSTRALIA	JANSSEN	DRUG	2. RECRUITING	3	670	18 YEARS	N/A	FALLOPIAN TUBE NEOPLASMS
NCT01868061	AUSTRALIA	HOFFMANN-LA ROCHE	DRUG	2. RECRUITING	3	1,050	18 YEARS	75 YEARS	ASTHMA
NCT00867815	AUSTRALIA	BAYER	DRUG	2. RECRUITING	4	284	40 YEARS	N/A	OPTIC NEUROPATHY
NCT01574703	AUSTRALIA	PFIZER	DRUG	2. RECRUITING	4	8,000	18 YEARS	75 YEARS	SMOKING CESSATION
NCT01511913	AUSTRALIA	BMS		2. RECRUITING	NA	1,800	18 YEARS	N/A	MELANOMA
NCT01393626	AUSTRIA	PFIZER	DRUG	2. RECRUITING	2	275	18 YEARS	75 YEARS	CROHN'S DISEASE
NCT01697579	AUSTRIA	MERCK	DRUG	2. RECRUITING	2	256	N/A	17 YEARS	CHEMOTHERAPY NAUSEA/ VOMITING

¹ Identifier: The official study ID given by ClinicalTrials.gov.

² When the type field is empty, it is commonly a noninterventional study.

³ "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

(Return to Page 1)

(See Studies Opening Additional Sites in a Country, Page 26)

Studies Opening Additional Sites in a Country, *from Page 25*

IDENTIFIER ¹	COUNTRY	SPONSOR	TYPE ²	STATUS	PHASE ³	SIZE (N)	MIN AGE	MAX AGE	CONDITION
NCT01740336	AUSTRIA	GENENTECH	DRUG	2. RECRUITING	2	180	18 YEARS	N/A	BREAST CANCER
NCT01201356	AUSTRIA	NOVARTIS	DRUG	2. RECRUITING	3	5,000	18 YEARS	N/A	MULTIPLE SCLEROSIS
NCT01480479	AUSTRIA	CELLDEX	DRUG	2. RECRUITING	3	440	18 YEARS	N/A	GLIOBLASTOMA
NCT01560624	AUSTRIA	UNITED THERAPEUTICS	DRUG	2. RECRUITING	3	858	18 YEARS	75 YEARS	PULMONARY HYPERTENSION
NCT01560637	AUSTRIA	UNITED THERAPEUTICS	DRUG	2. RECRUITING	3	858	18 YEARS	75 YEARS	PULMONARY HYPERTENSION
NCT01663402	AUSTRIA	SANOFI	DRUG	2. RECRUITING	3	18,000	40 YEARS	N/A	ACUTE CORONARY SYNDROME
NCT01703208	AUSTRIA	MERCK	DRUG	2. RECRUITING	3	4,000	40 YEARS	N/A	DIABETES
NCT01752322	AUSTRIA	GRENENTHAL	DRUG	2. RECRUITING	3	600	18 YEARS	N/A	POSTOPERATIVE PAIN
NCT01828099	AUSTRIA	NOVARTIS	DRUG	2. RECRUITING	3	348	18 YEARS	N/A	LUNG CANCER
NCT01511913	AUSTRIA	BMS		2. RECRUITING	NA	1,800	18 YEARS	N/A	MELANOMA
NCT01671007	AUSTRIA	BOEHRINGER INGELHEIM		2. RECRUITING	NA	18,091	18 YEARS	N/A	ATRIAL FIBRILLATION
NCT01840410	BELGIUM	NOVARTIS	DRUG	1. PLANNING	3	187	12 YEARS	N/A	MACULAR DEGENERATION
NCT01895777	BELGIUM	BOEHRINGER INGELHEIM	DRUG	1. PLANNING	3	270	N/A	17 YEARS	THROMBOEMBOLISM
NCT01628393	BELGIUM	RECEPTOS	DRUG	2. RECRUITING	2	210	18 YEARS	55 YEARS	MULTIPLE SCLEROSIS
NCT01740336	BELGIUM	GENENTECH	DRUG	2. RECRUITING	2	180	18 YEARS	N/A	BREAST CANCER
NCT01767090	BELGIUM	ASTELLAS	DRUG	2. RECRUITING	2	600	18 YEARS	45 YEARS	ENDOMETRIOSIS
NCT00625378	BELGIUM	BAYER	DRUG	2. RECRUITING	3	1,000	16 YEARS	N/A	NEOPLASMS
NCT01201356	BELGIUM	NOVARTIS	DRUG	2. RECRUITING	3	5,000	18 YEARS	N/A	MULTIPLE SCLEROSIS
NCT01566695	BELGIUM	CELGENE	DRUG	2. RECRUITING	3	386	18 YEARS	N/A	MYELODYSPLASTIC
NCT01663402	BELGIUM	SANOFI	DRUG	2. RECRUITING	3	18,000	40 YEARS	N/A	ACUTE CORONARY SYNDROME
NCT01682512	BELGIUM	BOEHRINGER INGELHEIM	DRUG	2. RECRUITING	3	306	18 YEARS	80 YEARS	ARTHRITIS, RHEUMATOID
NCT01703208	BELGIUM	MERCK	DRUG	2. RECRUITING	3	4,000	40 YEARS	N/A	DIABETES
NCT01752322	BELGIUM	GRENENTHAL	DRUG	2. RECRUITING	3	600	18 YEARS	N/A	POSTOPERATIVE PAIN

1 Identifier: The official study ID given by ClinicalTrials.gov.

2 When the type field is empty, it is commonly a noninterventional study.

3 "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

Studies Opening Additional Sites in a Country, from Page 26

IDENTIFIER ¹	COUNTRY	SPONSOR	TYPE ²	STATUS	PHASE ³	SIZE (N)	MIN AGE	MAX AGE	CONDITION
NCT01757405	BELGIUM	BAXTER	BIOLOGICAL	2. RECRUITING	3	34	12 YEARS	65 YEARS	HEMOPHILIA B
NCT01767467	BELGIUM	GSK	BIOLOGICAL	2. RECRUITING	3	502	18 YEARS	N/A	HERPES ZOSTER
NCT01868061	BELGIUM	HOFFMANN-LA ROCHE	DRUG	2. RECRUITING	3	1,050	18 YEARS	75 YEARS	ASTHMA
NCT01697358	BELGIUM	MEDTRONIC	DEVICE	2. RECRUITING	4	300	18 YEARS	N/A	PAIN IN LEG
NCT01791361	BELGIUM	AMGEN	OTHER	2. RECRUITING	NA	450	18 YEARS	N/A	COLORECTAL CANCER
NCT01835431	BRAZIL	NOVO NORDISK	DRUG	1. PLANNING	3	346	1 YEAR	17 YEARS	DIABETES
NCT00625378	BRAZIL	BAYER	DRUG	2. RECRUITING	3	1,000	16 YEARS	N/A	NEOPLASMS
NCT01201356	BRAZIL	NOVARTIS	DRUG	2. RECRUITING	3	5,000	18 YEARS	N/A	MULTIPLE SCLEROSIS
NCT01480479	BRAZIL	CELLDEX	DRUG	2. RECRUITING	3	440	18 YEARS	N/A	GLIOBLASTOMA
NCT01663402	BRAZIL	SANOFI	DRUG	2. RECRUITING	3	18,000	40 YEARS	N/A	ACUTE CORONARY SYNDROME
NCT01708174	BRAZIL	NOVARTIS	DRUG	2. RECRUITING	3	109	N/A	N/A	MEDULLOBLASTOMA
NCT01731600	BRAZIL	NOVO NORDISK	DRUG	2. RECRUITING	3	60	N/A	11 YEARS	HAEMOPHILIA A
NCT01734785	BRAZIL	BOEHRINGER INGELHEIM	DRUG	2. RECRUITING	3	444	18 YEARS	N/A	DIABETES
NCT01828099	BRAZIL	NOVARTIS	DRUG	2. RECRUITING	3	348	18 YEARS	N/A	LUNG CANCER
NCT01511913	BRAZIL	BMS		2. RECRUITING	NA	1,800	18 YEARS	N/A	MELANOMA
NCT01928979	BULGARIA	BAYER	OTHER	1. PLANNING	NA	150	18 YEARS	N/A	ATRIAL FIBRILLATION
NCT01393626	BULGARIA	PFIZER	DRUG	2. RECRUITING	2	275	18 YEARS	75 YEARS	CROHN'S DISEASE
NCT01628393	BULGARIA	RECEPTOS	DRUG	2. RECRUITING	2	210	18 YEARS	55 YEARS	MULTIPLE SCLEROSIS
NCT01767090	BULGARIA	ASTELLAS	DRUG	2. RECRUITING	2	600	18 YEARS	45 YEARS	ENDOMETRIOSIS
NCT00625378	BULGARIA	BAYER	DRUG	2. RECRUITING	3	1,000	16 YEARS	N/A	NEOPLASMS
NCT01479244	BULGARIA	GALENA	BIOLOGICAL	2. RECRUITING	3	700	18 YEARS	N/A	BREAST CANCER
NCT01663402	BULGARIA	SANOFI	DRUG	2. RECRUITING	3	18,000	40 YEARS	N/A	ACUTE CORONARY SYNDROME
NCT01682512	BULGARIA	BOEHRINGER INGELHEIM	DRUG	2. RECRUITING	3	306	18 YEARS	80 YEARS	ARTHRITIS, RHEUMATOID

1 Identifier: The official study ID given by ClinicalTrials.gov.

2 When the type field is empty, it is commonly a noninterventional study.

3 "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

(Return to Page 1)

(See Studies Opening Additional Sites in a Country, Page 28)

Studies Opening Additional Sites in a Country, from Page 27

IDENTIFIER ¹	COUNTRY	SPONSOR	TYPE ²	STATUS	PHASE ³	SIZE (N)	MIN AGE	MAX AGE	CONDITION
NCT01703208	BULGARIA	MERCK	DRUG	2. RECRUITING	3	4,000	40 YEARS	N/A	DIABETES
NCT01868061	BULGARIA	HOFFMANN-LA ROCHE	DRUG	2. RECRUITING	3	1,050	18 YEARS	75 YEARS	ASTHMA
NCT01574703	BULGARIA	PFIZER	DRUG	2. RECRUITING	4	8,000	18 YEARS	75 YEARS	SMOKING CESSATION
NCT01671007	BULGARIA	BOEHRINGER INGELHEIM		2. RECRUITING	NA	18,091	18 YEARS	N/A	ATRIAL FIBRILLATION
NCT01840410	CANADA	NOVARTIS	DRUG	1. PLANNING	3	187	12 YEARS	N/A	MACULAR DEGENERATION
NCT01295827	CANADA	MERCK	DRUG	2. RECRUITING	1	1,067	18 YEARS	N/A	SOLID TUMOR
NCT01393626	CANADA	PFIZER	DRUG	2. RECRUITING	2	275	18 YEARS	75 YEARS	CROHN'S DISEASE
NCT01656395	CANADA	MERCK	DRUG	2. RECRUITING	2	1,475	18 YEARS	65 YEARS	ASTHMA
NCT01697579	CANADA	MERCK	DRUG	2. RECRUITING	2	256	N/A	17 YEARS	CHEMOTHERAPY NAUSEA/ VOMITING
NCT01762852	CANADA	GSK	DRUG	2. RECRUITING	2	94	18 YEARS	75 YEARS	GLOMERULONEPHRITIS
NCT00625378	CANADA	BAYER	DRUG	2. RECRUITING	3	1,000	16 YEARS	N/A	NEOPLASMS
NCT01201356	CANADA	NOVARTIS	DRUG	2. RECRUITING	3	5,000	18 YEARS	N/A	MULTIPLE SCLEROSIS
NCT01479244	CANADA	GALENA	BIOLOGICAL	2. RECRUITING	3	700	18 YEARS	N/A	BREAST CANCER
NCT01480479	CANADA	CELLDEX	DRUG	2. RECRUITING	3	440	18 YEARS	N/A	GLIOBLASTOMA
NCT01560624	CANADA	UNITED THERAPEUTICS	DRUG	2. RECRUITING	3	858	18 YEARS	75 YEARS	PULMONARY HYPERTENSION
NCT01560637	CANADA	UNITED THERAPEUTICS	DRUG	2. RECRUITING	3	858	18 YEARS	75 YEARS	PULMONARY HYPERTENSION
NCT01566695	CANADA	CELGENE	DRUG	2. RECRUITING	3	386	18 YEARS	N/A	MYELODYSPLASTIC
NCT01663402	CANADA	SANOFI	DRUG	2. RECRUITING	3	18,000	40 YEARS	N/A	ACUTE CORONARY SYNDROME
NCT01682512	CANADA	BOEHRINGER INGELHEIM	DRUG	2. RECRUITING	3	306	18 YEARS	80 YEARS	ARTHRITIS, RHEUMATOID
NCT01703208	CANADA	MERCK	DRUG	2. RECRUITING	3	4,000	40 YEARS	N/A	DIABETES
NCT01708174	CANADA	NOVARTIS	DRUG	2. RECRUITING	3	109	N/A	N/A	MEDULLOBLASTOMA
NCT01731600	CANADA	NOVO NORDISK	DRUG	2. RECRUITING	3	60	N/A	11 YEARS	HAEMOPHILIA A
NCT01767467	CANADA	GSK	BIOLOGICAL	2. RECRUITING	3	502	18 YEARS	N/A	HERPES ZOSTER

¹ Identifier: The official study ID given by ClinicalTrials.gov.

² When the type field is empty, it is commonly a noninterventional study.

³ "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

Studies Opening Additional Sites in a Country, from Page 28

IDENTIFIER ¹	COUNTRY	SPONSOR	TYPE ²	STATUS	PHASE ³	SIZE (N)	MIN AGE	MAX AGE	CONDITION
NCT01868061	CANADA	HOFFMANN-LA ROCHE	DRUG	2. RECRUITING	3	1,050	18 YEARS	75 YEARS	ASTHMA
NCT00867815	CANADA	BAYER	DRUG	2. RECRUITING	4	284	40 YEARS	N/A	OPTIC NEUROPATHY
NCT01574703	CANADA	PFIZER	DRUG	2. RECRUITING	4	8,000	18 YEARS	75 YEARS	SMOKING CESSATION
NCT01511913	CANADA	BMS		2. RECRUITING	NA	1,800	18 YEARS	N/A	MELANOMA
NCT01697579	CHILE	MERCK	DRUG	2. RECRUITING	2	256	N/A	17 YEARS	CHEMOTHERAPY NAUSEA/ VOMITING
NCT01663402	CHILE	SANOFI	DRUG	2. RECRUITING	3	18,000	40 YEARS	N/A	ACUTE CORONARY SYNDROME
NCT00625378	CHINA	BAYER	DRUG	2. RECRUITING	3	1,000	16 YEARS	N/A	NEOPLASMS
NCT01560624	CHINA	UNITED THERAPEUTICS	DRUG	2. RECRUITING	3	858	18 YEARS	75 YEARS	PULMONARY HYPERTENSION
NCT01560637	CHINA	UNITED THERAPEUTICS	DRUG	2. RECRUITING	3	858	18 YEARS	75 YEARS	PULMONARY HYPERTENSION
NCT01922102	CHINA	NOVARTIS	DRUG	2. RECRUITING	3	475	18 YEARS	N/A	VISUAL IMPAIRMENT
NCT01697579	COLOMBIA	MERCK	DRUG	2. RECRUITING	2	256	N/A	17 YEARS	CHEMOTHERAPY NAUSEA/ VOMITING
NCT00625378	COLOMBIA	BAYER	DRUG	2. RECRUITING	3	1,000	16 YEARS	N/A	NEOPLASMS
NCT01480479	COLOMBIA	CELLEX	DRUG	2. RECRUITING	3	440	18 YEARS	N/A	GLIOBLASTOMA
NCT01641926	COLOMBIA	MERCK	BIOLOGICAL	2. RECRUITING	3	1,400	18 YEARS	N/A	HEPATITIS B, CHRONIC
NCT01663402	COLOMBIA	SANOFI	DRUG	2. RECRUITING	3	18,000	40 YEARS	N/A	ACUTE CORONARY SYNDROME
NCT01828099	COLOMBIA	NOVARTIS	DRUG	2. RECRUITING	3	348	18 YEARS	N/A	LUNG CANCER
NCT01489111	CROATIA	NOVO NORDISK	DRUG	2. RECRUITING	3	18	12 YEARS	N/A	HAEMOPHILIA A
NCT01682759	CROATIA	MERCK	DRUG	2. RECRUITING	3	680	18 YEARS	N/A	DIABETES
NCT01671007	CROATIA	BOEHRINGER INGELHEIM		2. RECRUITING	NA	18,091	18 YEARS	N/A	ATRIAL FIBRILLATION
NCT01835431	CZECH REP	NOVO NORDISK	DRUG	1. PLANNING	3	346	1 YEAR	17 YEARS	DIABETES
NCT01895777	CZECH REP	BOEHRINGER INGELHEIM	DRUG	1. PLANNING	3	270	N/A	17 YEARS	THROMBOEMBOLISM
NCT01751776	CZECH REP	BOEHRINGER INGELHEIM	DRUG	2. RECRUITING	1	121	18 YEARS	70 YEARS	HEALTHY

1 Identifier: The official study ID given by ClinicalTrials.gov.

2 When the type field is empty, it is commonly a noninterventional study.

3 "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

(Return to Page 1)

(See Studies Opening Additional Sites in a Country, Page 30)

Studies Opening Additional Sites in a Country, *from Page 29*

IDENTIFIER ¹	COUNTRY	SPONSOR	TYPE ²	STATUS	PHASE ³	SIZE (N)	MIN AGE	MAX AGE	CONDITION
NCT01393626	CZECH REP	PFIZER	DRUG	2. RECRUITING	2	275	18 YEARS	75 YEARS	CROHN'S DISEASE
NCT01740336	CZECH REP	GENENTECH	DRUG	2. RECRUITING	2	180	18 YEARS	N/A	BREAST CANCER
NCT01201356	CZECH REP	NOVARTIS	DRUG	2. RECRUITING	3	5,000	18 YEARS	N/A	MULTIPLE SCLEROSIS
NCT01479244	CZECH REP	GALENA	BIOLOGICAL	2. RECRUITING	3	700	18 YEARS	N/A	BREAST CANCER
NCT01480479	CZECH REP	CELLDEX	DRUG	2. RECRUITING	3	440	18 YEARS	N/A	GLIOBLASTOMA
NCT01566695	CZECH REP	CELGENE	DRUG	2. RECRUITING	3	386	18 YEARS	N/A	MYELOYDYSPLASTIC
NCT01663402	CZECH REP	SANOFI	DRUG	2. RECRUITING	3	18,000	40 YEARS	N/A	ACUTE CORONARY SYNDROME
NCT01703208	CZECH REP	MERCK	DRUG	2. RECRUITING	3	4,000	40 YEARS	N/A	DIABETES
NCT01671007	CZECH REP	BOEHRINGER INGELHEIM		2. RECRUITING	NA	18,091	18 YEARS	N/A	ATRIAL FIBRILLATION
NCT01907100	DENMARK	BOEHRINGER INGELHEIM	DRUG	1. PLANNING	2	86	18 YEARS	N/A	MESOTHELIOMA
NCT01840410	DENMARK	NOVARTIS	DRUG	1. PLANNING	3	187	12 YEARS	N/A	MACULAR DEGENERATION
NCT01201356	DENMARK	NOVARTIS	DRUG	2. RECRUITING	3	5,000	18 YEARS	N/A	MULTIPLE SCLEROSIS
NCT01566695	DENMARK	CELGENE	DRUG	2. RECRUITING	3	386	18 YEARS	N/A	MYELOYDYSPLASTIC
NCT01663402	DENMARK	SANOFI	DRUG	2. RECRUITING	3	18,000	40 YEARS	N/A	ACUTE CORONARY SYNDROME
NCT01703208	DENMARK	MERCK	DRUG	2. RECRUITING	3	4,000	40 YEARS	N/A	DIABETES
NCT01752322	DENMARK	GREENTHAL	DRUG	2. RECRUITING	3	600	18 YEARS	N/A	POSTOPERATIVE PAIN
NCT01671007	DENMARK	BOEHRINGER INGELHEIM		2. RECRUITING	NA	18,091	18 YEARS	N/A	ATRIAL FIBRILLATION
NCT01791361	DENMARK	AMGEN	OTHER	2. RECRUITING	NA	450	18 YEARS	N/A	COLORECTAL CANCER
NCT01201356	EGYPT	NOVARTIS	DRUG	2. RECRUITING	3	5,000	18 YEARS	N/A	MULTIPLE SCLEROSIS
NCT01734785	EL SALVADOR	BOEHRINGER INGELHEIM	DRUG	2. RECRUITING	3	444	18 YEARS	N/A	DIABETES
NCT01671007	EL SALVADOR	BOEHRINGER INGELHEIM		2. RECRUITING	NA	18,091	18 YEARS	N/A	ATRIAL FIBRILLATION
NCT01697579	ESTONIA	MERCK	DRUG	2. RECRUITING	2	256	N/A	17 YEARS	CHEMOTHERAPY NAUSEA/ VOMITING
NCT01201356	ESTONIA	NOVARTIS	DRUG	2. RECRUITING	3	5,000	18 YEARS	N/A	MULTIPLE SCLEROSIS

1 Identifier: The official study ID given by ClinicalTrials.gov.

2 When the type field is empty, it is commonly a noninterventional study.

3 "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

(Return to Page 1)

(See Studies Opening Additional Sites in a Country, Page 31)

Studies Opening Additional Sites in a Country, from Page 30

IDENTIFIER ¹	COUNTRY	SPONSOR	TYPE ²	STATUS	PHASE ³	SIZE (N)	MIN AGE	MAX AGE	CONDITION
NCT01663402	ESTONIA	SANOFI	DRUG	2. RECRUITING	3	18,000	40 YEARS	N/A	ACUTE CORONARY SYNDROME
NCT01682512	ESTONIA	BOEHRINGER INGELHEIM	DRUG	2. RECRUITING	3	306	18 YEARS	80 YEARS	ARTHRITIS, RHEUMATOID
NCT01671007	ESTONIA	BOEHRINGER INGELHEIM		2. RECRUITING	NA	18,091	18 YEARS	N/A	ATRIAL FIBRILLATION
NCT01201356	FINLAND	NOVARTIS	DRUG	2. RECRUITING	3	5,000	18 YEARS	N/A	MULTIPLE SCLEROSIS
NCT01566695	FINLAND	CELGENE	DRUG	2. RECRUITING	3	386	18 YEARS	N/A	MYELODYSPLASTIC
NCT01663402	FINLAND	SANOFI	DRUG	2. RECRUITING	3	18,000	40 YEARS	N/A	ACUTE CORONARY SYNDROME
NCT01767467	FINLAND	GSK	BIOLOGICAL	2. RECRUITING	3	502	18 YEARS	N/A	HERPES ZOSTER
NCT01574703	FINLAND	PFIZER	DRUG	2. RECRUITING	4	8,000	18 YEARS	75 YEARS	SMOKING CESSATION
NCT01907100	FRANCE	BOEHRINGER INGELHEIM	DRUG	1. PLANNING	2	86	18 YEARS	N/A	MESOTHELIOMA
NCT01928979	FRANCE	BAYER	OTHER	1. PLANNING	NA	150	18 YEARS	N/A	ATRIAL FIBRILLATION
NCT01295827	FRANCE	MERCK	DRUG	2. RECRUITING	1	1,067	18 YEARS	N/A	SOLID TUMOR
NCT01393626	FRANCE	PFIZER	DRUG	2. RECRUITING	2	275	18 YEARS	75 YEARS	CROHN'S DISEASE
NCT01656395	FRANCE	MERCK	DRUG	2. RECRUITING	2	1,475	18 YEARS	65 YEARS	ASTHMA
NCT01762852	FRANCE	GSK	DRUG	2. RECRUITING	2	94	18 YEARS	75 YEARS	GLOMERULONEPHRITIS
NCT00625378	FRANCE	BAYER	DRUG	2. RECRUITING	3	1,000	16 YEARS	N/A	NEOPLASMS
NCT01201356	FRANCE	NOVARTIS	DRUG	2. RECRUITING	3	5,000	18 YEARS	N/A	MULTIPLE SCLEROSIS
NCT01489111	FRANCE	NOVO NORDISK	DRUG	2. RECRUITING	3	18	12 YEARS	N/A	HAEMOPHILIA A
NCT01560624	FRANCE	UNITED THERAPEUTICS	DRUG	2. RECRUITING	3	858	18 YEARS	75 YEARS	PULMONARY HYPERTENSION
NCT01560637	FRANCE	UNITED THERAPEUTICS	DRUG	2. RECRUITING	3	858	18 YEARS	75 YEARS	PULMONARY HYPERTENSION
NCT01663402	FRANCE	SANOFI	DRUG	2. RECRUITING	3	18,000	40 YEARS	N/A	ACUTE CORONARY SYNDROME
NCT01682512	FRANCE	BOEHRINGER INGELHEIM	DRUG	2. RECRUITING	3	306	18 YEARS	80 YEARS	ARTHRITIS, RHEUMATOID
NCT01708174	FRANCE	NOVARTIS	DRUG	2. RECRUITING	3	109	N/A	N/A	MEDULLOBLASTOMA
NCT01731600	FRANCE	NOVO NORDISK	DRUG	2. RECRUITING	3	60	N/A	11 YEARS	HAEMOPHILIA A

1 Identifier: The official study ID given by ClinicalTrials.gov.

2 When the type field is empty, it is commonly a noninterventional study.

3 "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

(Return to Page 1)

(See Studies Opening Additional Sites in a Country, Page 32)

Studies Opening Additional Sites in a Country, from Page 31

IDENTIFIER ¹	COUNTRY	SPONSOR	TYPE ²	STATUS	PHASE ³	SIZE (N)	MIN AGE	MAX AGE	CONDITION
NCT01734785	FRANCE	BOEHRINGER INGELHEIM	DRUG	2. RECRUITING	3	444	18 YEARS	N/A	DIABETES
NCT01752322	FRANCE	GREENTHAL	DRUG	2. RECRUITING	3	600	18 YEARS	N/A	POSTOPERATIVE PAIN
NCT01767467	FRANCE	GSK	BIOLOGICAL	2. RECRUITING	3	502	18 YEARS	N/A	HERPES ZOSTER
NCT01828099	FRANCE	NOVARTIS	DRUG	2. RECRUITING	3	348	18 YEARS	N/A	LUNG CANCER
NCT01828112	FRANCE	NOVARTIS	DRUG	2. RECRUITING	3	236	18 YEARS	N/A	LUNG CANCER
NCT01868061	FRANCE	HOFFMANN-LA ROCHE	DRUG	2. RECRUITING	3	1,050	18 YEARS	75 YEARS	ASTHMA
NCT01697358	FRANCE	MEDTRONIC	DEVICE	2. RECRUITING	4	300	18 YEARS	N/A	PAIN IN LEG
NCT01511913	FRANCE	BMS		2. RECRUITING	NA	1,800	18 YEARS	N/A	MELANOMA
NCT01671007	FRANCE	BOEHRINGER INGELHEIM		2. RECRUITING	NA	18,091	18 YEARS	N/A	ATRIAL FIBRILLATION
NCT01791361	FRANCE	AMGEN	OTHER	2. RECRUITING	NA	450	18 YEARS	N/A	COLORECTAL CANCER
NCT01628393	GEORGIA	RECEPTOS	DRUG	2. RECRUITING	2	210	18 YEARS	55 YEARS	MULTIPLE SCLEROSIS
NCT01703208	GEORGIA	MERCK	DRUG	2. RECRUITING	3	4,000	40 YEARS	N/A	DIABETES
NCT01907100	GERMANY	BOEHRINGER INGELHEIM	DRUG	1. PLANNING	2	86	18 YEARS	N/A	MESOTHELIOMA
NCT01928979	GERMANY	BAYER	OTHER	1. PLANNING	NA	150	18 YEARS	N/A	ATRIAL FIBRILLATION
NCT01751776	GERMANY	BOEHRINGER INGELHEIM	DRUG	2. RECRUITING	1	121	18 YEARS	70 YEARS	HEALTHY
NCT01393626	GERMANY	PFIZER	DRUG	2. RECRUITING	2	275	18 YEARS	75 YEARS	CROHN'S DISEASE
NCT01656395	GERMANY	MERCK	DRUG	2. RECRUITING	2	1,475	18 YEARS	65 YEARS	ASTHMA
NCT01697579	GERMANY	MERCK	DRUG	2. RECRUITING	2	256	N/A	17 YEARS	CHEMOTHERAPY NAUSEA/ VOMITING
NCT01762852	GERMANY	GSK	DRUG	2. RECRUITING	2	94	18 YEARS	75 YEARS	GLOMERULONEPHRITIS
NCT00625378	GERMANY	BAYER	DRUG	2. RECRUITING	3	1,000	16 YEARS	N/A	NEOPLASMS
NCT01201356	GERMANY	NOVARTIS	DRUG	2. RECRUITING	3	5,000	18 YEARS	N/A	MULTIPLE SCLEROSIS
NCT01489111	GERMANY	NOVO NORDISK	DRUG	2. RECRUITING	3	18	12 YEARS	N/A	HAEMOPHILIA A
NCT01560624	GERMANY	UNITED THERAPEUTICS	DRUG	2. RECRUITING	3	858	18 YEARS	75 YEARS	PULMONARY HYPERTENSION

1 Identifier: The official study ID given by ClinicalTrials.gov.

2 When the type field is empty, it is commonly a noninterventonal study.

3 "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventonal study, but it can also represent an interventonal device trial.

Studies Opening Additional Sites in a Country, from Page 32

IDENTIFIER ¹	COUNTRY	SPONSOR	TYPE ²	STATUS	PHASE ³	SIZE (N)	MIN AGE	MAX AGE	CONDITION
NCT01560637	GERMANY	UNITED THERAPEUTICS	DRUG	2. RECRUITING	3	858	18 YEARS	75 YEARS	PULMONARY HYPERTENSION
NCT01566695	GERMANY	CELGENE	DRUG	2. RECRUITING	3	386	18 YEARS	N/A	MYELODYSPLASTIC
NCT01663402	GERMANY	SANOFI	DRUG	2. RECRUITING	3	18,000	40 YEARS	N/A	ACUTE CORONARY SYNDROME
NCT01682512	GERMANY	BOEHRINGER INGELHEIM	DRUG	2. RECRUITING	3	306	18 YEARS	80 YEARS	ARTHRITIS, RHEUMATOID
NCT01682759	GERMANY	MERCK	DRUG	2. RECRUITING	3	680	18 YEARS	N/A	DIABETES
NCT01703208	GERMANY	MERCK	DRUG	2. RECRUITING	3	4,000	40 YEARS	N/A	DIABETES
NCT01708174	GERMANY	NOVARTIS	DRUG	2. RECRUITING	3	109	N/A	N/A	MEDULLOBLASTOMA
NCT01731600	GERMANY	NOVO NORDISK	DRUG	2. RECRUITING	3	60	N/A	11 YEARS	HAEMOPHILIA A
NCT01828099	GERMANY	NOVARTIS	DRUG	2. RECRUITING	3	348	18 YEARS	N/A	LUNG CANCER
NCT01828112	GERMANY	NOVARTIS	DRUG	2. RECRUITING	3	236	18 YEARS	N/A	LUNG CANCER
NCT01868061	GERMANY	HOFFMANN-LA ROCHE	DRUG	2. RECRUITING	3	1,050	18 YEARS	75 YEARS	ASTHMA
NCT00867815	GERMANY	BAYER	DRUG	2. RECRUITING	4	284	40 YEARS	N/A	OPTIC NEUROPATHY
NCT01574703	GERMANY	PFIZER	DRUG	2. RECRUITING	4	8,000	18 YEARS	75 YEARS	SMOKING CESSATION
NCT01697358	GERMANY	MEDTRONIC	DEVICE	2. RECRUITING	4	300	18 YEARS	N/A	PAIN IN LEG
NCT01511913	GERMANY	BMS		2. RECRUITING	NA	1,800	18 YEARS	N/A	MELANOMA
NCT01598844	GERMANY	JENAVALVE	DEVICE	2. RECRUITING	NA	180	N/A	N/A	AORTIC STENOSIS
NCT01671007	GERMANY	BOEHRINGER INGELHEIM		2. RECRUITING	NA	18,091	18 YEARS	N/A	ATRIAL FIBRILLATION
NCT01791361	GERMANY	AMGEN	OTHER	2. RECRUITING	NA	450	18 YEARS	N/A	COLORECTAL CANCER
NCT01916278	GERMANY	Q-MED	DEVICE	2. RECRUITING	NA	MISSING	18 YEARS	65 YEARS	LIP FILLER INJECTIONS
NCT01393626	GREECE	PFIZER	DRUG	2. RECRUITING	2	275	18 YEARS	75 YEARS	CROHN'S DISEASE
NCT01697579	GREECE	MERCK	DRUG	2. RECRUITING	2	256	N/A	17 YEARS	CHEMOTHERAPY NAUSEA/ VOMITING
NCT01201356	GREECE	NOVARTIS	DRUG	2. RECRUITING	3	5,000	18 YEARS	N/A	MULTIPLE SCLEROSIS
NCT01480479	GREECE	CELLDEX	DRUG	2. RECRUITING	3	440	18 YEARS	N/A	GLIOBLASTOMA

1 Identifier: The official study ID given by ClinicalTrials.gov.

2 When the type field is empty, it is commonly a noninterventional study.

3 "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

(Return to Page 1)

(See **Studies Opening Additional Sites in a Country**, Page 34)

Studies Opening Additional Sites in a Country, from Page 33

IDENTIFIER ¹	COUNTRY	SPONSOR	TYPE ²	STATUS	PHASE ³	SIZE (N)	MIN AGE	MAX AGE	CONDITION
NCT01731600	GREECE	NOVO NORDISK	DRUG	2. RECRUITING	3	60	N/A	11 YEARS	HAEMOPHILIA A
NCT01828099	GREECE	NOVARTIS	DRUG	2. RECRUITING	3	348	18 YEARS	N/A	LUNG CANCER
NCT01671007	GREECE	BOEHRINGER INGELHEIM		2. RECRUITING	NA	18,091	18 YEARS	N/A	ATRIAL FIBRILLATION
NCT01201356	GUATEMALA	NOVARTIS	DRUG	2. RECRUITING	3	5,000	18 YEARS	N/A	MULTIPLE SCLEROSIS
NCT00625378	HONG KONG	BAYER	DRUG	2. RECRUITING	3	1,000	16 YEARS	N/A	NEOPLASMS
NCT01663402	HONG KONG	SANOFI	DRUG	2. RECRUITING	3	18,000	40 YEARS	N/A	ACUTE CORONARY SYNDROME
NCT01703208	HONG KONG	MERCK	DRUG	2. RECRUITING	3	4,000	40 YEARS	N/A	DIABETES
NCT01767467	HONG KONG	GSK	BIOLOGICAL	2. RECRUITING	3	502	18 YEARS	N/A	HERPES ZOSTER
NCT01828112	HONG KONG	NOVARTIS	DRUG	2. RECRUITING	3	236	18 YEARS	N/A	LUNG CANCER
NCT01840410	HUNGARY	NOVARTIS	DRUG	1. PLANNING	3	187	12 YEARS	N/A	MACULAR DEGENERATION
NCT01393626	HUNGARY	PFIZER	DRUG	2. RECRUITING	2	275	18 YEARS	75 YEARS	CROHN'S DISEASE
NCT01697579	HUNGARY	MERCK	DRUG	2. RECRUITING	2	256	N/A	17 YEARS	CHEMOTHERAPY NAUSEA/ VOMITING
NCT01767090	HUNGARY	ASTELLAS	DRUG	2. RECRUITING	2	600	18 YEARS	45 YEARS	ENDOMETRIOSIS
NCT01201356	HUNGARY	NOVARTIS	DRUG	2. RECRUITING	3	5,000	18 YEARS	N/A	MULTIPLE SCLEROSIS
NCT01479244	HUNGARY	GALENA	BIOLOGICAL	2. RECRUITING	3	700	18 YEARS	N/A	BREAST CANCER
NCT01480479	HUNGARY	CELLDEX	DRUG	2. RECRUITING	3	440	18 YEARS	N/A	GLIOBLASTOMA
NCT01489111	HUNGARY	NOVO NORDISK	DRUG	2. RECRUITING	3	18	12 YEARS	N/A	HAEMOPHILIA A
NCT01663402	HUNGARY	SANOFI	DRUG	2. RECRUITING	3	18,000	40 YEARS	N/A	ACUTE CORONARY SYNDROME
NCT01682512	HUNGARY	BOEHRINGER INGELHEIM	DRUG	2. RECRUITING	3	306	18 YEARS	80 YEARS	ARTHRITIS, RHEUMATOID
NCT01682759	HUNGARY	MERCK	DRUG	2. RECRUITING	3	680	18 YEARS	N/A	DIABETES
NCT01703208	HUNGARY	MERCK	DRUG	2. RECRUITING	3	4,000	40 YEARS	N/A	DIABETES
NCT01708174	HUNGARY	NOVARTIS	DRUG	2. RECRUITING	3	109	N/A	N/A	MEDULLOBLASTOMA
NCT01828099	HUNGARY	NOVARTIS	DRUG	2. RECRUITING	3	348	18 YEARS	N/A	LUNG CANCER

1 Identifier: The official study ID given by ClinicalTrials.gov.

2 When the type field is empty, it is commonly a noninterventonal study.

3 "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventonal study, but it can also represent an interventonal device trial.

(Return to Page 1)

(See Studies Opening Additional Sites in a Country, Page 35)

Studies Opening Additional Sites in a Country, from Page 34

IDENTIFIER ¹	COUNTRY	SPONSOR	TYPE ²	STATUS	PHASE ³	SIZE (N)	MIN AGE	MAX AGE	CONDITION
NCT01868061	HUNGARY	HOFFMANN-LA ROCHE	DRUG	2. RECRUITING	3	1,050	18 YEARS	75 YEARS	ASTHMA
NCT01480479	INDIA	CELLDEX	DRUG	2. RECRUITING	3	440	18 YEARS	N/A	GLIOBLASTOMA
NCT01757405	INDIA	BAXTER	BIOLOGICAL	2. RECRUITING	3	34	12 YEARS	65 YEARS	HEMOPHILIA B
NCT01828099	INDIA	NOVARTIS	DRUG	2. RECRUITING	3	348	18 YEARS	N/A	LUNG CANCER
NCT01201356	IRELAND	NOVARTIS	DRUG	2. RECRUITING	3	5,000	18 YEARS	N/A	MULTIPLE SCLEROSIS
NCT01682512	IRELAND	BOEHRINGER INGELHEIM	DRUG	2. RECRUITING	3	306	18 YEARS	80 YEARS	ARTHRITIS, RHEUMATOID
NCT01511913	IRELAND	BMS		2. RECRUITING	NA	1,800	18 YEARS	N/A	MELANOMA
NCT01201356	ISRAEL	NOVARTIS	DRUG	2. RECRUITING	3	5,000	18 YEARS	N/A	MULTIPLE SCLEROSIS
NCT01479244	ISRAEL	GALENA	BIOLOGICAL	2. RECRUITING	3	700	18 YEARS	N/A	BREAST CANCER
NCT01663402	ISRAEL	SANOFI	DRUG	2. RECRUITING	3	18,000	40 YEARS	N/A	ACUTE CORONARY SYNDROME
NCT01703208	ISRAEL	MERCK	DRUG	2. RECRUITING	3	4,000	40 YEARS	N/A	DIABETES
NCT01708174	ISRAEL	NOVARTIS	DRUG	2. RECRUITING	3	109	N/A	N/A	MEDULLOBLASTOMA
NCT01731600	ISRAEL	NOVO NORDISK	DRUG	2. RECRUITING	3	60	N/A	11 YEARS	HAEMOPHILIA A
NCT01828112	ISRAEL	NOVARTIS	DRUG	2. RECRUITING	3	236	18 YEARS	N/A	LUNG CANCER
NCT01841684	ISRAEL	MERCK	DRUG	2. RECRUITING	3	45	18 YEARS	N/A	HYPERCHOLESTEROLEMIA
NCT01846611	ISRAEL	JANSSEN	DRUG	2. RECRUITING	3	670	18 YEARS	N/A	FALLOPIAN TUBE NEOPLASMS
NCT01868061	ISRAEL	HOFFMANN-LA ROCHE	DRUG	2. RECRUITING	3	1,050	18 YEARS	75 YEARS	ASTHMA
NCT01511913	ISRAEL	BMS		2. RECRUITING	NA	1,800	18 YEARS	N/A	MELANOMA
NCT01907100	ITALY	BOEHRINGER INGELHEIM	DRUG	1. PLANNING	2	86	18 YEARS	N/A	MESOTHELIOMA
NCT01840410	ITALY	NOVARTIS	DRUG	1. PLANNING	3	187	12 YEARS	N/A	MACULAR DEGENERATION
NCT01628393	ITALY	RECEPTOS	DRUG	2. RECRUITING	2	210	18 YEARS	55 YEARS	MULTIPLE SCLEROSIS
NCT01656395	ITALY	MERCK	DRUG	2. RECRUITING	2	1,475	18 YEARS	65 YEARS	ASTHMA
NCT01697579	ITALY	MERCK	DRUG	2. RECRUITING	2	256	N/A	17 YEARS	CHEMOTHERAPY NAUSEA/ VOMITING

1 Identifier: The official study ID given by ClinicalTrials.gov.

2 When the type field is empty, it is commonly a noninterventional study.

3 "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

Studies Opening Additional Sites in a Country, *from Page 35*

IDENTIFIER ¹	COUNTRY	SPONSOR	TYPE ²	STATUS	PHASE ³	SIZE (N)	MIN AGE	MAX AGE	CONDITION
NCT01762852	ITALY	GSK	DRUG	2. RECRUITING	2	94	18 YEARS	75 YEARS	GLOMERULONEPHRITIS
NCT00625378	ITALY	BAYER	DRUG	2. RECRUITING	3	1,000	16 YEARS	N/A	NEOPLASMS
NCT01201356	ITALY	NOVARTIS	DRUG	2. RECRUITING	3	5,000	18 YEARS	N/A	MULTIPLE SCLEROSIS
NCT01489111	ITALY	NOVO NORDISK	DRUG	2. RECRUITING	3	18	12 YEARS	N/A	HAEMOPHILIA A
NCT01560624	ITALY	UNITED THERAPEUTICS	DRUG	2. RECRUITING	3	858	18 YEARS	75 YEARS	PULMONARY HYPERTENSION
NCT01560637	ITALY	UNITED THERAPEUTICS	DRUG	2. RECRUITING	3	858	18 YEARS	75 YEARS	PULMONARY HYPERTENSION
NCT01566695	ITALY	CELGENE	DRUG	2. RECRUITING	3	386	18 YEARS	N/A	MYELODYSPLASTIC
NCT01663402	ITALY	SANOFI	DRUG	2. RECRUITING	3	18,000	40 YEARS	N/A	ACUTE CORONARY SYNDROME
NCT01682512	ITALY	BOEHRINGER INGELHEIM	DRUG	2. RECRUITING	3	306	18 YEARS	80 YEARS	ARTHRITIS, RHEUMATOID
NCT01703208	ITALY	MERCK	DRUG	2. RECRUITING	3	4,000	40 YEARS	N/A	DIABETES
NCT01708174	ITALY	NOVARTIS	DRUG	2. RECRUITING	3	109	N/A	N/A	MEDULLOBLASTOMA
NCT01731600	ITALY	NOVO NORDISK	DRUG	2. RECRUITING	3	60	N/A	11 YEARS	HAEMOPHILIA A
NCT01752322	ITALY	GRENENTHAL	DRUG	2. RECRUITING	3	600	18 YEARS	N/A	POSTOPERATIVE PAIN
NCT01767467	ITALY	GSK	BIOLOGICAL	2. RECRUITING	3	502	18 YEARS	N/A	HERPES ZOSTER
NCT01828099	ITALY	NOVARTIS	DRUG	2. RECRUITING	3	348	18 YEARS	N/A	LUNG CANCER
NCT01828112	ITALY	NOVARTIS	DRUG	2. RECRUITING	3	236	18 YEARS	N/A	LUNG CANCER
NCT01868061	ITALY	HOFFMANN-LA ROCHE	DRUG	2. RECRUITING	3	1,050	18 YEARS	75 YEARS	ASTHMA
NCT00867815	ITALY	BAYER	DRUG	2. RECRUITING	4	284	40 YEARS	N/A	OPTIC NEUROPATHY
NCT01393626	JAPAN	PFIZER	DRUG	2. RECRUITING	2	275	18 YEARS	75 YEARS	CROHN'S DISEASE
NCT01656395	JAPAN	MERCK	DRUG	2. RECRUITING	2	1,475	18 YEARS	65 YEARS	ASTHMA
NCT01767090	JAPAN	ASTELLAS	DRUG	2. RECRUITING	2	600	18 YEARS	45 YEARS	ENDOMETRIOSIS
NCT01098110	JAPAN	MERCK	DRUG	2. RECRUITING	3	528	20 YEARS	64 YEARS	SCHIZOPHRENIA
NCT01489111	JAPAN	NOVO NORDISK	DRUG	2. RECRUITING	3	18	12 YEARS	N/A	HAEMOPHILIA A
NCT01731600	JAPAN	NOVO NORDISK	DRUG	2. RECRUITING	3	60	N/A	11 YEARS	HAEMOPHILIA A

1 Identifier: The official study ID given by ClinicalTrials.gov.

2 When the type field is empty, it is commonly a noninterventional study.

3 "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

(Return to Page 1)

(See Studies Opening Additional Sites in a Country, Page 37)

Studies Opening Additional Sites in a Country, from Page 36

IDENTIFIER ¹	COUNTRY	SPONSOR	TYPE ²	STATUS	PHASE ³	SIZE (N)	MIN AGE	MAX AGE	CONDITION
NCT01757405	JAPAN	BAXTER	BIOLOGICAL	2. RECRUITING	3	34	12 YEARS	65 YEARS	HEMOPHILIA B
NCT01828099	JAPAN	NOVARTIS	DRUG	2. RECRUITING	3	348	18 YEARS	N/A	LUNG CANCER
NCT01828112	JAPAN	NOVARTIS	DRUG	2. RECRUITING	3	236	18 YEARS	N/A	LUNG CANCER
NCT01868061	JAPAN	HOFFMANN-LA ROCHE	DRUG	2. RECRUITING	3	1,050	18 YEARS	75 YEARS	ASTHMA
NCT01393626	KOREA, SOUTH	PFIZER	DRUG	2. RECRUITING	2	275	18 YEARS	75 YEARS	CROHN'S DISEASE
NCT00625378	KOREA, SOUTH	BAYER	DRUG	2. RECRUITING	3	1,000	16 YEARS	N/A	NEOPLASMS
NCT01098110	KOREA, SOUTH	MERCK	DRUG	2. RECRUITING	3	528	20 YEARS	64 YEARS	SCHIZOPHRENIA
NCT01201356	KOREA, SOUTH	NOVARTIS	DRUG	2. RECRUITING	3	5,000	18 YEARS	N/A	MULTIPLE SCLEROSIS
NCT01489111	KOREA, SOUTH	NOVO NORDISK	DRUG	2. RECRUITING	3	18	12 YEARS	N/A	HAEMOPHILIA A
NCT01560624	KOREA, SOUTH	UNITED THERAPEUTICS	DRUG	2. RECRUITING	3	858	18 YEARS	75 YEARS	PULMONARY HYPERTENSION
NCT01560637	KOREA, SOUTH	UNITED THERAPEUTICS	DRUG	2. RECRUITING	3	858	18 YEARS	75 YEARS	PULMONARY HYPERTENSION
NCT01641926	KOREA, SOUTH	MERCK	BIOLOGICAL	2. RECRUITING	3	1,400	18 YEARS	N/A	HEPATITIS B, CHRONIC
NCT01663402	KOREA, SOUTH	SANOFI	DRUG	2. RECRUITING	3	18,000	40 YEARS	N/A	ACUTE CORONARY SYNDROME
NCT01682759	KOREA, SOUTH	MERCK	DRUG	2. RECRUITING	3	680	18 YEARS	N/A	DIABETES
NCT01703208	KOREA, SOUTH	MERCK	DRUG	2. RECRUITING	3	4,000	40 YEARS	N/A	DIABETES
NCT01734785	KOREA, SOUTH	BOEHRINGER INGELHEIM	DRUG	2. RECRUITING	3	444	18 YEARS	N/A	DIABETES
NCT01767467	KOREA, SOUTH	GSK	BIOLOGICAL	2. RECRUITING	3	502	18 YEARS	N/A	HERPES ZOSTER
NCT01840410	LATVIA	NOVARTIS	DRUG	1. PLANNING	3	187	12 YEARS	N/A	MACULAR DEGENERATION
NCT01663402	LATVIA	SANOFI	DRUG	2. RECRUITING	3	18,000	40 YEARS	N/A	ACUTE CORONARY SYNDROME
NCT01671007	LATVIA	BOEHRINGER INGELHEIM		2. RECRUITING	NA	18,091	18 YEARS	N/A	ATRIAL FIBRILLATION
NCT01682759	LEBANON	MERCK	DRUG	2. RECRUITING	3	680	18 YEARS	N/A	DIABETES
NCT01703208	LEBANON	MERCK	DRUG	2. RECRUITING	3	4,000	40 YEARS	N/A	DIABETES
NCT01828099	LEBANON	NOVARTIS	DRUG	2. RECRUITING	3	348	18 YEARS	N/A	LUNG CANCER

1 Identifier: The official study ID given by ClinicalTrials.gov.

2 When the type field is empty, it is commonly a noninterventional study.

3 "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

Studies Opening Additional Sites in a Country, from Page 37

IDENTIFIER ¹	COUNTRY	SPONSOR	TYPE ²	STATUS	PHASE ³	SIZE (N)	MIN AGE	MAX AGE	CONDITION
NCT01840410	LITHUANIA	NOVARTIS	DRUG	1. PLANNING	3	187	12 YEARS	N/A	MACULAR DEGENERATION
NCT01697579	LITHUANIA	MERCK	DRUG	2. RECRUITING	2	256	N/A	17 YEARS	CHEMOTHERAPY NAUSEA/ VOMITING
NCT01663402	LITHUANIA	SANOFI	DRUG	2. RECRUITING	3	18,000	40 YEARS	N/A	ACUTE CORONARY SYNDROME
NCT01682759	LITHUANIA	MERCK	DRUG	2. RECRUITING	3	680	18 YEARS	N/A	DIABETES
NCT01703208	LITHUANIA	MERCK	DRUG	2. RECRUITING	3	4,000	40 YEARS	N/A	DIABETES
NCT01731600	LITHUANIA	NOVO NORDISK	DRUG	2. RECRUITING	3	60	N/A	11 YEARS	HAEMOPHILIA A
NCT01835431	MACEDONIA	NOVO NORDISK	DRUG	1. PLANNING	3	346	1 YEAR	17 YEARS	DIABETES
NCT01201356	MALAYSIA	NOVARTIS	DRUG	2. RECRUITING	3	5,000	18 YEARS	N/A	MULTIPLE SCLEROSIS
NCT01489111	MALAYSIA	NOVO NORDISK	DRUG	2. RECRUITING	3	18	12 YEARS	N/A	HAEMOPHILIA A
NCT01663402	MALAYSIA	SANOFI	DRUG	2. RECRUITING	3	18,000	40 YEARS	N/A	ACUTE CORONARY SYNDROME
NCT01682759	MALAYSIA	MERCK	DRUG	2. RECRUITING	3	680	18 YEARS	N/A	DIABETES
NCT01703208	MALAYSIA	MERCK	DRUG	2. RECRUITING	3	4,000	40 YEARS	N/A	DIABETES
NCT01731600	MALAYSIA	NOVO NORDISK	DRUG	2. RECRUITING	3	60	N/A	11 YEARS	HAEMOPHILIA A
NCT01930188	MEXICO	NOVO NORDISK	DRUG	1. PLANNING	3	1,200	18 YEARS	N/A	DIABETES
NCT01480479	MEXICO	CELLEX	DRUG	2. RECRUITING	3	440	18 YEARS	N/A	GLIOBLASTOMA
NCT01663402	MEXICO	SANOFI	DRUG	2. RECRUITING	3	18,000	40 YEARS	N/A	ACUTE CORONARY SYNDROME
NCT01511913	MEXICO	BMS		2. RECRUITING	NA	1,800	18 YEARS	N/A	MELANOMA
NCT01751776	NETHERLANDS	BOEHRINGER INGELHEIM	DRUG	2. RECRUITING	1	121	18 YEARS	70 YEARS	HEALTHY
NCT01762852	NETHERLANDS	GSK	DRUG	2. RECRUITING	2	94	18 YEARS	75 YEARS	GLOMERULONEPHRITIS
NCT01201356	NETHERLANDS	NOVARTIS	DRUG	2. RECRUITING	3	5,000	18 YEARS	N/A	MULTIPLE SCLEROSIS
NCT01489111	NETHERLANDS	NOVO NORDISK	DRUG	2. RECRUITING	3	18	12 YEARS	N/A	HAEMOPHILIA A
NCT01560624	NETHERLANDS	UNITED THERAPEUTICS	DRUG	2. RECRUITING	3	858	18 YEARS	75 YEARS	PULMONARY HYPERTENSION

¹ Identifier: The official study ID given by ClinicalTrials.gov.

² When the type field is empty, it is commonly a noninterventional study.

³ "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

Studies Opening Additional Sites in a Country, from Page 38

IDENTIFIER ¹	COUNTRY	SPONSOR	TYPE ²	STATUS	PHASE ³	SIZE (N)	MIN AGE	MAX AGE	CONDITION
NCT01560637	NETHERLANDS	UNITED THERAPEUTICS	DRUG	2. RECRUITING	3	858	18 YEARS	75 YEARS	PULMONARY HYPERTENSION
NCT01663402	NETHERLANDS	SANOFI	DRUG	2. RECRUITING	3	18,000	40 YEARS	N/A	ACUTE CORONARY SYNDROME
NCT01682512	NETHERLANDS	BOEHRINGER INGELHEIM	DRUG	2. RECRUITING	3	306	18 YEARS	80 YEARS	ARTHRITIS, RHEUMATOID
NCT01703208	NETHERLANDS	MERCK	DRUG	2. RECRUITING	3	4,000	40 YEARS	N/A	DIABETES
NCT01708174	NETHERLANDS	NOVARTIS	DRUG	2. RECRUITING	3	109	N/A	N/A	MEDULLOBLASTOMA
NCT01828099	NETHERLANDS	NOVARTIS	DRUG	2. RECRUITING	3	348	18 YEARS	N/A	LUNG CANCER
NCT01828112	NETHERLANDS	NOVARTIS	DRUG	2. RECRUITING	3	236	18 YEARS	N/A	LUNG CANCER
NCT01697358	NETHERLANDS	MEDTRONIC	DEVICE	2. RECRUITING	4	300	18 YEARS	N/A	PAIN IN LEG
NCT01897532	NETHERLANDS	BOEHRINGER INGELHEIM	DRUG	2. RECRUITING	4	8,300	18 YEARS	N/A	DIABETES
NCT01671007	NETHERLANDS	BOEHRINGER INGELHEIM		2. RECRUITING	NA	18,091	18 YEARS	N/A	ATRIAL FIBRILLATION
NCT01791361	NETHERLANDS	AMGEN	OTHER	2. RECRUITING	NA	450	18 YEARS	N/A	COLORECTAL CANCER
NCT01911897	NETHERLANDS	VASCULAR DYNAMICS	DEVICE	2. RECRUITING	NA	20	18 YEARS	80 YEARS	HYPERTENSION
NCT01751776	NEW ZEALAND	BOEHRINGER INGELHEIM	DRUG	2. RECRUITING	1	121	18 YEARS	70 YEARS	HEALTHY
NCT00625378	NEW ZEALAND	BAYER	DRUG	2. RECRUITING	3	1,000	16 YEARS	N/A	NEOPLASMS
NCT01480479	NEW ZEALAND	CELLDEX	DRUG	2. RECRUITING	3	440	18 YEARS	N/A	GLIOBLASTOMA
NCT01663402	NEW ZEALAND	SANOFI	DRUG	2. RECRUITING	3	18,000	40 YEARS	N/A	ACUTE CORONARY SYNDROME
NCT01682512	NEW ZEALAND	BOEHRINGER INGELHEIM	DRUG	2. RECRUITING	3	306	18 YEARS	80 YEARS	ARTHRITIS, RHEUMATOID
NCT01703208	NEW ZEALAND	MERCK	DRUG	2. RECRUITING	3	4,000	40 YEARS	N/A	DIABETES
NCT01734785	NEW ZEALAND	BOEHRINGER INGELHEIM	DRUG	2. RECRUITING	3	444	18 YEARS	N/A	DIABETES
NCT01767467	NEW ZEALAND	GSK	BIOLOGICAL	2. RECRUITING	3	502	18 YEARS	N/A	HERPES ZOSTER
NCT01846611	NEW ZEALAND	JANSSEN	DRUG	2. RECRUITING	3	670	18 YEARS	N/A	FALLOPIAN TUBE NEOPLASMS
NCT01868061	NEW ZEALAND	HOFFMANN-LA ROCHE	DRUG	2. RECRUITING	3	1,050	18 YEARS	75 YEARS	ASTHMA
NCT01574703	NEW ZEALAND	PFIZER	DRUG	2. RECRUITING	4	8,000	18 YEARS	75 YEARS	SMOKING CESSATION

¹ Identifier: The official study ID given by ClinicalTrials.gov.

² When the type field is empty, it is commonly a noninterventional study.

³ "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

(Return to Page 1)

(See **Studies Opening Additional Sites in a Country**, Page 40)

Studies Opening Additional Sites in a Country, from Page 39

IDENTIFIER ¹	COUNTRY	SPONSOR	TYPE ²	STATUS	PHASE ³	SIZE (N)	MIN AGE	MAX AGE	CONDITION
NCT01295827	NORWAY	MERCK	DRUG	2. RECRUITING	1	1,067	18 YEARS	N/A	SOLID TUMOR
NCT01201356	NORWAY	NOVARTIS	DRUG	2. RECRUITING	3	5,000	18 YEARS	N/A	MULTIPLE SCLEROSIS
NCT01489111	NORWAY	NOVO NORDISK	DRUG	2. RECRUITING	3	18	12 YEARS	N/A	HAEMOPHILIA A
NCT01663402	NORWAY	SANOFI	DRUG	2. RECRUITING	3	18,000	40 YEARS	N/A	ACUTE CORONARY SYNDROME
NCT01734785	NORWAY	BOEHRINGER INGELHEIM	DRUG	2. RECRUITING	3	444	18 YEARS	N/A	DIABETES
NCT01841684	NORWAY	MERCK	DRUG	2. RECRUITING	3	45	18 YEARS	N/A	HYPERCHOLESTEROLEMIA
NCT01671007	NORWAY	BOEHRINGER INGELHEIM		2. RECRUITING	NA	18,091	18 YEARS	N/A	ATRIAL FIBRILLATION
NCT01201356	PANAMA	NOVARTIS	DRUG	2. RECRUITING	3	5,000	18 YEARS	N/A	MULTIPLE SCLEROSIS
NCT01767467	PANAMA	GSK	BIOLOGICAL	2. RECRUITING	3	502	18 YEARS	N/A	HERPES ZOSTER
NCT01656395	PERU	MERCK	DRUG	2. RECRUITING	2	1,475	18 YEARS	65 YEARS	ASTHMA
NCT01201356	PERU	NOVARTIS	DRUG	2. RECRUITING	3	5,000	18 YEARS	N/A	MULTIPLE SCLEROSIS
NCT01480479	PERU	CELLEX	DRUG	2. RECRUITING	3	440	18 YEARS	N/A	GLIOBLASTOMA
NCT01663402	PERU	SANOFI	DRUG	2. RECRUITING	3	18,000	40 YEARS	N/A	ACUTE CORONARY SYNDROME
NCT01868061	PERU	HOFFMANN-LA ROCHE	DRUG	2. RECRUITING	3	1,050	18 YEARS	75 YEARS	ASTHMA
NCT01663402	PHILIPPINES	SANOFI	DRUG	2. RECRUITING	3	18,000	40 YEARS	N/A	ACUTE CORONARY SYNDROME
NCT01835431	POLAND	NOVO NORDISK	DRUG	1. PLANNING	3	346	1 YEAR	17 YEARS	DIABETES
NCT01840410	POLAND	NOVARTIS	DRUG	1. PLANNING	3	187	12 YEARS	N/A	MACULAR DEGENERATION
NCT01928979	POLAND	BAYER	OTHER	1. PLANNING	NA	150	18 YEARS	N/A	ATRIAL FIBRILLATION
NCT01628393	POLAND	RECEPTOS	DRUG	2. RECRUITING	2	210	18 YEARS	55 YEARS	MULTIPLE SCLEROSIS
NCT01767090	POLAND	ASTELLAS	DRUG	2. RECRUITING	2	600	18 YEARS	45 YEARS	ENDOMETRIOSIS
NCT00625378	POLAND	BAYER	DRUG	2. RECRUITING	3	1,000	16 YEARS	N/A	NEOPLASMS
NCT01201356	POLAND	NOVARTIS	DRUG	2. RECRUITING	3	5,000	18 YEARS	N/A	MULTIPLE SCLEROSIS
NCT01479244	POLAND	GALENA	BIOLOGICAL	2. RECRUITING	3	700	18 YEARS	N/A	BREAST CANCER

1 Identifier: The official study ID given by ClinicalTrials.gov.

2 When the type field is empty, it is commonly a noninterventional study.

3 "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

Studies Opening Additional Sites in a Country, from Page 40

IDENTIFIER ¹	COUNTRY	SPONSOR	TYPE ²	STATUS	PHASE ³	SIZE (N)	MIN AGE	MAX AGE	CONDITION
NCT01480479	POLAND	CELLDEX	DRUG	2. RECRUITING	3	440	18 YEARS	N/A	GLIOBLASTOMA
NCT01663402	POLAND	SANOFI	DRUG	2. RECRUITING	3	18,000	40 YEARS	N/A	ACUTE CORONARY SYNDROME
NCT01682512	POLAND	BOEHRINGER INGELHEIM	DRUG	2. RECRUITING	3	306	18 YEARS	80 YEARS	ARTHRITIS, RHEUMATOID
NCT01682759	POLAND	MERCK	DRUG	2. RECRUITING	3	680	18 YEARS	N/A	DIABETES
NCT01703208	POLAND	MERCK	DRUG	2. RECRUITING	3	4,000	40 YEARS	N/A	DIABETES
NCT01708174	POLAND	NOVARTIS	DRUG	2. RECRUITING	3	109	N/A	N/A	MEDULLOBLASTOMA
NCT01757405	POLAND	BAXTER	BIOLOGICAL	2. RECRUITING	3	34	12 YEARS	65 YEARS	HEMOPHILIA B
NCT01868061	POLAND	HOFFMANN-LA ROCHE	DRUG	2. RECRUITING	3	1,050	18 YEARS	75 YEARS	ASTHMA
NCT01840410	PORTUGAL	NOVARTIS	DRUG	1. PLANNING	3	187	12 YEARS	N/A	MACULAR DEGENERATION
NCT01697579	PORTUGAL	MERCK	DRUG	2. RECRUITING	2	256	N/A	17 YEARS	CHEMOTHERAPY NAUSEA/ VOMITING
NCT01201356	PORTUGAL	NOVARTIS	DRUG	2. RECRUITING	3	5,000	18 YEARS	N/A	MULTIPLE SCLEROSIS
NCT01566695	PORTUGAL	CELGENE	DRUG	2. RECRUITING	3	386	18 YEARS	N/A	MYELODYSPLASTIC
NCT01663402	PORTUGAL	SANOFI	DRUG	2. RECRUITING	3	18,000	40 YEARS	N/A	ACUTE CORONARY SYNDROME
NCT01682512	PORTUGAL	BOEHRINGER INGELHEIM	DRUG	2. RECRUITING	3	306	18 YEARS	80 YEARS	ARTHRITIS, RHEUMATOID
NCT01671007	PORTUGAL	BOEHRINGER INGELHEIM		2. RECRUITING	NA	18,091	18 YEARS	N/A	ATRIAL FIBRILLATION
NCT01393626	ROMANIA	PFIZER	DRUG	2. RECRUITING	2	275	18 YEARS	75 YEARS	CROHN'S DISEASE
NCT01628393	ROMANIA	RECEPTOS	DRUG	2. RECRUITING	2	210	18 YEARS	55 YEARS	MULTIPLE SCLEROSIS
NCT01697579	ROMANIA	MERCK	DRUG	2. RECRUITING	2	256	N/A	17 YEARS	CHEMOTHERAPY NAUSEA/ VOMITING
NCT01201356	ROMANIA	NOVARTIS	DRUG	2. RECRUITING	3	5,000	18 YEARS	N/A	MULTIPLE SCLEROSIS
NCT01479244	ROMANIA	GALENA	BIOLOGICAL	2. RECRUITING	3	700	18 YEARS	N/A	BREAST CANCER
NCT01663402	ROMANIA	SANOFI	DRUG	2. RECRUITING	3	18,000	40 YEARS	N/A	ACUTE CORONARY SYNDROME
NCT01703208	ROMANIA	MERCK	DRUG	2. RECRUITING	3	4,000	40 YEARS	N/A	DIABETES

1 Identifier: The official study ID given by ClinicalTrials.gov.

2 When the type field is empty, it is commonly a noninterventional study.

3 "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

(Return to Page 1)

(See Studies Opening Additional Sites in a Country, Page 42)

Studies Opening Additional Sites in a Country, from Page 41

IDENTIFIER ¹	COUNTRY	SPONSOR	TYPE ²	STATUS	PHASE ³	SIZE (N)	MIN AGE	MAX AGE	CONDITION
NCT01757405	ROMANIA	BAXTER	BIOLOGICAL	2. RECRUITING	3	34	12 YEARS	65 YEARS	HEMOPHILIA B
NCT01671007	ROMANIA	BOEHRINGER INGELHEIM		2. RECRUITING	NA	18,091	18 YEARS	N/A	ATRIAL FIBRILLATION
NCT01835431	RUSSIA	NOVO NORDISK	DRUG	1. PLANNING	3	346	1 YEAR	17 YEARS	DIABETES
NCT01840410	RUSSIA	NOVARTIS	DRUG	1. PLANNING	3	187	12 YEARS	N/A	MACULAR DEGENERATION
NCT01928979	RUSSIA	BAYER	OTHER	1. PLANNING	NA	150	18 YEARS	N/A	ATRIAL FIBRILLATION
NCT00625378	RUSSIA	BAYER	DRUG	2. RECRUITING	3	1,000	16 YEARS	N/A	NEOPLASMS
NCT01201356	RUSSIA	NOVARTIS	DRUG	2. RECRUITING	3	5,000	18 YEARS	N/A	MULTIPLE SCLEROSIS
NCT01479244	RUSSIA	GALENA	BIOLOGICAL	2. RECRUITING	3	700	18 YEARS	N/A	BREAST CANCER
NCT01663402	RUSSIA	SANOFI	DRUG	2. RECRUITING	3	18,000	40 YEARS	N/A	ACUTE CORONARY SYNDROME
NCT01703208	RUSSIA	MERCK	DRUG	2. RECRUITING	3	4,000	40 YEARS	N/A	DIABETES
NCT01708174	RUSSIA	NOVARTIS	DRUG	2. RECRUITING	3	109	N/A	N/A	MEDULLOBLASTOMA
NCT01757405	RUSSIA	BAXTER	BIOLOGICAL	2. RECRUITING	3	34	12 YEARS	65 YEARS	HEMOPHILIA B
NCT01846611	RUSSIA	JANSSEN	DRUG	2. RECRUITING	3	670	18 YEARS	N/A	FALLOPIAN TUBE NEOPLASMS
NCT01868061	RUSSIA	HOFFMANN-LA ROCHE	DRUG	2. RECRUITING	3	1,050	18 YEARS	75 YEARS	ASTHMA
NCT01574703	RUSSIA	PFIZER	DRUG	2. RECRUITING	4	8,000	18 YEARS	75 YEARS	SMOKING CESSATION
NCT01835431	SERBIA	NOVO NORDISK	DRUG	1. PLANNING	3	346	1 YEAR	17 YEARS	DIABETES
NCT01885208	SERBIA	NOVO NORDISK	DRUG	1. PLANNING	3	798	18 YEARS	N/A	DIABETES
NCT01628393	SERBIA	RECEPTOS	DRUG	2. RECRUITING	2	210	18 YEARS	55 YEARS	MULTIPLE SCLEROSIS
NCT01663402	SERBIA	SANOFI	DRUG	2. RECRUITING	3	18,000	40 YEARS	N/A	ACUTE CORONARY SYNDROME
NCT01703208	SERBIA	MERCK	DRUG	2. RECRUITING	3	4,000	40 YEARS	N/A	DIABETES
NCT01838044	SINGAPORE	PFIZER	DRUG	1. PLANNING	4	366	18 YEARS	75 YEARS	BACK PAIN
NCT01663402	SINGAPORE	SANOFI	DRUG	2. RECRUITING	3	18,000	40 YEARS	N/A	ACUTE CORONARY SYNDROME
NCT01767467	SINGAPORE	GSK	BIOLOGICAL	2. RECRUITING	3	502	18 YEARS	N/A	HERPES ZOSTER

1 Identifier: The official study ID given by ClinicalTrials.gov.

2 When the type field is empty, it is commonly a noninterventional study.

3 "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

(Return to Page 1)

(See Studies Opening Additional Sites in a Country, Page 43)

Studies Opening Additional Sites in a Country, from Page 42

IDENTIFIER ¹	COUNTRY	SPONSOR	TYPE ²	STATUS	PHASE ³	SIZE (N)	MIN AGE	MAX AGE	CONDITION
NCT01828099	SINGAPORE	NOVARTIS	DRUG	2. RECRUITING	3	348	18 YEARS	N/A	LUNG CANCER
NCT01828112	SINGAPORE	NOVARTIS	DRUG	2. RECRUITING	3	236	18 YEARS	N/A	LUNG CANCER
NCT01840410	SLOVAKIA	NOVARTIS	DRUG	1. PLANNING	3	187	12 YEARS	N/A	MACULAR DEGENERATION
NCT01201356	SLOVAKIA	NOVARTIS	DRUG	2. RECRUITING	3	5,000	18 YEARS	N/A	MULTIPLE SCLEROSIS
NCT01663402	SLOVAKIA	SANOFI	DRUG	2. RECRUITING	3	18,000	40 YEARS	N/A	ACUTE CORONARY SYNDROME
NCT01703208	SLOVAKIA	MERCK	DRUG	2. RECRUITING	3	4,000	40 YEARS	N/A	DIABETES
NCT01574703	SLOVAKIA	PFIZER	DRUG	2. RECRUITING	4	8,000	18 YEARS	75 YEARS	SMOKING CESSATION
NCT01835431	SLOVENIA	NOVO NORDISK	DRUG	1. PLANNING	3	346	1 YEAR	17 YEARS	DIABETES
NCT01671007	SLOVENIA	BOEHRINGER INGELHEIM		2. RECRUITING	NA	18,091	18 YEARS	N/A	ATRIAL FIBRILLATION
NCT01840410	SOUTH AFRICA	NOVARTIS	DRUG	1. PLANNING	3	187	12 YEARS	N/A	MACULAR DEGENERATION
NCT01393626	SOUTH AFRICA	PFIZER	DRUG	2. RECRUITING	2	275	18 YEARS	75 YEARS	CROHN'S DISEASE
NCT01201356	SOUTH AFRICA	NOVARTIS	DRUG	2. RECRUITING	3	5,000	18 YEARS	N/A	MULTIPLE SCLEROSIS
NCT01663402	SOUTH AFRICA	SANOFI	DRUG	2. RECRUITING	3	18,000	40 YEARS	N/A	ACUTE CORONARY SYNDROME
NCT01703208	SOUTH AFRICA	MERCK	DRUG	2. RECRUITING	3	4,000	40 YEARS	N/A	DIABETES
NCT01846611	SOUTH AFRICA	JANSSEN	DRUG	2. RECRUITING	3	670	18 YEARS	N/A	FALLOPIAN TUBE NEOPLASMS
NCT01868061	SOUTH AFRICA	HOFFMANN-LA ROCHE	DRUG	2. RECRUITING	3	1,050	18 YEARS	75 YEARS	ASTHMA
NCT01574703	SOUTH AFRICA	PFIZER	DRUG	2. RECRUITING	4	8,000	18 YEARS	75 YEARS	SMOKING CESSATION
NCT01835431	SPAIN	NOVO NORDISK	DRUG	1. PLANNING	3	346	1 YEAR	17 YEARS	DIABETES
NCT01840410	SPAIN	NOVARTIS	DRUG	1. PLANNING	3	187	12 YEARS	N/A	MACULAR DEGENERATION
NCT01751776	SPAIN	BOEHRINGER INGELHEIM	DRUG	2. RECRUITING	1	121	18 YEARS	70 YEARS	HEALTHY
NCT01393626	SPAIN	PFIZER	DRUG	2. RECRUITING	2	275	18 YEARS	75 YEARS	CROHN'S DISEASE
NCT01665391	SPAIN	GENZYME	DRUG	2. RECRUITING	2	88	18 YEARS	N/A	GLOMERULO-SCLEROSIS
NCT01697579	SPAIN	MERCK	DRUG	2. RECRUITING	2	256	N/A	17 YEARS	CHEMOTHERAPY NAUSEA/ VOMITING

1 Identifier: The official study ID given by ClinicalTrials.gov.

2 When the type field is empty, it is commonly a noninterventional study.

3 "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

(Return to Page 1)

(See Studies Opening Additional Sites in a Country, Page 44)

Studies Opening Additional Sites in a Country, from Page 43

IDENTIFIER ¹	COUNTRY	SPONSOR	TYPE ²	STATUS	PHASE ³	SIZE (N)	MIN AGE	MAX AGE	CONDITION
NCT01740336	SPAIN	GENENTECH	DRUG	2. RECRUITING	2	180	18 YEARS	N/A	BREAST CANCER
NCT01762852	SPAIN	GSK	DRUG	2. RECRUITING	2	94	18 YEARS	75 YEARS	GLOMERULONEPHRITIS
NCT01786668	SPAIN	PFIZER	DRUG	2. RECRUITING	2	200	18 YEARS	N/A	ANKYLOSING SPONDYLITIS
NCT00625378	SPAIN	BAYER	DRUG	2. RECRUITING	3	1,000	16 YEARS	N/A	NEOPLASMS
NCT01201356	SPAIN	NOVARTIS	DRUG	2. RECRUITING	3	5,000	18 YEARS	N/A	MULTIPLE SCLEROSIS
NCT01489111	SPAIN	NOVO NORDISK	DRUG	2. RECRUITING	3	18	12 YEARS	N/A	HAEMOPHILIA A
NCT01566695	SPAIN	CELGENE	DRUG	2. RECRUITING	3	386	18 YEARS	N/A	MYELODYSPLASTIC
NCT01663402	SPAIN	SANOFI	DRUG	2. RECRUITING	3	18,000	40 YEARS	N/A	ACUTE CORONARY SYNDROME
NCT01682512	SPAIN	BOEHRINGER INGELHEIM	DRUG	2. RECRUITING	3	306	18 YEARS	80 YEARS	ARTHRITIS, RHEUMATOID
NCT01703208	SPAIN	MERCK	DRUG	2. RECRUITING	3	4,000	40 YEARS	N/A	DIABETES
NCT01708174	SPAIN	NOVARTIS	DRUG	2. RECRUITING	3	109	N/A	N/A	MEDULLOBLASTOMA
NCT01734785	SPAIN	BOEHRINGER INGELHEIM	DRUG	2. RECRUITING	3	444	18 YEARS	N/A	DIABETES
NCT01752322	SPAIN	GREENTHAL	DRUG	2. RECRUITING	3	600	18 YEARS	N/A	POSTOPERATIVE PAIN
NCT01757405	SPAIN	BAXTER	BIOLOGICAL	2. RECRUITING	3	34	12 YEARS	65 YEARS	HEMOPHILIA B
NCT01767467	SPAIN	GSK	BIOLOGICAL	2. RECRUITING	3	502	18 YEARS	N/A	HERPES ZOSTER
NCT01828099	SPAIN	NOVARTIS	DRUG	2. RECRUITING	3	348	18 YEARS	N/A	LUNG CANCER
NCT01828112	SPAIN	NOVARTIS	DRUG	2. RECRUITING	3	236	18 YEARS	N/A	LUNG CANCER
NCT01868061	SPAIN	HOFFMANN-LA ROCHE	DRUG	2. RECRUITING	3	1,050	18 YEARS	75 YEARS	ASTHMA
NCT01574703	SPAIN	PFIZER	DRUG	2. RECRUITING	4	8,000	18 YEARS	75 YEARS	SMOKING CESSATION
NCT01697358	SPAIN	MEDTRONIC	DEVICE	2. RECRUITING	4	300	18 YEARS	N/A	PAIN IN LEG
NCT01511913	SPAIN	BMS		2. RECRUITING	NA	1,800	18 YEARS	N/A	MELANOMA
NCT01671007	SPAIN	BOEHRINGER INGELHEIM		2. RECRUITING	NA	18,091	18 YEARS	N/A	ATRIAL FIBRILLATION
NCT01791361	SPAIN	AMGEN	OTHER	2. RECRUITING	NA	450	18 YEARS	N/A	COLORECTAL CANCER
NCT01201356	SWEDEN	NOVARTIS	DRUG	2. RECRUITING	3	5,000	18 YEARS	N/A	MULTIPLE SCLEROSIS

1 Identifier: The official study ID given by ClinicalTrials.gov.

2 When the type field is empty, it is commonly a noninterventional study.

3 "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

(Return to Page 1)

(See Studies Opening Additional Sites in a Country, Page 45)

Studies Opening Additional Sites in a Country, from Page 44

IDENTIFIER ¹	COUNTRY	SPONSOR	TYPE ²	STATUS	PHASE ³	SIZE (N)	MIN AGE	MAX AGE	CONDITION
NCT01489111	SWEDEN	NOVO NORDISK	DRUG	2. RECRUITING	3	18	12 YEARS	N/A	HAEMOPHILIA A
NCT01566695	SWEDEN	CELGENE	DRUG	2. RECRUITING	3	386	18 YEARS	N/A	MYELODYSPLASTIC
NCT01663402	SWEDEN	SANOFI	DRUG	2. RECRUITING	3	18,000	40 YEARS	N/A	ACUTE CORONARY SYNDROME
NCT01703208	SWEDEN	MERCK	DRUG	2. RECRUITING	3	4,000	40 YEARS	N/A	DIABETES
NCT01708174	SWEDEN	NOVARTIS	DRUG	2. RECRUITING	3	109	N/A	N/A	MEDULLOBLASTOMA
NCT01767467	SWEDEN	GSK	BIOLOGICAL	2. RECRUITING	3	502	18 YEARS	N/A	HERPES ZOSTER
NCT01828099	SWEDEN	NOVARTIS	DRUG	2. RECRUITING	3	348	18 YEARS	N/A	LUNG CANCER
NCT01671007	SWEDEN	BOEHRINGER INGELHEIM		2. RECRUITING	NA	18,091	18 YEARS	N/A	ATRIAL FIBRILLATION
NCT01840410	SWITZERLAND	NOVARTIS	DRUG	1. PLANNING	3	187	12 YEARS	N/A	MACULAR DEGENERATION
NCT01697579	SWITZERLAND	MERCK	DRUG	2. RECRUITING	2	256	N/A	17 YEARS	CHEMOTHERAPY NAUSEA/ VOMITING
NCT01201356	SWITZERLAND	NOVARTIS	DRUG	2. RECRUITING	3	5,000	18 YEARS	N/A	MULTIPLE SCLEROSIS
NCT01489111	SWITZERLAND	NOVO NORDISK	DRUG	2. RECRUITING	3	18	12 YEARS	N/A	HAEMOPHILIA A
NCT01663402	SWITZERLAND	SANOFI	DRUG	2. RECRUITING	3	18,000	40 YEARS	N/A	ACUTE CORONARY SYNDROME
NCT01708174	SWITZERLAND	NOVARTIS	DRUG	2. RECRUITING	3	109	N/A	N/A	MEDULLOBLASTOMA
NCT01731600	SWITZERLAND	NOVO NORDISK	DRUG	2. RECRUITING	3	60	N/A	11 YEARS	HAEMOPHILIA A
NCT01828112	SWITZERLAND	NOVARTIS	DRUG	2. RECRUITING	3	236	18 YEARS	N/A	LUNG CANCER
NCT01511913	SWITZERLAND	BMS		2. RECRUITING	NA	1,800	18 YEARS	N/A	MELANOMA
NCT01598844	SWITZERLAND	JENAVALVE	DEVICE	2. RECRUITING	NA	180	N/A	N/A	AORTIC STENOSIS
NCT01697579	TAIWAN	MERCK	DRUG	2. RECRUITING	2	256	N/A	17 YEARS	CHEMOTHERAPY NAUSEA/ VOMITING
NCT00625378	TAIWAN	BAYER	DRUG	2. RECRUITING	3	1,000	16 YEARS	N/A	NEOPLASMS
NCT01480479	TAIWAN	CELLEX	DRUG	2. RECRUITING	3	440	18 YEARS	N/A	GLIOBLASTOMA
NCT01489111	TAIWAN	NOVO NORDISK	DRUG	2. RECRUITING	3	18	12 YEARS	N/A	HAEMOPHILIA A

1 Identifier: The official study ID given by ClinicalTrials.gov.

2 When the type field is empty, it is commonly a noninterventional study.

3 "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

(Return to Page 1)

(See Studies Opening Additional Sites in a Country, Page 46)

Studies Opening Additional Sites in a Country, from Page 45

IDENTIFIER ¹	COUNTRY	SPONSOR	TYPE ²	STATUS	PHASE ³	SIZE (N)	MIN AGE	MAX AGE	CONDITION
NCT01560624	TAIWAN	UNITED THERAPEUTICS	DRUG	2. RECRUITING	3	858	18 YEARS	75 YEARS	PULMONARY HYPERTENSION
NCT01560637	TAIWAN	UNITED THERAPEUTICS	DRUG	2. RECRUITING	3	858	18 YEARS	75 YEARS	PULMONARY HYPERTENSION
NCT01641926	TAIWAN	MERCK	BIOLOGICAL	2. RECRUITING	3	1,400	18 YEARS	N/A	HEPATITIS B, CHRONIC
NCT01663402	TAIWAN	SANOFI	DRUG	2. RECRUITING	3	18,000	40 YEARS	N/A	ACUTE CORONARY SYNDROME
NCT01734785	TAIWAN	BOEHRINGER INGELHEIM	DRUG	2. RECRUITING	3	444	18 YEARS	N/A	DIABETES
NCT01767467	TAIWAN	GSK	BIOLOGICAL	2. RECRUITING	3	502	18 YEARS	N/A	HERPES ZOSTER
NCT01828099	TAIWAN	NOVARTIS	DRUG	2. RECRUITING	3	348	18 YEARS	N/A	LUNG CANCER
NCT01480479	THAILAND	CELLDEX	DRUG	2. RECRUITING	3	440	18 YEARS	N/A	GLIOBLASTOMA
NCT01828099	THAILAND	NOVARTIS	DRUG	2. RECRUITING	3	348	18 YEARS	N/A	LUNG CANCER
NCT01922102	THAILAND	NOVARTIS	DRUG	2. RECRUITING	3	475	18 YEARS	N/A	VISUAL IMPAIRMENT
NCT01895777	TURKEY	BOEHRINGER INGELHEIM	DRUG	1. PLANNING	3	270	N/A	17 YEARS	THROMBOEMBOLISM
NCT01928979	TURKEY	BAYER	OTHER	1. PLANNING	NA	150	18 YEARS	N/A	ATRIAL FIBRILLATION
NCT01697579	TURKEY	MERCK	DRUG	2. RECRUITING	2	256	N/A	17 YEARS	CHEMOTHERAPY NAUSEA/ VOMITING
NCT01201356	TURKEY	NOVARTIS	DRUG	2. RECRUITING	3	5,000	18 YEARS	N/A	MULTIPLE SCLEROSIS
NCT01489111	TURKEY	NOVO NORDISK	DRUG	2. RECRUITING	3	18	12 YEARS	N/A	HAEMOPHILIA A
NCT01731600	TURKEY	NOVO NORDISK	DRUG	2. RECRUITING	3	60	N/A	11 YEARS	HAEMOPHILIA A
NCT01767467	TURKEY	GSK	BIOLOGICAL	2. RECRUITING	3	502	18 YEARS	N/A	HERPES ZOSTER
NCT01828099	TURKEY	NOVARTIS	DRUG	2. RECRUITING	3	348	18 YEARS	N/A	LUNG CANCER
NCT01828112	TURKEY	NOVARTIS	DRUG	2. RECRUITING	3	236	18 YEARS	N/A	LUNG CANCER
NCT00625378	UKRAINE	BAYER	DRUG	2. RECRUITING	3	1,000	16 YEARS	N/A	NEOPLASMS
NCT01479244	UKRAINE	GALENA	BIOLOGICAL	2. RECRUITING	3	700	18 YEARS	N/A	BREAST CANCER
NCT01663402	UKRAINE	SANOFI	DRUG	2. RECRUITING	3	18,000	40 YEARS	N/A	ACUTE CORONARY SYNDROME
NCT01731600	UKRAINE	NOVO NORDISK	DRUG	2. RECRUITING	3	60	N/A	11 YEARS	HAEMOPHILIA A

1 Identifier: The official study ID given by ClinicalTrials.gov.

2 When the type field is empty, it is commonly a noninterventional study.

3 "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

(Return to Page 1)

(See Studies Opening Additional Sites in a Country, Page 47)

Studies Opening Additional Sites in a Country, from Page 46

IDENTIFIER ¹	COUNTRY	SPONSOR	TYPE ²	STATUS	PHASE ³	SIZE (N)	MIN AGE	MAX AGE	CONDITION
NCT01757405	UKRAINE	BAXTER	BIOLOGICAL	2. RECRUITING	3	34	12 YEARS	65 YEARS	HEMOPHILIA B
NCT01907100	UK	BOEHRINGER INGELHEIM	DRUG	1. PLANNING	2	86	18 YEARS	N/A	MESOTHELIOMA
NCT01295827	UK	MERCK	DRUG	2. RECRUITING	1	1,067	18 YEARS	N/A	SOLID TUMOR
NCT01656395	UK	MERCK	DRUG	2. RECRUITING	2	1,475	18 YEARS	65 YEARS	ASTHMA
NCT01697579	UK	MERCK	DRUG	2. RECRUITING	2	256	N/A	17 YEARS	CHEMOTHERAPY NAUSEA/ VOMITING
NCT01740336	UK	GENENTECH	DRUG	2. RECRUITING	2	180	18 YEARS	N/A	BREAST CANCER
NCT01762852	UK	GSK	DRUG	2. RECRUITING	2	94	18 YEARS	75 YEARS	GLOMERULONEPHRITIS
NCT01767090	UK	ASTELLAS	DRUG	2. RECRUITING	2	600	18 YEARS	45 YEARS	ENDOMETRIOSIS
NCT00625378	UK	BAYER	DRUG	2. RECRUITING	3	1,000	16 YEARS	N/A	NEOPLASMS
NCT01201356	UK	NOVARTIS	DRUG	2. RECRUITING	3	5,000	18 YEARS	N/A	MULTIPLE SCLEROSIS
NCT01479244	UK	GALENA	BIOLOGICAL	2. RECRUITING	3	700	18 YEARS	N/A	BREAST CANCER
NCT01480479	UK	CELLDEX	DRUG	2. RECRUITING	3	440	18 YEARS	N/A	GLIOBLASTOMA
NCT01489111	UK	NOVO NORDISK	DRUG	2. RECRUITING	3	18	12 YEARS	N/A	HAEMOPHILIA A
NCT01560624	UK	UNITED THERAPEUTICS	DRUG	2. RECRUITING	3	858	18 YEARS	75 YEARS	PULMONARY HYPERTENSION
NCT01560637	UK	UNITED THERAPEUTICS	DRUG	2. RECRUITING	3	858	18 YEARS	75 YEARS	PULMONARY HYPERTENSION
NCT01566695	UK	CELGENE	DRUG	2. RECRUITING	3	386	18 YEARS	N/A	MYELODYSPLASTIC
NCT01663402	UK	SANOFI	DRUG	2. RECRUITING	3	18,000	40 YEARS	N/A	ACUTE CORONARY SYNDROME
NCT01682512	UK	BOEHRINGER INGELHEIM	DRUG	2. RECRUITING	3	306	18 YEARS	80 YEARS	ARTHRITIS, RHEUMATOID
NCT01708174	UK	NOVARTIS	DRUG	2. RECRUITING	3	109	N/A	N/A	MEDULLOBLASTOMA
NCT01731600	UK	NOVO NORDISK	DRUG	2. RECRUITING	3	60	N/A	11 YEARS	HAEMOPHILIA A
NCT01767467	UK	GSK	BIOLOGICAL	2. RECRUITING	3	502	18 YEARS	N/A	HERPES ZOSTER
NCT01828099	UK	NOVARTIS	DRUG	2. RECRUITING	3	348	18 YEARS	N/A	LUNG CANCER
NCT01828112	UK	NOVARTIS	DRUG	2. RECRUITING	3	236	18 YEARS	N/A	LUNG CANCER

¹ Identifier: The official study ID given by ClinicalTrials.gov.

² When the type field is empty, it is commonly a noninterventional study.

³ "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

(Return to Page 1)

(See **Studies Opening Additional Sites in a Country**, Page 48)

Studies Opening Additional Sites in a Country, *from Page 47*

IDENTIFIER ¹	COUNTRY	SPONSOR	TYPE ²	STATUS	PHASE ³	SIZE (N)	MIN AGE	MAX AGE	CONDITION
NCT01846611	UK	JANSSEN	DRUG	2. RECRUITING	3	670	18 YEARS	N/A	FALLOPIAN TUBE NEOPLASMS
NCT01697358	UK	MEDTRONIC	DEVICE	2. RECRUITING	4	300	18 YEARS	N/A	PAIN IN LEG
NCT01511913	UK	BMS		2. RECRUITING	NA	1,800	18 YEARS	N/A	MELANOMA
NCT01928459	USA	NOVARTIS	DRUG	1. PLANNING	1	55	18 YEARS	N/A	SOLID TUMORS
NCT01295827	USA	MERCK	DRUG	2. RECRUITING	1	1,067	18 YEARS	N/A	SOLID TUMOR
NCT01562275	USA	GENENTECH	DRUG	2. RECRUITING	1	108	18 YEARS	N/A	NEOPLASMS
NCT01831427	USA	GILEAD	DRUG	2. RECRUITING	1	74	18 YEARS	65 YEARS	ULCERATIVE COLITIS
NCT01857193	USA	NOVARTIS	DRUG	2. RECRUITING	1	185	18 YEARS	N/A	BREAST CANCER
NCT01393626	USA	PFIZER	DRUG	2. RECRUITING	2	275	18 YEARS	75 YEARS	CROHN'S DISEASE
NCT01628393	USA	RECEPTOS	DRUG	2. RECRUITING	2	210	18 YEARS	55 YEARS	MULTIPLE SCLEROSIS
NCT01656395	USA	MERCK	DRUG	2. RECRUITING	2	1,475	18 YEARS	65 YEARS	ASTHMA
NCT01665391	USA	GENZYME	DRUG	2. RECRUITING	2	88	18 YEARS	N/A	GLOMERULO-SCLEROSIS
NCT01697579	USA	MERCK	DRUG	2. RECRUITING	2	256	N/A	17 YEARS	CHEMOTHERAPY NAUSEA/ VOMITING
NCT01740336	USA	GENENTECH	DRUG	2. RECRUITING	2	180	18 YEARS	N/A	BREAST CANCER
NCT01762852	USA	GSK	DRUG	2. RECRUITING	2	94	18 YEARS	75 YEARS	GLOMERULONE-PHRITIS
NCT01786668	USA	PFIZER	DRUG	2. RECRUITING	2	200	18 YEARS	N/A	ANKYLOSING SPONDYLITIS
NCT01843374	USA	MEDIMMUNE	DRUG	2. RECRUITING	2	180	18 YEARS	N/A	MESOTHELIOMA
NCT01905657	USA	MERCK	BIOLOGICAL	2. RECRUITING	2	920	18 YEARS	N/A	LUNG CANCER
NCT00625378	USA	BAYER	DRUG	2. RECRUITING	3	1,000	16 YEARS	N/A	NEOPLASMS
NCT01201356	USA	NOVARTIS	DRUG	2. RECRUITING	3	5,000	18 YEARS	N/A	MULTIPLE SCLEROSIS
NCT01479244	USA	GALENA	BIOLOGICAL	2. RECRUITING	3	700	18 YEARS	N/A	BREAST CANCER
NCT01480479	USA	CELLDEX	DRUG	2. RECRUITING	3	440	18 YEARS	N/A	GLIOBLASTOMA
NCT01489111	USA	NOVO NORDISK	DRUG	2. RECRUITING	3	18	12 YEARS	N/A	HAEMOPHILIA A
NCT01560624	USA	UNITED THERAPEUTICS	DRUG	2. RECRUITING	3	858	18 YEARS	75 YEARS	PULMONARY HYPERTENSION

1 Identifier: The official study ID given by ClinicalTrials.gov.

2 When the type field is empty, it is commonly a noninterventional study.

3 "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

(Return to Page 1)

(See **Studies Opening Additional Sites in a Country**, Page 49)

Studies Opening Additional Sites in a Country, from Page 48

IDENTIFIER ¹	COUNTRY	SPONSOR	TYPE ²	STATUS	PHASE ³	SIZE (N)	MIN AGE	MAX AGE	CONDITION
NCT01560637	USA	UNITED THERAPEUTICS	DRUG	2. RECRUITING	3	858	18 YEARS	75 YEARS	PULMONARY HYPERTENSION
NCT01566695	USA	CELGENE	DRUG	2. RECRUITING	3	386	18 YEARS	N/A	MYELODYSPLASTIC
NCT01663402	USA	SANOFI	DRUG	2. RECRUITING	3	18,000	40 YEARS	N/A	ACUTE CORONARY SYNDROME
NCT01682512	USA	BOEHRINGER INGELHEIM	DRUG	2. RECRUITING	3	306	18 YEARS	80 YEARS	ARTHRITIS, RHEUMATOID
NCT01682759	USA	MERCK	DRUG	2. RECRUITING	3	680	18 YEARS	N/A	DIABETES
NCT01703208	USA	MERCK	DRUG	2. RECRUITING	3	4,000	40 YEARS	N/A	DIABETES
NCT01708174	USA	NOVARTIS	DRUG	2. RECRUITING	3	109	N/A	N/A	MEDULLOBLASTOMA
NCT01731600	USA	NOVO NORDISK	DRUG	2. RECRUITING	3	60	N/A	11 YEARS	HAEMOPHILIA A
NCT01734785	USA	BOEHRINGER INGELHEIM	DRUG	2. RECRUITING	3	444	18 YEARS	N/A	DIABETES
NCT01757405	USA	BAXTER	BIOLOGICAL	2. RECRUITING	3	34	12 YEARS	65 YEARS	HEMOPHILIA B
NCT01767467	USA	GSK	BIOLOGICAL	2. RECRUITING	3	502	18 YEARS	N/A	HERPES ZOSTER
NCT01814748	USA	MERCK	DRUG	2. RECRUITING	3	200	18 YEARS	44 YEARS	DIABETES
NCT01828112	USA	NOVARTIS	DRUG	2. RECRUITING	3	236	18 YEARS	N/A	LUNG CANCER
NCT01841684	USA	MERCK	DRUG	2. RECRUITING	3	45	18 YEARS	N/A	HYPERCHOLESTEROLEMIA
NCT01846611	USA	JANSSEN	DRUG	2. RECRUITING	3	670	18 YEARS	N/A	FALLOPIAN TUBE NEOPLASMS
NCT01868061	USA	HOFFMANN-LA ROCHE	DRUG	2. RECRUITING	3	1,050	18 YEARS	75 YEARS	ASTHMA
NCT00867815	USA	BAYER	DRUG	2. RECRUITING	4	284	40 YEARS	N/A	OPTIC NEUROPATHY
NCT01574703	USA	PFIZER	DRUG	2. RECRUITING	4	8,000	18 YEARS	75 YEARS	SMOKING CESSATION
NCT01697358	USA	MEDTRONIC	DEVICE	2. RECRUITING	4	300	18 YEARS	N/A	PAIN IN LEG
NCT01897532	USA	BOEHRINGER INGELHEIM	DRUG	2. RECRUITING	4	8,300	18 YEARS	N/A	DIABETES
NCT01478438	USA	NOVIAN	DEVICE	2. RECRUITING	NA	60	18 YEARS	80 YEARS	MALIGNANT TUMOR
NCT01511913	USA	BMS		2. RECRUITING	NA	1,800	18 YEARS	N/A	MELANOMA
NCT01839526	USA	GENZYME	DRUG	2. RECRUITING	NA	100	5 YEARS	25 YEARS	FABRY DISEASE

1 Identifier: The official study ID given by ClinicalTrials.gov.

2 When the type field is empty, it is commonly a noninterventional study.

3 "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

(Return to Page 1)

STUDY SITES BY COUNTRY

This table lists all countries with first-time and additional study sites that launched in the past week.

COUNTRY	STUDIES OPENING A FIRST SITE IN A NEW COUNTRY	STUDIES OPENING ADDITIONAL SITES IN A COUNTRY	TOTAL TRIALS	COUNTRY	STUDIES OPENING A FIRST SITE IN A NEW COUNTRY	STUDIES OPENING ADDITIONAL SITES IN A COUNTRY	TOTAL TRIALS
ARGENTINA	3	7	10	KOREA, SOUTH	4	13	17
AUSTRALIA	4	26	30	LATVIA	1	3	4
AUSTRIA	0	13	13	LEBANON	1	3	4
BELGIUM	9	17	26	LITHUANIA	2	6	8
BRAZIL	1	10	11	MACEDONIA	0	1	1
BULGARIA	1	12	13	MALAYSIA	0	6	6
CANADA	14	23	37	MEXICO	7	4	11
CHILE	1	2	3	NETHERLANDS	5	17	22
CHINA	4	4	8	NEW ZEALAND	1	11	12
COLOMBIA	1	6	7	NORWAY	2	7	9
COSTA RICA	1	0	1	PANAMA	0	2	2
CROATIA	0	3	3	PERU	0	5	5
CZECH REPUBLIC	3	12	15	PHILIPPINES	2	1	3
DENMARK	1	9	10	POLAND	5	16	21
EGYPT	0	1	1	PORTUGAL	1	7	8
EL SALVADOR	0	2	2	ROMANIA	2	9	11
ESTONIA	0	5	5	RUSSIA	5	13	18
FINLAND	1	5	6	SERBIA	0	5	5
FRANCE	10	25	35	SINGAPORE	2	5	7
GEORGIA	0	2	2	SLOVAKIA	0	5	5
GERMANY	11	30	41	SLOVENIA	0	2	2
GREECE	2	7	9	SOUTH AFRICA	3	8	11
GUATEMALA	0	1	1	SPAIN	9	29	38
HONG KONG	2	5	7	SWEDEN	2	9	11
HUNGARY	3	15	18	SWITZERLAND	2	10	12
INDIA	4	3	7	TAIWAN	5	11	16
IRELAND	0	3	3	THAILAND	4	3	7
ISRAEL	3	11	14	TURKEY	2	9	11
ITALY	8	23	31	UKRAINE	4	5	9
JAPAN	7	10	17	UNITED KINGDOM	11	25	36
				UNITED STATES	35	44	79

(Return to Page 1)

STUDIES UNDER PLANNING

This table lists all registered studies that are still under planning, have no site location listed and was first registered during the past year. About 10% of the studies listed as in the planning stage are replaced each week.

IDENTIFIER ¹	SPONSOR	TYPE ²	STATUS	PHASE ³	SIZE (N)	MIN AGE	MAX AGE	CONDITION
NCT01691261	PFIZER	BIOLOGICAL	1. PLANNING	1	10	61 YEARS	N/A	MACULAR DEGENERATION
NCT01705158	ARCAGY	DRUG	1. PLANNING	1	88	18 YEARS	N/A	OVARIAN CANCER
NCT01728207	IMMUNOMEDICS	DRUG	1. PLANNING	1	50	18 YEARS	N/A	LYMPHOMA
NCT01748864	ENDOCYTE	DRUG	1. PLANNING	1	10	18 YEARS	N/A	HEALTHY
NCT01771159	URO-RESEARCH	DEVICE	1. PLANNING	1	10	18 YEARS	N/A	URINARY INCONTINENCE
NCT01792102	ONCOTHERAPEUTICS	DRUG	1. PLANNING	1	38	18 YEARS	N/A	MULTIPLE MYELOMA
NCT01800175	OCULAR THERAPEUTIX	DEVICE	1. PLANNING	1	60	40 YEARS	N/A	HEALTHY
NCT01803399	GSK	DRUG	1. PLANNING	1	40	18 YEARS	65 YEARS	INFECTIONS, BACTERIAL
NCT01805024	SANTHERA	DRUG	1. PLANNING	1	24	5 YEARS	16 YEARS	MUSCULAR DYSTROPHY
NCT01812382	GSK	DRUG	1. PLANNING	1	3	18 YEARS	55 YEARS	SKIN INFECTIONS
NCT01812603	GW	DRUG	1. PLANNING	1	6	18 YEARS	N/A	CANCER
NCT01812616	GW	DRUG	1. PLANNING	1	20	18 YEARS	N/A	CANCER
NCT01817855	ASTRAZENECA	DRUG	1. PLANNING	1	34	18 YEARS	55 YEARS	HEALTHY
NCT01818869	ASTRAZENECA	DRUG	1. PLANNING	1	24	18 YEARS	50 YEARS	HEALTHY
NCT01847404	GSK	DRUG	1. PLANNING	1	24	18 YEARS	45 YEARS	ULCERS, DUODENAL/GASTRIC
NCT01847417	GSK	DRUG	1. PLANNING	1	24	18 YEARS	45 YEARS	ULCERS, DUODENAL/GASTRIC
NCT01852825	MERCK	BIOLOGICAL	1. PLANNING	1	34	18 YEARS	55 YEARS	ALLERGIC RHINO-CONJUNCTIVITIS
NCT01866306	MERCK	BIOLOGICAL	1. PLANNING	1	73	18 YEARS	55 YEARS	ASTHMA
NCT01870037	ION	DRUG	1. PLANNING	1	18	18 YEARS	N/A	OVERACTIVE BLADDER
NCT01870102	DAEWON	DRUG	1. PLANNING	1	MISSING	20 YEARS	40 YEARS	HEALTHY
NCT01870726	NOVARTIS	DRUG	1. PLANNING	1	60	18 YEARS	N/A	GLIOBLASTOMA
NCT01876251	PFIZER	DRUG	1. PLANNING	1	60	18 YEARS	N/A	BREAST CANCER

¹ Identifier: The official study ID given by ClinicalTrials.gov.

² When the type field is empty, it is commonly a noninterventional study.

³ "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

Studies Under Planning, from Page 51

IDENTIFIER ¹	SPONSOR	TYPE ²	STATUS	PHASE ³	SIZE (N)	MIN AGE	MAX AGE	CONDITION
NCT01877382	DAIICHI SANKYO	DRUG	1. PLANNING	1	21	18 YEARS	N/A	LYMPHOMA
NCT01879722	TAKEDA	DRUG	1. PLANNING	1	60	18 YEARS	55 YEARS	SCHIZOPHRENIA
NCT01881789	ONYX	DRUG	1. PLANNING	1	59	18 YEARS	N/A	MULTIPLE MYELOMA
NCT01882296	AHN-GOOK	DRUG	1. PLANNING	1	40	20 YEARS	45 YEARS	HEALTHY
NCT01890473	BMS	DRUG	1. PLANNING	1	216	18 YEARS	N/A	RHEUMATOID ARTHRITIS
NCT01894243	ASTRAZENECA	DRUG	1. PLANNING	1	30	18 YEARS	75 YEARS	SOLID TUMOURS
NCT01894256	ASTRAZENECA	DRUG	1. PLANNING	1	42	18 YEARS	75 YEARS	SOLID TUMOURS
NCT01894360	GSK	DRUG	1. PLANNING	1	80	18 YEARS	55 YEARS	SYSTEMIC LUPUS ERYTHEMATOSUS
NCT01895946	ASTRAZENECA	DRUG	1. PLANNING	1	24	18 YEARS	N/A	TUMORS
NCT01896323	CELGENE	DRUG	1. PLANNING	1	14	18 YEARS	65 YEARS	HEALTHY
NCT01899703	GSK	DRUG	1. PLANNING	1	40	18 YEARS	75 YEARS	CHOLESTASIS, INTRAHEPATIC
NCT01900028	ASTRAZENECA	PROCEDURE	1. PLANNING	1	48	18 YEARS	N/A	SOLID TUMOURS
NCT01900522	TAKEDA	DRUG	1. PLANNING	1	64	18 YEARS	N/A	SCHIZOPHRENIA
NCT01902550	JANSSEN	DRUG	1. PLANNING	1	12	18 YEARS	45 YEARS	HEALTHY
NCT01906125	PFIZER	DRUG	1. PLANNING	1	60	18 YEARS	55 YEARS	HEALTHY
NCT01906307	LA JOLLA	DRUG	1. PLANNING	1	25	18 YEARS	N/A	HEPATORENAL SYNDROME
NCT01907360	IRONSHORE	DRUG	1. PLANNING	1	72	6 YEARS	17 YEARS	ADHD
NCT01918176	PFIZER	DRUG	1. PLANNING	1	26	18 YEARS	55 YEARS	HEALTHY
NCT01918202	PFIZER	DRUG	1. PLANNING	1	12	21 YEARS	55 YEARS	HEALTHY
NCT01920061	PFIZER	DRUG	1. PLANNING	1	85	18 YEARS	N/A	NEOPLASM
NCT01921140	ASTRAZENECA	DRUG	1. PLANNING	1	48	18 YEARS	N/A	SOLID TUMOURS
NCT01922050	LEO	DRUG	1. PLANNING	1	588	18 YEARS	N/A	ACTINIC KERATOSIS
NCT01923389	PFIZER	OTHER	1. PLANNING	1	20	21 YEARS	70 YEARS	DIABETES
NCT01924091	PARTNERSHIP FOR MICROBICIDES	DRUG	1. PLANNING	1	MISS-ING	18 YEARS	N/A	PHARMAOKINETICS

¹ Identifier: The official study ID given by ClinicalTrials.gov.

² When the type field is empty, it is commonly a noninterventional study.

³ "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

Studies Under Planning, from Page 52

IDENTIFIER ¹	SPONSOR	TYPE ²	STATUS	PHASE ³	SIZE (N)	MIN AGE	MAX AGE	CONDITION
NCT01924650	PFIZER	DRUG	1. PLANNING	1	24	18 YEARS	55 YEARS	HEALTHY
NCT01924676	PFIZER	DRUG	1. PLANNING	1	18	18 YEARS	55 YEARS	HEALTHY
NCT01926002	MERCK	DRUG	1. PLANNING	1	16	18 YEARS	55 YEARS	ASTHMA
NCT01926509	MERCK	DRUG	1. PLANNING	1	18	18 YEARS	70 YEARS	PULMONARY HYPERTENSION
NCT01927705	KANG STEM	GENETIC	1. PLANNING	1	30	20 YEARS	60 YEARS	ATOPIC DERMATITIS
NCT01928394	BMS	BIOLOGICAL	1. PLANNING	1	160	18 YEARS	N/A	SOLID TUMORS
NCT01928862	FERRING	DRUG	1. PLANNING	1	75	9 YEARS	16 YEARS	BOWEL PREPARATION
NCT01929330	GSK	DRUG	1. PLANNING	1	36	18 YEARS	65 YEARS	ALOPECIA
NCT01929603	ASTRAZENECA	PROCEDURE	1. PLANNING	1	18	18 YEARS	N/A	SOLID TUMOURS
NCT01929629	ASTRAZENECA	DRUG	1. PLANNING	1	96	18 YEARS	55 YEARS	GONOCOCCAL INFECTION
NCT01929746	BIOGEN	BIOLOGICAL	1. PLANNING	1	56	18 YEARS	55 YEARS	HEALTHY
NCT01930045	MERCK	DRUG	1. PLANNING	1	18	18 YEARS	N/A	HIV
NCT01930058	MERCK	DRUG	1. PLANNING	1	50	18 YEARS	65 YEARS	HCV INFECTION
NCT01930552	SANOFI	DRUG	1. PLANNING	1	20	18 YEARS	N/A	NEOPLASM
NCT01933672	PFIZER	DRUG	1. PLANNING	1	30	18 YEARS	70 YEARS	DIABETES
NCT01934153	GSK	DRUG	1. PLANNING	1	24	30 YEARS	55 YEARS	HYPERHIDROSIS
NCT01934205	GSK	DRUG	1. PLANNING	1	60	18 YEARS	55 YEARS	INFECTIONS, BACTERIAL
NCT01934647	MERCK	DRUG	1. PLANNING	1	20	18 YEARS	70 YEARS	PULMONARY HYPERTENSION
NCT01937338	ASTRAZENECA	DRUG	1. PLANNING	1	26	18 YEARS	55 YEARS	LPS CHALLENGE, NEUTROPHILS
NCT01937702	PROFIL	OTHER	1. PLANNING	1	80	18 YEARS	74 YEARS	DIABETES
NCT01937715	PFIZER	DRUG	1. PLANNING	1	180	18 YEARS	N/A	COLORECTAL CANCER
NCT01937975	MERCK	DRUG	1. PLANNING	1	24	18 YEARS	80 YEARS	RENAL IMPAIRMENT
NCT01938443	GSK	DRUG	1. PLANNING	1	35	18 YEARS	N/A	CANCER
NCT01938456	GSK	DRUG	1. PLANNING	1	6	20 YEARS	N/A	LUNG CANCER

1 Identifier: The official study ID given by ClinicalTrials.gov.

2 When the type field is empty, it is commonly a noninterventional study.

3 "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

(Return to Page 1)

(See Studies Under Planning, Page 54)

Studies Under Planning, from Page 53

IDENTIFIER ¹	SPONSOR	TYPE ²	STATUS	PHASE ³	SIZE (N)	MIN AGE	MAX AGE	CONDITION
NCT01938482	GSK	DRUG	1. PLANNING	1	48	18 YEARS	65 YEARS	ACNE VULGARIS
NCT01938612	ASTRAZENECA	DRUG	1. PLANNING	1	24	20 YEARS	N/A	SOLID TUMORS
NCT01940510	HOFFMANN-LA ROCHE	DRUG	1. PLANNING	1	22	18 YEARS	55 YEARS	HEALTHY
NCT01943513	BIOGEN	BIOLOGICAL	1. PLANNING	1	34	18 YEARS	35 YEARS	HEALTHY
NCT01943838	SANOFI	DRUG	1. PLANNING	1	24	18 YEARS	N/A	NEOPLASM
NCT01943851	GSK	DRUG	1. PLANNING	1	70	18 YEARS	N/A	CANCER
NCT01750931	GSK	DRUG	1. PLANNING	2	28	18 YEARS	45 YEARS	ARTHRITIS, RHEUMATOID
NCT01755598	GSK	BIOLOGICAL	1. PLANNING	2	4500	18 YEARS	50 YEARS	TUBERCULOSIS
NCT01769027	CNS ONLUS	DRUG	1. PLANNING	2	30	4 YEARS	40 YEARS	PANDAS
NCT01793441	HOFFMANN-LA ROCHE	DRUG	1. PLANNING	2	150	18 YEARS	45 YEARS	AUTISTIC DISORDER
NCT01798121	JHP	BIOLOGICAL	1. PLANNING	2	90	18 YEARS	60 YEARS	TUBERCULOSIS IDENTIFICATION
NCT01798745	JANSSEN	DRUG	1. PLANNING	2	110	18 YEARS	N/A	HEART FAILURE
NCT01806896	PFIZER	DRUG	1. PLANNING	2	65	18 YEARS	70 YEARS	HUNTINGTON
NCT01850004	BMS	DRUG	1. PLANNING	2	75	18 YEARS	N/A	CHRONIC MYELOID LEUKEMIA
NCT01852110	MERCK	DRUG	1. PLANNING	2	640	55 YEARS	85 YEARS	ALZHEIMER ¹
NCT01857232	ACACIA PHARMA LTD	DRUG	1. PLANNING	2	315	18 YEARS	N/A	CHEMOTHERAPY NASUEA/ VOMITING
NCT01861249	SANOFI	DRUG	1. PLANNING	2	80	18 YEARS	N/A	ULCERATIVE COLITIS
NCT01864148	BIOGEN	DRUG	1. PLANNING	2	396	18 YEARS	58 YEARS	MULTIPLE SCLEROSIS
NCT01867710	JANSSEN	DRUG	1. PLANNING	2	144	18 YEARS	N/A	PROSTATE CANCER
NCT01887327	INFACARE	DRUG	1. PLANNING	2	90	N/A	72 HOURS	HYPERBILIRUBI-NEMIA
NCT01889797	PRECOG	BIOLOGICAL	1. PLANNING	2	150	18 YEARS	N/A	LYMPHOMA
NCT01890746	GSK	DRUG	1. PLANNING	2	120	18 YEARS	N/A	LEUKAEMIA, ACUTE
NCT01891331	VIAMET	DRUG	1. PLANNING	2	48	18 YEARS	65 YEARS	CANDIDIASIS, VULVOVAGINAL

¹ Identifier: The official study ID given by ClinicalTrials.gov.

² When the type field is empty, it is commonly a noninterventional study.

³ "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

Studies Under Planning, from Page 54

IDENTIFIER ¹	SPONSOR	TYPE ²	STATUS	PHASE ³	SIZE (N)	MIN AGE	MAX AGE	CONDITION
NCT01891344	CLOVIS ONCOLOGY	DRUG	1. PLANNING	2	180	18 YEARS	N/A	PERITONEAL CANCER
NCT01899768	GSK	DRUG	1. PLANNING	2	30	18 YEARS	N/A	COUGH
NCT01899833	CELL>POINT	RADIATION	1. PLANNING	2	60	18 YEARS	N/A	CORONARY ARTERY DISEASE
NCT01900431	SANOFI	DRUG	1. PLANNING	2	57	18 YEARS	N/A	UVEITIS
NCT01908192	SYNEURX	DRUG	1. PLANNING	2	126	12 YEARS	16 YEARS	SCHIZOPHRENIA
NCT01911273	PFIZER	DRUG	1. PLANNING	2	180	18 YEARS	N/A	CARCINOMA, HEPATOCELLULAR
NCT01912196	MSI	DRUG	1. PLANNING	2	286	21 YEARS	70 YEARS	DEPRESSIVE DISORDER
NCT01915472	IMMUNOMEDICS	DRUG	1. PLANNING	2	50	18 YEARS	N/A	COLORECTAL CANCER
NCT01915940	FORSIGHT	DRUG	1. PLANNING	2	126	18 YEARS	N/A	OCULAR HYPERTENSION
NCT01920594	GSK	DRUG	1. PLANNING	2	150	18 YEARS	N/A	SURGICAL PROCEDURES
NCT01922089	NOVARTIS	DRUG	1. PLANNING	2	480	18 YEARS	N/A	HEART FAILURE
NCT01923181	NOVO NORDISK	DRUG	1. PLANNING	2	603	18 YEARS	N/A	DIABETES
NCT01925209	NOVARTIS	DRUG	1. PLANNING	2	240	36 YEARS	85 YEARS	MYOSITIS
NCT01925261	ORTHOTROPHIX	DRUG	1. PLANNING	2	120	25 YEARS	75 YEARS	KNEE OSTEOARTHRITIS
NCT01925274	PFIZER	DRUG	1. PLANNING	2	150	18 YEARS	N/A	COLORECTAL CANCER
NCT01925950	SOLIGENIX	DRUG	1. PLANNING	2	40	18 YEARS	N/A	GASTROINTESTINAL GRAFT VS HOST
NCT01927913	SHIRE	DRUG	1. PLANNING	2	50	18 YEARS	N/A	METABOLIC DISEASES
NCT01930175	NOVARTIS	DRUG	1. PLANNING	2	30	20 YEARS	70 YEARS	PEMPHIGUS VULGARIS
NCT01932762	MERCK	DRUG	1. PLANNING	2	30	18 YEARS	N/A	HEPATITIS C
NCT01933061	CELGENE	DRUG	1. PLANNING	2	80	18 YEARS	N/A	MELANOMA
NCT01934192	GSK	DRUG	1. PLANNING	2	150	18 YEARS	85 YEARS	GASTROPARESIS
NCT01938625	JANSSEN	DRUG	1. PLANNING	2	40	18 YEARS	N/A	HEPATITIS C, CHRONIC
NCT01939366	GRENENTHAL	DRUG	1. PLANNING	2	350	18 YEARS	80 YEARS	DIABETES
NCT01939548	PFIZER	DRUG	1. PLANNING	2	249	18 YEARS	65 YEARS	SCHIZOPHRENIA

¹ Identifier: The official study ID given by ClinicalTrials.gov.

² When the type field is empty, it is commonly a noninterventional study.

³ "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

(Return to Page 1)

(See Studies Under Planning, Page 56)

Studies Under Planning, from Page 55

IDENTIFIER ¹	SPONSOR	TYPE ²	STATUS	PHASE ³	SIZE (N)	MIN AGE	MAX AGE	CONDITION
NCT01939899	MILLENNIUM	DRUG	1. PLANNING	2	58	18 YEARS	N/A	FOLLICULAR LYMPHOMA
NCT01940601	TEVA	DRUG	1. PLANNING	2	36	2 YEARS	17 YEARS	SOLID TUMORS
NCT01941043	CERECOR	DRUG	1. PLANNING	2	135	18 YEARS	70 YEARS	DEPRESSIVE DISORDER
NCT01943864	GSK	DRUG	1. PLANNING	2	20	20 YEARS	80 YEARS	CANCER
NCT01693120	MEDTRONIC	DEVICE	1. PLANNING	3	300	18 YEARS	70 YEARS	ATRIAL FIBRILLATION
NCT01694966	COSMO	DRUG	1. PLANNING	3	1270	50 YEARS	75 YEARS	COLORECTAL CANCER
NCT01701349	OXIGENE	DRUG	1. PLANNING	3	300	18 YEARS	N/A	THYROID CANCER
NCT01709084	JANSEN	DRUG	1. PLANNING	3	426	18 YEARS	N/A	HIV
NCT01753180	MATRIZYME	BIOLOGICAL	1. PLANNING	3	MISS-ING	18 YEARS	80 YEARS	CHRONIC TOTAL OCCLUSIONS
NCT01762644	PERLE	DRUG	1. PLANNING	3	60	8 YEARS	60 YEARS	DIABETES
NCT01762657	PERLE	DRUG	1. PLANNING	3	60	8 YEARS	60 YEARS	DIABETES
NCT01782131	MERCK	DRUG	1. PLANNING	3	600	18 YEARS	N/A	FUNGAL INFECTIONS
NCT01787149	TSH	DRUG	1. PLANNING	3	129	20 YEARS	N/A	RHEUMATOID ARTHRITIS
NCT01803646	AURIS	DRUG	1. PLANNING	3	330	18 YEARS	75 YEARS	ACUTE PERIPHERAL TINNITUS
NCT01814904	MITSUBISHI	DRUG	1. PLANNING	3	140	2 YEARS	18 YEARS	CHRONIC KIDNEY DISEASE
NCT01814917	MITSUBISHI	DRUG	1. PLANNING	3	100	2 YEARS	18 YEARS	CHRONIC KIDNEY DISEASE
NCT01815424	PFIZER	DRUG	1. PLANNING	3	264	18 YEARS	N/A	PSORIASIS
NCT01818687	MITSUBISHI	DRUG	1. PLANNING	3	45	2 YEARS	18 YEARS	CHRONIC KIDNEY DISEASE
NCT01829347	VITAL THER.	BIOLOGICAL	1. PLANNING	3	120	18 YEARS	N/A	ACUTE ALCOHOLIC HEPATITIS
NCT01838551	CORTENDO	DRUG	1. PLANNING	3	90	18 YEARS	N/A	ENDOGENOUS CUSHING'S SYNDROME
NCT01844856	TETRAPHASE	DRUG	1. PLANNING	3	536	18 YEARS	N/A	INTRA-ABDOMINAL INFECTIONS
NCT01846832	JANSEN	DRUG	1. PLANNING	3	150	18 YEARS	70 YEARS	INFECTION
NCT01847014	ACTELION	DRUG	1. PLANNING	3	275	18 YEARS	80 YEARS	PULMONARY HYPERTENSION

¹ Identifier: The official study ID given by ClinicalTrials.gov.

² When the type field is empty, it is commonly a noninterventional study.

³ "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

Studies Under Planning, from Page 56

IDENTIFIER ¹	SPONSOR	TYPE ²	STATUS	PHASE ³	SIZE (N)	MIN AGE	MAX AGE	CONDITION
NCT01848106	REGADO	DRUG	1. PLANNING	3	13200	18 YEARS	N/A	CORONARY ARTERY DISEASE
NCT01850030	ABBOTT	DRUG	1. PLANNING	3	1066	19 YEARS	41 YEARS	FEMALE INFERTILITY
NCT01863680	MERCK SERONO	DRUG	1. PLANNING	3	130	20 YEARS	45 YEARS	EMBRYO TRANSFER
NCT01863732	NOVARTIS	BIOLOGICAL	1. PLANNING	3	300	N/A	N/A	SPONDYLITIS, ANKYLOSING
NCT01863888	SANOFI	DRUG	1. PLANNING	3	68	18 YEARS	55 YEARS	MULTIPLE SCLEROSIS
NCT01868048	GW	DRUG	1. PLANNING	3	300	18 YEARS	N/A	MULTIPLE SCLEROSIS
NCT01870362	CD PHARMA INDIA	DRUG	1. PLANNING	3	30	25 YEARS	60 YEARS	CHRONIC PERIODONTITIS
NCT01870778	NOVARTIS	DRUG	1. PLANNING	3	6375	18 YEARS	N/A	ACUTE HEART FAILURE
NCT01875874	VITAL THER.	DRUG	1. PLANNING	3	126	18 YEARS	65 YEARS	FULMINANT HEPATIC FAILURE
NCT01876368	NOVARTIS	DRUG	1. PLANNING	3	526	18 YEARS	N/A	HYPERTENSION
NCT01876784	ASTRAZENECA	DRUG	1. PLANNING	3	227	18 YEARS	N/A	THYROID CANCER
NCT01877668	PFIZER	DRUG	1. PLANNING	3	400	18 YEARS	N/A	PSORIATIC ARTHRITIS
NCT01877915	JANSSEN	DRUG	1. PLANNING	3	5000	18 YEARS	95 YEARS	CORONARY ARTERY DISEASE
NCT01879410	GSK	DRUG	1. PLANNING	3	710	40 YEARS	N/A	COPD
NCT01879618	PFIZER	DRUG	1. PLANNING	3	150	18 YEARS	N/A	CHRONIC RENAL FAILURE
NCT01882712	GALDERMA	DRUG	1. PLANNING	3	84	18 YEARS	N/A	ERYTHEMA
NCT01884311	BIO	BIOLOGICAL	1. PLANNING	3	45	2 YEARS	75 YEARS	HYPER-IGM SYNDROME
NCT01888484	OCTAPHARMA	BIOLOGICAL	1. PLANNING	3	64	2 YEARS	75 YEARS	IMMUNE DEFICIENCY
NCT01890122	TAKEDA	DRUG	1. PLANNING	3	640	18 YEARS	75 YEARS	DIABETES
NCT01890798	GSK	DRUG	1. PLANNING	3	55	5 YEARS	N/A	MUSCULAR DYSTROPHIES
NCT01890902	IMPRIMIS	DRUG	1. PLANNING	3	350	35 YEARS	N/A	ACUTE PAIN OSTEOARTHRITIS
NCT01891643	BMS	DRUG	1. PLANNING	3	750	18 YEARS	N/A	MYELOMA
NCT01892345	ALEXION	DRUG	1. PLANNING	3	93	18 YEARS	N/A	NEUROMYELITIS OPTICA
NCT01892436	NOVARTIS	DRUG	1. PLANNING	3	515	N/A	N/A	PSORIATIC ARTHRITIS

1 Identifier: The official study ID given by ClinicalTrials.gov.

2 When the type field is empty, it is commonly a noninterventional study.

3 "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

Studies Under Planning, from Page 57

IDENTIFIER ¹	SPONSOR	TYPE ²	STATUS	PHASE ³	SIZE (N)	MIN AGE	MAX AGE	CONDITION
NCT01894022	GSK	DRUG	1. PLANNING	3	160	18 YEARS	75 YEARS	HYPERTENSION
NCT01896895	MERZ	DRUG	1. PLANNING	3	60	18 YEARS	80 YEARS	BILATERAL BLEPHAROSPASM
NCT01898520	GW	DRUG	1. PLANNING	3	72	8 YEARS	18 YEARS	CEREBRAL PALSY
NCT01899742	GSK	DRUG	1. PLANNING	3	666	40 YEARS	N/A	COPD
NCT01901900	NOVARTIS	BIOLOGICAL	1. PLANNING	3	454	N/A	N/A	RHEUMATOID ARTHRITIS
NCT01905592	TESARO	DRUG	1. PLANNING	3	306	18 YEARS	N/A	BRCA2 GENE MUTATION
NCT01908933	AERIS	DEVICE	1. PLANNING	3	25	40 YEARS	N/A	COPD
NCT01911364	CHIESI	DRUG	1. PLANNING	3	3686	40 YEARS	N/A	COPD
NCT01911858	BBRAUN MEDICAL	DEVICE	1. PLANNING	3	40	18 YEARS	N/A	THIRD DEGREE BURNS
NCT01912456	CSL BEHRING	BIOLOGICAL	1. PLANNING	3	80	12 YEARS	N/A	HEREDITARY ANGIOEDEMA
NCT01913353	BAVARIAN NORDIC	BIOLOGICAL	1. PLANNING	3	MISSING	18 YEARS	40 YEARS	HEALTHY
NCT01913405	BAXTER	BIOLOGICAL	1. PLANNING	3	30	12 YEARS	65 YEARS	HEMOPHILIA A
NCT01913483	MEDICINES	DRUG	1. PLANNING	3	3900	18 YEARS	N/A	PERIPHERAL ENDOVASCULAR INTERVENTIONS
NCT01913847	HANMI	DRUG	1. PLANNING	3	144	20 YEARS	N/A	SYSTOLIC DYSFUNCTION
NCT01917331	CHIESI	DRUG	1. PLANNING	3	1863	40 YEARS	N/A	COPD
NCT01919801	SHIRE	DRUG	1. PLANNING	3	118	18 YEARS	N/A	ANGIOTENSIN CONVERTING ENZYME
NCT01920477	GSK	BIOLOGICAL	1. PLANNING	3	136	18 YEARS	70 YEARS	PEMPHIGUS
NCT01922258	OTSUKA	DRUG	1. PLANNING	3	230	55 YEARS	90 YEARS	NERVOUS SYSTEM DISEASES
NCT01924533	ASTRAZENECA	DRUG	1. PLANNING	3	500	18 YEARS	N/A	GASTRIC CANCER
NCT01926886	HOFFMANN-LA ROCHE	DRUG	1. PLANNING	3	100	18 YEARS	N/A	BREAST CANCER
NCT01928771	ASTRAZENECA	BIOLOGICAL	1. PLANNING	3	1134	18 YEARS	75 YEARS	ASTHMA
NCT01929317	GSK	DRUG	1. PLANNING	3	80	20 YEARS	N/A	PARKINSON
NCT01933932	ASTRAZENECA	DRUG	1. PLANNING	3	634	18 YEARS	N/A	LUNG CANCER
NCT01934010	AURIS	DRUG	1. PLANNING	3	330	18 YEARS	76 YEARS	ACUTE PERIPHERAL TINNITUS

¹ Identifier: The official study ID given by ClinicalTrials.gov.

² When the type field is empty, it is commonly a noninterventional study.

³ "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

(Return to Page 1)

(See Studies Under Planning, Page 59)

Studies Under Planning, from Page 58

IDENTIFIER ¹	SPONSOR	TYPE ²	STATUS	PHASE ³	SIZE (N)	MIN AGE	MAX AGE	CONDITION
NCT01934140	GSK	BIOLOGICAL	1. PLANNING	3	400	17 YEARS	66 YEARS	MENINGOCOCCAL DISEASE
NCT01936688	MERCK	DRUG	1. PLANNING	3	1050	18 YEARS	N/A	PSORIASIS
NCT01938001	CELGENE	DRUG	1. PLANNING	3	350	18 YEARS	N/A	LYMPHOMA
NCT01938144	PFIZER	DRUG	1. PLANNING	3	750	18 YEARS	N/A	COMMON COLD
NCT01939002	BIOGEN	BIOLOGICAL	1. PLANNING	3	200	18 YEARS	65 YEARS	MULTIPLE SCLEROSIS
NCT01939158	GSK	BIOLOGICAL	1. PLANNING	3	800	12 MONTHS	14 MONTHS	MENINGOCOCCAL DISEASE
NCT01940848	BAYER	DRUG	1. PLANNING	3	237	18 YEARS	N/A	IRRITABLE BOWEL SYNDROME
NCT01940887	OPHTHOTECH	DRUG	1. PLANNING	3	622	50 YEARS	N/A	MACULAR DEGENERATION
NCT01941004	NOVARTIS	DRUG	1. PLANNING	3	132	18 YEARS	50 YEARS	MULTIPLE SCLEROSIS (RELAPSING REMITTING)
NCT01942135	PFIZER	DRUG	1. PLANNING	3	417	18 YEARS	N/A	BREAST CANCER
NCT01942733	H LUNDBECK	DRUG	1. PLANNING	3	50	18 YEARS	65 YEARS	SLEEP DISTURBANCES
NCT01942785	H LUNDBECK	DRUG	1. PLANNING	3	50	18 YEARS	65 YEARS	DEPRESSION
NCT01944059	TARGETED MEDICAL	DRUG	1. PLANNING	3	60	18 YEARS	65 YEARS	MIGRAINE
NCT01692470	JANSSEN	DRUG	1. PLANNING	4	60	18 YEARS	N/A	HIV
NCT01758198	BMS	BIOLOGICAL	1. PLANNING	4	300	20 YEARS	N/A	RHEUMATOID ARTHRITIS
NCT01770223	MERCK	DRUG	1. PLANNING	4	100	18 YEARS	N/A	HEPATITIS C
NCT01790828	PFIZER	DRUG	1. PLANNING	4	600	N/A	N/A	HEMOPHILIA A
NCT01793142	PFIZER	DRUG	1. PLANNING	4	3000	19 YEARS	N/A	POSTMENOPAUSAL
NCT01816633	CYTOMEDIX	DEVICE	1. PLANNING	4	380	18 YEARS	N/A	DIABETIC FOOT ULCERS
NCT01816672	CYTOMEDIX	DEVICE	1. PLANNING	4	280	18 YEARS	N/A	DIABETIC FOOT ULCER
NCT01817543	CYTOMEDIX	DEVICE	1. PLANNING	4	385	18 YEARS	N/A	LEG ULCER
NCT01819142	CYTOMEDIX	DEVICE	1. PLANNING	4	400	18 YEARS	N/A	PRESSURE ULCER
NCT01824576	ADVANCED CIRCULATORY	DEVICE	1. PLANNING	4	10	18 YEARS	N/A	CEREBRAL PERFUSION
NCT01834937	INSIGHTEC	DEVICE	1. PLANNING	4	50	18 YEARS	N/A	PAIN METASTASES
NCT01841437	GLAUKOS	DEVICE	1. PLANNING	4	500	N/A	N/A	GLAUCOMA
NCT01841450	GLAUKOS	DEVICE	1. PLANNING	4	360	22 YEARS	N/A	GLAUCOMA
NCT01848210	TAKEDA	DRUG	1. PLANNING	4	336	18 YEARS	75 YEARS	CHRONIC VENOUS INSUFFICIENCY

1 Identifier: The official study ID given by ClinicalTrials.gov.

2 When the type field is empty, it is commonly a noninterventional study.

3 "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

(Return to Page 1)

(See Studies Under Planning, Page 60)

Studies Under Planning, from Page 59

IDENTIFIER ¹	SPONSOR	TYPE ²	STATUS	PHASE ³	SIZE (N)	MIN AGE	MAX AGE	CONDITION
NCT01856569	PFIZER	OTHER	1. PLANNING	4	150	18 YEARS	75 YEARS	ANKYLOSING SPONDYLITIS
NCT01863849	OMNINVEST	BIOLOGICAL	1. PLANNING	4	120	18 YEARS	N/A	INFLUENZA
NCT01864200	BTS	BIOLOGICAL	1. PLANNING	4	232	14 YEARS	N/A	AGKISTRODON CONTORTRIX ENVENOMATION
NCT01870843	XIAN-JANSSEN	DRUG	1. PLANNING	4	260	18 YEARS	65 YEARS	DEPRESSIVE DISORDER
NCT01884337	BMS	DRUG	1. PLANNING	4	750	18 YEARS	N/A	ANTICOAGULATION
NCT01884350	BMS	DRUG	1. PLANNING	4	1112	18 YEARS	N/A	ATRIAL FIBRILLATION
NCT01887483	DANISCO	DIETARY SUP.	1. PLANNING	4	230	18 YEARS	65 YEARS	IRRITABLE BOWEL SYNDROME
NCT01896479	EXELIXIS	DRUG	1. PLANNING	4	112	18 YEARS	N/A	THYROID CANCER
NCT01897766	PFIZER	DRUG	1. PLANNING	4	500	3 YEARS	20 YEARS	SMALL FOR GESTATIONAL AGE
NCT01907854	NOVO NORDISK	DRUG	1. PLANNING	4	396	18 YEARS	N/A	DIABETES
NCT01909934	MILLENNIUM	DRUG	1. PLANNING	4	45	18 YEARS	N/A	LYMPHOMA
NCT01913054	JIANGSU NHWA	DRUG	1. PLANNING	4	2450	45 YEARS	75 YEARS	SAFETY OF GASTROSCOPY
NCT01915914	GSK	DRUG	1. PLANNING	4	120	1 YEAR	18 YEARS	SKIN DISEASES
NCT01916200	GSK	DRUG	1. PLANNING	4	256	18 YEARS	65 YEARS	DEPRESSIVE DISORDER
NCT01916226	GSK	DRUG	1. PLANNING	4	648	18 YEARS	N/A	RHINITIS
NCT01922141	NOVARTIS	DRUG	1. PLANNING	4	1395	65 YEARS	N/A	HYPERTENSION
NCT01924182	MEDTRONIC	DEVICE	1. PLANNING	4	222	18 YEARS	N/A	CHRONIC INTRACTABLE PAIN
NCT01926015	MERCK	BIOLOGICAL	1. PLANNING	4	190	42 DAYS	76 DAYS	ROTAVIRUS DISEASE
NCT01930708	BIOGEN	DRUG	1. PLANNING	4	1080	18 YEARS	N/A	MULTIPLE SCLEROSIS
NCT01936870	PFIZER	DRUG	1. PLANNING	4	2000	N/A	N/A	OVERACTIVE BLADDER (OAB)
NCT01937325	THE ALFRED	DRUG	1. PLANNING	4	20	16 YEARS	70 YEARS	CYSTIC FIBROSIS
NCT01943552	BOEHRINGER INGELHEIM	DRUG	1. PLANNING	4	192	50 YEARS	75 YEARS	COPD
NCT01683305	SILBIOTECH		1. PLANNING	NA	500	18 YEARS	N/A	TUMORS
NCT01685047	ST JUDE		1. PLANNING	NA	470	18 YEARS	N/A	CORONARY ARTERY DISEASE
NCT01688011	CELGENE		1. PLANNING	NA	1500	18 YEARS	N/A	LEUKEMIA
NCT01700543	ZIMMER	PROCEDURE	1. PLANNING	NA	160	18 YEARS	80 YEARS	RHEUMATOID ARTHRITIS
NCT01719263	UPTAKE	DEVICE	1. PLANNING	NA	69	40 YEARS	75 YEARS	EMPHYSEMA

¹ Identifier: The official study ID given by ClinicalTrials.gov.

² When the type field is empty, it is commonly a noninterventional study.

³ "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

(Return to Page 1)

(See Studies Under Planning, Page 61)

Studies Under Planning, from Page 60

IDENTIFIER ¹	SPONSOR	TYPE ²	STATUS	PHASE ³	SIZE (N)	MIN AGE	MAX AGE	CONDITION
NCT01728103	GEN-PROBE	DEVICE	1. PLANNING	NA	2100	16 YEARS	N/A	TRICHOMONAS INFECTIONS
NCT01728714	ASTRAZENECA		1. PLANNING	NA	250	18 YEARS	N/A	DIABETES
NCT01733368	ST JUDE		1. PLANNING	NA	200	18 YEARS	N/A	HEART FAILURE
NCT01741025	SI-BONE	DEVICE	1. PLANNING	NA	100	21 YEARS	70 YEARS	SACROILIAC JOINT PAIN
NCT01751139	GSK	PROCEDURE	1. PLANNING	NA	1500	6 MONTHS	N/A	DENGUE VACCINES
NCT01772225	GSK	OTHER	1. PLANNING	NA	900	18 YEARS	N/A	LUNG CANCER
NCT01777958	HOFFMANN-LA ROCHE		1. PLANNING	NA	478	18 YEARS	N/A	BREAST CANCER
NCT01781416	ASTRAZENECA		1. PLANNING	NA	800	50 YEARS	N/A	CARDIOVASCULAR RISK
NCT01793324	ASTRAZENECA		1. PLANNING	NA	600	18 YEARS	N/A	DEPRESSIVE DISORDER
NCT01795326	ASTRAZENECA		1. PLANNING	NA	800	N/A	N/A	DEPRESSIVE DISORDER
NCT01802788	ST JUDE	DEVICE	1. PLANNING	NA	1050	18 YEARS	N/A	AORTIC VALVE STENOSIS
NCT01818388	ZOLL CIRCULATION	DEVICE	1. PLANNING	NA	50	18 YEARS	N/A	CARDIAC ARREST
NCT01818947	ASTRAZENECA		1. PLANNING	NA	200	18 YEARS	N/A	LUNG CANCER
NCT01824563	ADVANCED BIONICS	OTHER	1. PLANNING	NA	120	18 YEARS	N/A	HEARING LOSS
NCT01829061	QUOTIENT		1. PLANNING	NA	165	18 YEARS	N/A	DIABETES
NCT01829152	VERIZON	DEVICE	1. PLANNING	NA	100	18 YEARS	N/A	HEART FAILURE
NCT01832493	MEDTRONIC	DEVICE	1. PLANNING	NA	60	18 YEARS	N/A	HEART FAILURE
NCT01832714	NEURO KINETICS		1. PLANNING	NA	180	19 YEARS	45 YEARS	CONCUSSION, SEVERE
NCT01834222	PFIZER	BIOLOGICAL	1. PLANNING	NA	600	50 YEARS	N/A	PNEUMOCOCCAL DISEASE
NCT01838980	MOTUS GI	DEVICE	1. PLANNING	NA	50	50 YEARS	69 YEARS	COLON CLEANSING
NCT01845103	CARDIOGENESIS		1. PLANNING	NA	22	18 YEARS	N/A	ANGINA
NCT01850199	PARC TAULI	OTHER	1. PLANNING	NA	20	18 YEARS	46 YEARS	GESTATIONAL DIABETES
NCT01851772	XOFT	DEVICE	1. PLANNING	NA	5	N/A	N/A	CERVICAL CANCER
NCT01859572	RENEURON		1. PLANNING	NA	200	18 YEARS	N/A	MOTOR ACTIVITY
NCT01860092	SECOND SIGHT		1. PLANNING	NA	53	25 YEARS	N/A	RETINITIS PIGMENTOSA
NCT01866475	VIDACARE	DEVICE	1. PLANNING	NA	120	21 YEARS	N/A	INTRASOSEOUS VASCULAR ACCESS
NCT01869101	TETHYS		1. PLANNING	NA	560	18 YEARS	N/A	PREDIABETES
NCT01878149	BAXANO		1. PLANNING	NA	40	18 YEARS	N/A	DEGENERATIVE DISC

¹ Identifier: The official study ID given by ClinicalTrials.gov.

² When the type field is empty, it is commonly a noninterventional study.

³ "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

(Return to Page 1)

(See Studies Under Planning, Page 62)

Studies Under Planning, from Page 61

IDENTIFIER ¹	SPONSOR	TYPE ²	STATUS	PHASE ³	SIZE (N)	MIN AGE	MAX AGE	CONDITION
NCT01885572	PFM	DEVICE	1. PLANNING	NA	260	18 YEARS	75 YEARS	BREAST RECONSTRUCTION
NCT01885585	BMS	DRUG	1. PLANNING	NA	3000	19 YEARS	N/A	THROMBOEMBOLISM
NCT01885598	BMS	DRUG	1. PLANNING	NA	3000	19 YEARS	N/A	ATRIAL FIBRILLATION
NCT01887639	ASTRAZENECA		1. PLANNING	NA	200	18 YEARS	75 YEARS	DEPRESSION
NCT01890447	GSK	OTHER	1. PLANNING	NA	700	18 YEARS	N/A	PERTUSSIS
NCT01892319	NOVO NORDISK	DRUG	1. PLANNING	NA	3075	N/A	N/A	DIABETES
NCT01896089	BIOLOGICTX		1. PLANNING	NA	100	18 YEARS	N/A	KIDNEY TRANSPLANTS
NCT01899573	GUIDED DELIVERY	DEVICE	1. PLANNING	NA	20	18 YEARS	N/A	MITRAL REGURGITATION
NCT01900691	COOK	DEVICE	1. PLANNING	NA	130	18 YEARS	N/A	STENTS
NCT01903187	ST JUDE	DEVICE	1. PLANNING	NA	590	18 YEARS	80 YEARS	HYPERTENSION
NCT01906294	IMS	DRUG	1. PLANNING	NA	12000	18 YEARS	N/A	DIABETES
NCT01907048	BAYER	BEHAVIORAL	1. PLANNING	NA	4000	18 YEARS	N/A	ANTICOAGULATION
NCT01907828	ST JUDE	DEVICE	1. PLANNING	NA	100	18 YEARS	N/A	CARDIAC ABLATION
NCT01910896	MERZ	DEVICE	1. PLANNING	NA	120	18 YEARS	N/A	SURGERY SCARS
NCT01911078	ST JUDE	PROCEDURE	1. PLANNING	NA	60	18 YEARS	80 YEARS	HYPERTENSION
NCT01911143	MEMED		1. PLANNING	NA	325	1 MONTH	18 YEARS	ARTHRITIS, INFECTIOUS
NCT01913613	DC DEVICE	DEVICE	1. PLANNING	NA	MISSING	40 YEARS	N/A	HEART FAILURE
NCT01915888	GSK	OTHER	1. PLANNING	NA	1	N/A	5 YEARS	GASTROENTERITIS
NCT01917968	BOSTON SCIENTIFIC	DEVICE	1. PLANNING	NA	414	18 YEARS	N/A	PELVIC PROLAPSE
NCT01919320	SYNCARDIA	DEVICE	1. PLANNING	NA	302	N/A	N/A	VENTRICULAR FAILURE
NCT01923792	CIRCASSIA		1. PLANNING	NA	105	18 YEARS	64 YEARS	RHINOCONJUNCTIVITIS
NCT01925794	CELONOVA	DEVICE	1. PLANNING	NA	296	18 YEARS	N/A	CORONARY ARTERY DISEASE
NCT01929291	GSK	BIOLOGICAL	1. PLANNING	NA	600	11 YEARS	64 YEARS	BOOSTRIX VACCINATION
NCT01933945	BAYER	PROCEDURE	1. PLANNING	NA	1670	N/A	N/A	CARCINOMA, HEPATOCELLULAR
NCT01934452	PFIZER	DRUG	1. PLANNING	NA	120	18 YEARS	80 YEARS	RENAL CELL CARCINOMA
NCT01936636	GALENA	DRUG	1. PLANNING	NA	2500	18 YEARS	N/A	CANCER PAIN
NCT01939249	BIOTRONIK	DEVICE	1. PLANNING	NA	585	18 YEARS	80 YEARS	CORONARY ARTERY DISEASE
NCT01940328	ECHONSENSE	DEVICE	1. PLANNING	NA	150	18 YEARS	N/A	PULMONARY EDEMA
NCT01940770	ASTRAZENECA		1. PLANNING	NA	1100	N/A	N/A	DIABETES

1 Identifier: The official study ID given by ClinicalTrials.gov.

2 When the type field is empty, it is commonly a noninterventional study.

3 "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

Studies Under Planning, from Page 62

IDENTIFIER ¹	SPONSOR	TYPE ²	STATUS	PHASE ³	SIZE (N)	MIN AGE	MAX AGE	CONDITION
NCT01942200	ONKOVIS		1. PLANNING	NA	350	N/A	N/A	CARCINOMA
NCT01944618	BMS	DRUG	1. PLANNING	NA	5000	18 YEARS	75 YEARS	DIABETES

STUDIES ENDED OR HALTED

This table lists studies that were terminated, suspended or withdrawn in the past week.

IDENTIFIER ¹	SPONSOR	TYPE ²	STATUS	PHASE ³	SIZE (N)	MIN AGE	MAX AGE	CONDITION
NCT01083732	BOEHRINGER INGELHEIM	DRUG	5. SUSPENDED	2	16	1 YEAR	11 YEARS	VENOUS THROMBOEMBOLISM
NCT01773174	BOEHRINGER INGELHEIM	DRUG	5. SUSPENDED	2	12	1 YEAR	11 YEARS	VENOUS THROMBOEMBOLISM
NCT01901146	AMGEN	DRUG	5. SUSPENDED	3	588	N/A	N/A	BREAST CANCER
NCT01366651	JANSSEN	DRUG	7. TERMINATED	1	1	N/A	1 YEAR	MENINGITIS
NCT01627002	PROTAFIN	BIOLOGICAL	7. TERMINATED	1	49	18 YEARS	65 YEARS	HEALTHY VOLUNTEERS
NCT01793649	GILEAD	DRUG	7. TERMINATED	1	7	18 YEARS	45 YEARS	COPD
NCT01214174	ICON	DRUG	7. TERMINATED	2	42	40 YEARS	N/A	OCULAR INFLAMMATION
NCT01554176	MERCK	DRUG	7. TERMINATED	2	129	21 YEARS	64 YEARS	DEPRESSIVE DISORDER
NCT01103063	PFIZER	DRUG	7. TERMINATED	3	5,044	16 YEARS	35 YEARS	PREVENTIVE TREATMENT PREGNANCY
NCT01302938	PFIZER	DRUG	7. TERMINATED	4	18	21 YEARS	N/A	OVERACTIVE BLADDER
NCT00519194	ST JUDE	DEVICE	7. TERMINATED	NA	112	18 YEARS	80 YEARS	ATRIAL FIBRILLATION
NCT01363921	GAMBRO	DEVICE	7. TERMINATED	NA	10	18 YEARS	N/A	CHRONIC KIDNEY FAILURE
NCT01832103	MERCK	DRUG	8. WITHDRAWN	1	0	18 YEARS	75 YEARS	RENAL INSUFFICIENCY
NCT01491659	PFIZER	DIETARY SUP.	8. WITHDRAWN	4	0	18 YEARS	70 YEARS	DIARRHOEA
NCT01727271	MERCK	DRUG	8. WITHDRAWN	4	0	18 YEARS	N/A	HEPATITIS B

¹ Identifier: The official study ID given by ClinicalTrials.gov.

² When the type field is empty, it is commonly a noninterventional study.

³ "NA" in the Phase field indicates that the sponsor has not provided any trial phase information; "NA" commonly represents a noninterventional study, but it can also represent an interventional device trial.

FDANEWS	Customer Service: Kim Williams (888) 838-5578 • +1 (703) 538-7600 customerservice@fdanews.com	Editorial: Dan Landrigan (703) 538-7649 dlandrigan@fdanews.com	Ad Sales: Jim Desborough (703) 538-7647 jdesborough@fdanews.com	Content Sales: Nelly Valentin (703) 538-7656 nvalentin@fdanews.com
	300 N. Washington St., Suite 200 • Falls Church, VA 22046-3431 • Phone: (888) 838-5578 • +1 (703) 538-7600 • Fax: +1 (703) 538-7676 www.fdanews.com			

Clinical Trial Magnifier Limited: Managing Director, Johan PE Karlberg
FDAnews: President, Cynthia Carter; Content Director: Dan Landrigan; Executive Editor: Meg Bryant

Copyright © 2013 by Clinical Trial Magnifier. All rights reserved. *Clinical Trial Magnifier Weekly* is produced jointly by Clinical Trial Magnifier Limited, which is responsible for the content, and FDAnews, which is responsible for production and distribution. *Clinical Trial Magnifier Weekly* (ISSN 2306-8388) monitors all the essential changes made in the U.S. trial registry for industry-sponsored clinical studies. It is published weekly, 52 issues. Price for nonprofit, academic, government, hospital, and study site subscribers, \$697. Price for for-profit, industry, and clinical research organizations, \$1,297. For site license pricing, contact Nelly Valentin, nvalentin@fdanews.com. Photocopying or reproducing in any form, including electronic or facsimile transmission, scanning or electronic storage is a violation of federal copyright law and is strictly prohibited without the publisher's express written permission.